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Abstract
The Pregnane X Receptor (PXR) is regarded as a central factor in the body’s response 
to alterations in chemical levels: It is activated by a variety of chemically unrelated 
endogenous and exogenous compounds and regulates genes involved in the uptake, 
metabolism, and excretion of these chemicals. The aim of this study was to delineate 
the molecular mechanisms underlying regulation of the PXR gene.
Initial in silico analysis of 2200 bp of DNA 5’ to the PXR putative transcription start 
site suggests a complex promoter with binding sites for a large number of both liver- 
enriched and ligand-activated transcription factors.
This region of the PXR proximal promoter was cloned from genomic DNA and a 
reporter gene assay deletion series constructed. Over-expression of liver-enriched and 
ligand-activated transcription factors in Huh? hepatoma cells was used to examine the 
role of these factors in regulating the PXR reporter gene. The liver-enriched 
transcription factors HNF3a/p and HNF4a showed positive regulation of fragments 
containing putative interaction sites for these factors. Amongst the ligand-activated 
transcription factors examined, GRa, ER and PPARa produced a net positive effect 
on PXR reporter gene expression, whereas PXR and CAR produced a net inhibitory 
effect, suggesting feedback regulation of PXR expression by PXR and CAR proteins, 
potentially to prevent disruption of cellular homeostasis.
The effect of PPARa action of PXR gene expression was examined in more detail, 
and I have demonstrated for the first time that PPARa regulates gene expression of 
the PXR by binding directly to its promoter. This is of particular interest as PPARa 
ligands are not classical PXR ligands, suggesting a complex relationship with 
implications for drug-drug interactions. In addition, PPARa-mediated activation of 
PXR gene expression is probably a cross species event, in contrast to the rodent-
I
specific carcinogenesis elicited by PPARa ligands, raising the important question of 
the implications of this activation in man.
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1 CHAPTER: Introduction
1.1 Regulation of the body’s homeostasis in response to fluctuating chemicals
1.1.1 Introduction
The human body must constantly monitor levels of both endogenous (endobiotic) and 
foreign (xenobiotic) chemicals. Maintaining the correct balance of these chemicals is 
vital both for normal cellular function and prevention of toxicity (Plant 2003). 
Specialist proteins within the body are involved with monitoring/controlling the 
absorption, distribution, metabolism and excretion (ADME) of both endo- and 
xenobiotics, thereby maintaining homeostasis.
1.1.2 Absorption
The absorption of a chemical is the first step in the ADME of that chemical. 
Xenobiotics can reach the blood stream via absorption through the skin, lung or 
intestine. The commonest route of absorption is oral, either deliberately (taking 
tablets) or in combination with food. This absorption can be passive, facilitated or 
active (Plant 2003).
1.1.3 Distribution
Absorbed chemicals are distributed through the blood to most of the organs. The 
highly perfused organs are more exposed to more chemicals, particularly the liver.
compared to other parts of the body, like muscles and tendons. The liver represents 
the organ of the highest metabolism activity as it contains the most abundant enzymes 
for the metabolism of xenobiotics and endobiotics (Yamazaki et al. 1996). Other 
organs possess some metabolism activity, especially the intestine and kidney 
(Yamazaki et al. 1996). The passage of a drug can be passive (Ayrton and Morgan 
2001), but for most drugs their uptake is mediated by membrane transporters, which 
are localised on the surface of the cells of different organs; examples of these 
transporters include the organic anion transporter proteins (OATPs), which transport 
organic anions into the cells (Hsiang et al. 1999) and organic cation transporters 
(OCTs), which conversely transport cations (Gorboulev et al. 1997). Among these, 
the OATP-2, highly expressed in the liver, mediates the transport of endobiotics, 
including bile acids, and xenobiotics, including pravastatin, amongst others (Hsiang et 
al. 1999) and OATP-C also expressed in the liver, mediates drug transport, bile salt 
and organic anions (Kullak-Ublick et al. 2001). These transporters are themselves 
regulated by regulatory proteins, and the pregnane X receptor is reported to be a key 
regulator of these genes (Guo et al. 2002; Stedman et al. 2005). This step of the 
uptake of drugs could be considered as a key step in the mechanisms of clearance, and 
the need to study the molecular mechanisms of regulation of transporters proteins is 
of big importance (Ayrton and Morgan 2001).
1.1.4 Metabolism
There are two phases of drug metabolism, including phase I, that acts to prepare 
compounds to be conjugated in phase II metabolism via functionalization reactions, 
whereas phase II adds large, polar conjugates to the chemical, thus increasing its 
excretion (Gibson and Skett 2001). This has two major consequences, increased
excretion of non-polar chemicals and the rapid removal of potentially harmful 
chemicals from the body.
1.1.4.1 Phase I
Phase I drug metabolism includes the oxidation, reduction, hydrolysis and hydration 
of substrates, increasing chemical reactivity and preparing substrates for Phase II 
metabolism (Gibson and Skett 2001). Hence, this phase is often referred to as the 
“functionalisation” phase of drug metabolism. Of the above mentioned reactions, 
oxidative reactions are the most predominant, with the majority being catalyzed by 
the cytochrome P450 enzymes.
Cytochrome P450 (haem-containing proteins GYP) have existed for over 3.5 billion 
years, with representatives in the animalia, plante, fungi, protista and monera 
kingdoms, with 57 expressed in humans (Nelson et al. 1996). They have an important 
role in the metabolism, both anabolic and catabolic, of endogenous compounds, 
including fatty acids, steroids and bile acids (Goodwin et al. 2002). They are also 
involved in the metabolism of xenobiotics, such as environmental pollutants, . 
carcinogens, and therapeutic drugs (Nelson et al. 1996). Cytochorme P450 enzymes 
are divided into sub-families, with differing substrate specificities. Table 1.1 shows 
the major cytochromes (CYPs) in human, and their functions (Gibson and Skett 
2001).
The CYP3A family may be considered as the most important Phase 1 drug 
metabolising enzymes, due to both the abundance of CYP3A4 in the liver (around 
30% of the total CYPs) and intestine and the ability to metabolize a large number of
3
structurally distinct chemicals (about 60% of therapeutic drugs) (Barwick et al. 1996). 
The key regulator of this class of CYP is the nuclear receptor pregnane X receptor 
(PXR), a nuclear receptor responding to diverse chemicals (Lehmann et al. 1998). 
This nuclear receptor regulates a number of enzymes involved in phase 1 metabolism, 
such as CYP2A6 (Madan et al. 2003), CYP2B6 (Goodwin et al. 2001) CYP2B10 
(Maglich et al. 2002), CYP2C9 enzymes (Watkins et al. 2003b). In addition, it also 
regulates enzymes involved in endobiotic metabolism, such as CYP7A1, a cholesterol 
7a-hydroxylase responsible for bile acid synthesis (Staudinger et al. 2001) and 
CYP24 the enzyme responsible for vitamin D hydroxylation (Pascussi et al. 2005).
Table 1-1 M ajor cytochrome P450 in human and their functions.
CYP450 family Function
CYP1-CYP3 Drug, xenobiotic and steroid metabolism
CYP4 Fatty acid, prostaglandin, leukotriene metabolism
CYP5 Thromboxane synthesis
CYP7 Cholesterol 7a-hydroxylation
CYPll Cholesterol side chain cleavage+steroid 11(3 hydroxylase
CYP17 Steroid 17a-hydroxylation
CYP19 Aromatisation of steroids
CYP21 Steroid 21-hydroxylase
CYP24 Vitamin D hydroxylation
CYP27 Cholesterol 27-hydroxylase
(Adapted from Gibson, and Skett, 2001)
Unfortunately, by the veiy nature of the chemical reaction, phase I drug metabolism 
may result in the generation of toxic compounds. For example, CYPlAl and 
CYP1A2 enzymes metabolise pro-carcinogens to carcinogens, including the 
polycyclic aromatic hydrocarbons, and heterocyclic aromatic amines that cause 
multiple-site cancers in rodents (Femandez-Salguero et al. 1995), and many of which 
are classified by lARC (International Agency for Research on Cancer) as possible or
potential human carcinogens. The drug metabolising enzymes CYP2E1 and CYP1A2 
have been implicated in paracetamol-induced toxicity in the liver (Zaher et al. 1998), 
while C YP IB 1 hydroxylates estradiol and may therefore participate in the 
carcinogenicity of the estrogens in mammary glands (Hayes et al. 1996). Phase I- 
mediated toxicity is not only associated with activation of chemicals. Toxicity caused 
by the CYP3A4 is mostly due to drug-drug interactions, where a co-administered 
chemical could alter the efficacy of a second chemical, which utilises the same 
metabolic route. For example the co-administration of the antidepressant herb St 
John’s Wort together with cyclosporine, can lead to graft rejection, or when co­
administered with theophylline, can lead to the loss of its bronchodilatator activity 
(Plant 2003).
1.1.4.2 Phase II
In this phase of metabolism, chemicals are further modified through the addition of 
large hydrophilic moieties, resulting in a sufficiently water-soluble metabolite that can 
be excreted from the body via the aqueous (urine) or faecal routes (Plant 2003). 
Many different reactions are involved in this conjugative phase, including 
glucuronidation, glycosidation, sulfation, méthylation, acétylation, glutathione 
conjugation, amino acid conjugation, and fatty acid conjugation (Gibson and Skett
2001). These reactions may be further sub-divided into type 1 reactions, involving 
high energy conjugates and type 2 reactions that utilize low energy conjugates (Plant 
2003). Glucuronidation and sulphation represent the major type 1 reactions, with the 
major enzyme family members being shown in Table 1.2. Glutathione conjugation is 
a major type 2 reaction, utilizing the low energy conjugate glutathione to react with 
high energy/chemically reactive substrates that might otherwise react non-specifically
5
with cellular components and cause toxicity: The major enzymes involved in 
glutathione conjugation are given in table 1.3. Their substrates include quinine 
containing chemicals, and the endogenous substrates including, arachidonic acid 
metabolites (leukotrienes) (Gibson and Skett 2001).
Table 1-2 M ajor human UDP-glucuronosyltransferase enzymes (UGT) and 
sulphotransferase enzymes (SULT) and substrates
Name Example substrate
UGT Family 1
UGTlAl Ethinyloestradiol
UGT1A3 Cyproheptadine
UGT1A4 Amitriptyline
UGT1A5 Pregnenalone-16a- carbonitrile
UGT1A6 Paracetamol
UGT Family 2
UGT2A1 3 -hy droxybipheny 1
UGT2B4 Androsterone
UGT2B7 Morphine
UGT2B17 Testosterone
SULT
SULTlAl Paracetamol
SULT1A2 2-Naphthol
SULT1A3 Dopamine
SULTIEI 17(3-oestradiol
SULT2A1 Dehydroepiandrosterone
(Adapted from Plant, 2003)
Table 1-3 M ajor enzymes involved in the glutathione S-transferase (GST) and 
their distribution
Name Expression
GSTal Unknown
GSTa2 Brain, heart, liver, prostate, kidney, lung
GSTa3 Unknown
GSTa4 Marrow, brain, heart, liver, kidney, lung
GSTpl Ubiquitous
GSTn2 Brain, skeletal muscle, liver, lung
(Adapted from Plant, 2003)
These enzymes are regulated by transcription factors to co-ordinate their metabolic 
action together with phase I metabolism. As seen in phase I, PXR is involved in the 
regulation of a number of phase II enzymes, including several sulfotransferases 
(Sonoda et al. 2002), Glutathione S-transferases (GST) (Falkner et al. 2001), 
glucuronosyl-transferases (Maglich et al. 2002; Gardner-Stephen et al. 2004). Thus 
PXR can co-ordinately regulate the expression of phase I and phase II drug 
metabolising enzymes. This is important to ensure rapid and efficient removal of bio 
reactive intermediates formed via phase I metabolism. An example of this is seen with 
paracetamol: under normal conditions paracetamol is cleaved via several routes, 
including CYP2E1 metabolism to form a highly reactive NAPQI intermediate, which 
is then cleaved by GST in phase II metabolism. If CYP2EI is over expressed (by for 
example excessive alcohol intake) or GST depleted (through excessive paracetamol 
intake for example) build-up of NAPQI occurs and centrilobular hepatotoxicity takes 
place (Plant 2003).
1.1.5 Excretion
The main routes for excretion are the liver and kidney (Ayrton and Morgan 2001). 
The excretion is an active process and is regulated by protein transporters (Ayrton and 
Morgan 2001). Their role is to transport the metabolised compounds out of the cells 
for excretion in the faeces or urine. Table 1.4 shows some protein transporters in the 
liver, intestine, and kidney. Members of the ATP-binding cassette family transporters 
are the main transport proteins involved in the elimination of toxic compounds, 
represented by three sub families, the multidrug resistance proteins (MDR), bile salt 
export pumps (BSEP) and the multidrug resistance related proteins (Hooiveld et al. 
2000). PXR constitutes an important regulator of some of these transporters: The
multidrug resistance protein (MDRl), has been demonstrated to be under the 
regulation of PXR (Geick et al. 2001), as well as the multidrug resistance related 
protein (MRP2), members of the ATP binding cassette family of transporter proteins 
(Kast et al. 2002) and MRP3 in mice (Maglich et al. 2002). This regulation has two 
major effects. First, by coordinating transporters levels with that of phase I and phase 
II, ADME ensures the most efficient clearance of a chemical. Second, PXR may cause 
the drug resistance mediated by these transporters, and the poor bioavailability of 
some drugs. This adds another level of regulation mediated by this receptor.
Table 1-4 Transporter proteins used in excretion in the liver, intestine and 
kidney.
Intestinal efflux Biliary excretion Renal secretion
P-gp, MRPl, MRP2, OCTl, 
0ATP3
P-gp, MDR3, MRP2 OATl, 0AT3, OATP, OCTl, 
0CT2, P-gp, MRPl
(Adapted from Plant, 2001)
OAT: organic anion transport, OATP: organic anion transport protein, OCT: organic 
cation transport.
Taken collectively, it can be seen that PXR plays a role in orchestrating the uptake, 
phase I and phase II metabolism and excretion of both endobiotics and xenobiotics. 
PXR has a pluripotent activity regulating genes of many different functions, some 
times down regulating genes as well as up regulating them. Investigation of the 
regulation of this receptor is therefore of great importance to understanding its 
functions in the body, and the biological consequences of these fiinctions.
1.2 Factors involved in the regulation of ADME genes
Cytochrome P450, phase II conjugating enzymes and membrane transporters play 
important roles in the body to maintain homeostasis, and as we have seen in the case
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of PXR, regulatory proteins named transcription factors are central to the regulation 
the genes that encodes these proteins. As the main site of CYPs expression and 
activity is in the liver, it is not surprising that liver enriched transcription factors 
(LETFs) are involved in regulating their expression: the effect of these factors will be 
discussed in section 1.2.1. Nuclear receptors are regarded as modulators of changes 
in the body homeostasis and are sensors of changes in the environment and regulate 
metabolic pathways in response to these changes by inducing target genes. PXR is an 
example of a nuclear receptor, and is regarded as the key regulator of the main 
metabolising enzyme CYP3A4 in human liver, but also genes involved in absorption, 
metabolism and excretion as discussed previously. Other nuclear receptors are also 
involved in the regulation of genes for different metabolic pathways; these are 
collectively known as ligand-activated transcription factors (LATFs), and the role of 
these factors in regulating gene expression will be discussed in section 1.2.2.
1.2.1 Liver enriched transcription factors
The liver enriched transcription factors (LETFs) are, as would be expected highly 
expressed in the liver, and have been reported to play important roles in the regulation 
of cytochrome P450s (Gonzalez and Lee 1996). These include, the hepatic nuclear 
factors HNF-1, HNF-3 and HNF-4, although this latter is sometimes classified as a 
nuclear receptor, and the CCAAT/enhancer-binding protein (C/EBP) (Cereghini
1996). These LETFs play important roles in the constitutive and tissue-specific 
expression of many hepatic genes (Cereghini 1996).
1.2.1.1 Hepatic nuclear factor 1 a
The hepatic nuclear factor 1 (HNFl) family is expressed in the liver, kidney, intestine 
and pancreas (Cereghini 1996). HNFl a  is implicated in the regulation of a number of 
hepatic genes, including the glucose-6-phosphatase transporter, albumin and a-1 
antitrypsin (Akiyama et al. 2000). HNFl a  has also been shown to be a positive 
regulator for a number of cytochrome P450 enzymes, such as CYP1A2 and CYP2E1 
(Akiyama and Gonzalez 2003; Cheung et al. 2003) and the membrane transporter the 
OATP-C (Jung and Kullak-Ublick 2003). Whereas HNFl a  up regulates specific 
genes, it may also down regulate others, including CYP4A, CYP7A1 and CYP27 
hydroxylase enzymes, which are involved in fatty acid metabolism and bile acid 
synthesis (Cheung et al. 2003). These in part, could explain the phenotype of patients 
with defined MOD Y 3 diabetes, resulting from mutation in the HNFl a  gene (Elbein 
et al. 1998). These patients suffer from high levels of fatty acids and increased 
resistance to antidiabetic drugs (due probably to impaired drug metabolism) (Cheung 
et al. 2003). Taken together HNFl a  plays an important role in the regulation of 
CYPs involved in drug metabolism and toxicity, bile acid and fatty acid metabolism.
1.2.1.2 Hepatocyte nuclear factor 3
HNF3s have been found to cause nucleosome re-positioning and activate gene 
expression (Shim et al. 1998). There are three isoforms, HNF3a,P,y, which have 90% 
identity in their DNA binding domains, and indeed bind to the same response element 
in the regulatory regions of target genes (Cereghini 1996). In HNF3p -/- mouse 
embryonic cells, the expression of HNF4a and H N Fla are both reduced, and HNF3a 
expression was undetectable (Duncan et al. 1998). As HNF3p is expressed early
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during foetal development (Duncan et al. 1998), this suggests that HNFSp is an 
important regulator of the expression of other LETFs, including H N Fla HNF3a and 
HNF4a.
The mutation of a HNF3/CEBPa binding site within the CYP3A4 proximal promoter 
reduced the xenobiotic-mediated expression of CYP3A4 by glucocorticoids but not 
the macrolide antibiotic rifampicin, suggesting that HNF3/CEBPa mediates the 
CYP3A4 transcriptional activation in response to glucocorticoids (El-Sankary et al.
2002). By comparison, disruption of a second binding site for HNF3 within the 
CYP3A4 proximal promoter led to a diminished activation of CYP3A4 expression in 
response to phénobarbital and clotrimazole, and an increase in response to 
metyrapone (Bombail et al. 2004), suggesting HNF3 regulation of CYP3A4 is 
complex. HNF3s are also involved in the basal expression of CYP3A4, with HNF3y 
mediating the C/EBPa-mediated increase in the level of CYP3A4 mRNA (Rodriguez- 
Antona et al. 2003). Taken collectively, these data suggest that LETFs play an 
important role in regulating/refining the activation of CYP3A4 gene expression in 
both basal and in response to different xenobiotic exposure.
1.2.1.3 Hepatocyte nuclear factor 4
HNF4 is a LETF, often described as an orphan nuclear receptor, due to its lack of a 
known endogenous ligand (Cereghini 1996). HNF4a contains a LBD, which might be 
activated by fatty acids (Dhe-Paganon et al. 2002), suggesting that this factor plays a 
role in fatty acids metabolism. LBD of HNF4a contains two binding sites, an acyl 
binding site and a site conferring thioesterase activity, these two sites modulate the 
transcriptional activity of the HNF4a (Hertz et al. 2005). In addition, this factor is
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reported to be involved in cholesterol and glucose metabolism (Spath and Weiss
1997), foetal development (Li et al. 2000) and liver maturation (Kamiya et al. 2003). 
Jover et al (2001), used an antisense expression plasmid for the HNF4a mRNA, and 
showed the involvement of this factor in the regulation of drug metabolising enzymes. 
The expression of CYP3A4, CYP3A5, CYP2A6 and to a lesser extent CYP2B6, 
CYP2C9 and CYP2D6 was reduced in human hepatocytes (Jover et al. 2001). A 
putative molecular mechanism for the induction of CYP3A4 was proposed by the 
identification of a putative binding site for the HNF4a within the CYP3A4 distal 
promoter, where HNF4a enhanced the PXR-mediated transactivation of CYP3A4 in 
basal conditions and in presence of the PXR ligand, rifampicin (Tirona et al. 2003). 
This latter group showed that the expression of the PXR and CAR were both HNF4a 
dependent in foetal and adult liver mouse respectively. A putative molecular 
mechanism for the induction of the PXR by HNF4a was proposed by Kamiya et al, 
who showed that HNF4a binds to the proximal promoter of the PXR (Kamiya et al.
2003). These data show that the HNF4a is involved in the regulation of the CYP3A4 
gene by direct binding to its promoter, but also through regulation of nuclear receptors 
that in turn regulate CYP expression.
1.2.1.4 CCAAT enhancer binding protein
CAAT/enhancer binding protein (C/EBP) was first isolated from rat liver as a protein 
binding to CAAT sequences in promoters and enhancer elements (Antonson and 
Xanthopoulos 1995). Further experimentation has identified four different classes of 
the C/EBP, designated a , p, 5, and y. Of these, only C/EBPa has been reported to be 
involved in the transcriptional regulation of CYP gene expression, with the mRNA
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levels of CYP2B6, CYP2C9 and CYP2D6 increased following over-expression of 
C/EBPa in HepG2 cells (Jover et al. 1998). In addition, as discussed earlier, a 
putative binding site for CEPBa/HNF3 in the proximal promoter of CYP3A4 
conferred activation of CYP3A4 by glucocorticoids, suggesting that C/EBPa may be 
involved in response to fluctuating chemical levels (El-Sankary et al. 2002). This 
work was expanded by experiments showing that C/EBPa and HNF3y were also 
involved in the basal expression of CYP3A4 by binding to the distal promoter 
(Rodriguez-Antona et al. 2003); furthermore putative transcription factor:DNA 
interaction sites for HNF3, and C/EBPa were later identified in the proximal 
promoter of CYP3A4, modulating the xenobiotics response of this gene (Bombail et 
al. 2004).
1.2.2 Role of ligand-activated transcription factors
A central feature of genes whose protein products are involved in the ADME of 
chemicals is that their expression levels can be altered (Goodwin et al. 2002). Such a 
feature is required to allow an efficient response to changes in chemical levels within 
the body, increasing production of proteins that help to remove increased level of 
specific chemicals, and then returning to normal after the chemical stimulus has been 
removed. This activation is controlled to a large extent by a family of ligand-activated 
transcription factors (LATFs), which can be ‘switched-on’ by chemicals, and bind to 
response elements within the regulatory regions of genes involved in ADME and 
activate transcription.
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1.2.2.1 Structure of LATFs
All ligand-activated transcription factors have a number of shared features. These 
include a ligand binding domain, a DNA binding domain, and an N-terminal region 
composed of the variable A-B motif, which contains positive transcriptional activity 
(AF-1) which is ligand-independent but may interact with co-activators (Mclnemey et 
al. 1996; Bourguet et al. 2000; Leo and Chen 2000). Figure 1.1 shows the general 
structure of nuclear receptors.
Figure 1-1 Schematic representation of a nuclear receptor
(Taken from Bourguet et al, 2000)
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Region C represents the DNA binding domain, allows the binding of the receptor to 
response element within promoter of target genes. The N-terminal region composed 
of the A-B region and contains the ligand-independent transactivation domain (AF-1). 
The C-terminal region comprises the E region and F region. Ligand binds to receptor 
through ligand binding domain contained in the activation function 2 (AF-2). AD 
domain allows the dimerization and binding to co-activator or co-repressor. The 
funetion of the F region is not known. The C and E domains are linked by the D 
region.
The C region represents the highly conserved DBD, while the C-terminus contains the 
E region, the LBD that comprises the ligand-dependent activation function 2 (AF-2) 
and plays a critical role in transcriptional activation. The LBD consists of 10 a-helical
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segments (Bourguet et al. 2000). The binding of ligand results in conformational 
change of the LBD, and allows binding of co-activators or co-repressors. In addition, 
the C-terminal region contains an AD domain for dimerization (Leo and Chen 2000; 
Watkins et al. 2001). The DBD is composed of two sub domains called zinc fingers, 
which are responsible for interaction with DNA (Hu and Lazar 2000). The DBD and 
the LBD are linked via the hinge region D, and the F domain is variable and its 
function is currently not known. A region between C and D is the nuclear localisation 
signal by which the receptor is translocated to the nucleus.
Nuclear receptor when activated by a ligand, translocates to the nucleus to form a 
dimer with another nuclear receptor molecul, forming either a homodimer or 
heterodimer. The complex binds to response element within target genes and induces 
transcriptional activation and protein synthesis. Figure 1.2 shows the general function 
of a nuclear receptor
Figure 1-2 Diagram showing general function of nuclear receptors in living cells.
Cytoplasm Protein
mRNA
Nucleus
mRNA
Coding regionPromoter
Gene
Ligand (L) enters the cell and binds to receptor (R). The activated receptor 
translocates to the nucleus and associate with a dimmer partner (D). The complex 
binds to response element contained within promoter region of target genes and 
transactivate transcriptional activity.
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1.2.2.2 Aryl hydrocarbon receptor (AhR)
AhR expression is ubiquitous in the body, with inactive AhR (e.g. with no 
ligand/agonist present) associated with heat shock protein 90 (HSP90) in the 
cytoplasm (Perdew 1988). Upon ligand binding, a conformational change occurs, and 
HSP90 is released and the nuclear localization signal (NLS) revealed. AhR may then 
translocate to the nucleus, where it forms a heterodimer with the aryl hydrocarbon 
receptor nuclear translocator (ARNT) binds to its response element (AhREs) in the 
regulatory regions of target genes and activates transcription (Gonzalez and 
Femandez-Salguero 1998). Ligands for the AhR include polycyclic aromatic 
hydrocarbons (PAH) such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 
polychlorinated biphenyls (PCB) (Gonzalez and Femandez-Salguero 1998). As many 
of these chemicals are bioactivated by the AhR target genes CYPlAl and CYP1A2 to 
form highly reactive intermediates, exposure to PAHs and PCBs is often associated 
with increased rates of carcinogenesis (Femandez-Salguero et al. 1995). In addition to 
regulating expression of CYP genes, AhR is also involved in the transcriptional 
activation of several phase 11 enzymes, including UDP-glucuronosyltransferase and 
glutathione S-transferase family members, which also play a role in the AhR- 
mediated handling of pro-carcinogenic chemicals within the body (Hankinson 1995). 
AhR has also been shown to play an important role in maintaining normal body 
physiology, with AhR null mice showing deficiencies in the immune system, and 
heart hypertrophy (Femandez-Salguero et al. 1997). In addition, retinoic acid levels 
are elevated in AhR null mice, suggesting that the AhR may be involved in the 
metabolism of retinoic acid (Andreola et al. 1997). Such data implicates AhR in both 
endobiotic and xenobiotic metabolism, suggesting this receptor possess roles in both
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toxicity and maintaining the cell homeostasis (Gonzalez and Femandez-Salguero 
1998).
1.2.2.3 Farnesoid X receptor (NR1H4)
Famesoid X receptor (FXR) is a nuclear receptor known to be a bile acid sensor 
(Makishima et al. 1999). It is expressed in the liver, intestine and kidney (Forman et 
al. 1995) and forms a heterodimer with the RXRa upon activation by bile acids. This 
heterodimer binds to an inverted repeat with one separating nucleotide (IRl) within 
the regulatory regions of target genes (Makishima et al. 1999; Pineda Torra et al.
2003).
FXR is involved in the regulation of the bile salt biosynthesis. The receptor down 
regulates the expression of the enzyme involved in the bile salt biosynthesis, namely 
cholesterol 7a hydroxylase (CYP7A1) (Makishima et al. 1999). However, the action 
of the FXR towards its target gene CYP7A1 appears to be indirect. FXR induces the 
expression of the small heterodimer partner (SHP), which forms a heterodimer with 
the orphan nuclear receptor the liver receptor homolog 1 (LRH-1), and the 
heterodimer suppresses the transcriptional activation of the LRH-1 towards its target 
genes for bile acids synthesis, CYP7A1 and CYP8B1 (Goodwin et al. 2000; Lu et al. 
2000).
FXR also induces the expression of the phase II dmg metabolising enzymes including 
UGT2B4 (Barbier et al. 2003b) and the SULT2A1 (Song et al. 2001).
FXR also mediates the uptake, excretion and re-absorption of the bile acids back to 
the liver. This is achieved by the induction of OATP-8, a multispecific uptake system 
for organic anions, xenobiotics, and peptides (Jung et al. 2002), the induction of the 
membrane transporters the hepatic canalicular bile salt export pump (BSEP) (Plass et
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al. 2002). FXR also induces the human MDR-3 mediating the phospholipids secretion 
into bile (Huang et al. 2003) and ileal bile acid binding protein (I-BABP), a protein 
for the transport of the bile salt in the intestine back to the liver (Grober et al. 1999). 
FXR as well as the PXR and CAR regulate the human and rodents MRP-2 gene by 
binding to its proximal promoter to an ER-8 (Kast et al. 2002)
Overall, the FXR plays an important role in maintaining bile acid homeostasis in the 
body, by repressing their biosynthesis, inducing their conjugation, and their 
elimination.
1.2.2.4 Peroxisome proliferator activated receptor a  (NRICI)
The peroxisome proliferator-activated receptors (PPARs) are involved in the 
expression of genes involved in lipid metabolism (Francis et al. 2003). Peroxisomes 
are small cytoplasmic organelles that perform both p-oxidation of fatty acids and 
cholesterol metabolism (Gorton et al. 2000). There are three PPAR isoforms: PPAR 
a , PPARP or 6 and PPARy. PPARa is the major family member, and plays a role in 
fatty acid metabolism in several organs, particularly in the liver, kidney and intestine, 
where it is highly expressed (Gorton et al. 2000). PPARs forms a heterodimer with 
RXRa when activated, with the resultant complex binding to an imperfect direct 
repeat of AGGTGA separated by one nucleotide (DRl) (Johnson et al. 2002).
PPARa is activated by endogenous ligands, fatty acids, both saturated and 
unsaturated fatty acids, with a preference for higher acyl chain length species. 
Xenobiotic ligands for PPARa include hypolipidemic drugs such as the fibrates, as 
well as some herbicides, plasticizers and food flavourings (Francis et al. 2003).
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PPARy shows a much more restricted expression profile, being expressed 
predominantly in adipose tissues, intestine and spleen (Francis et al. 2003). Its major 
physiological role is in regulating adipocyte differentiation, with polyunsaturated fatty 
acids as its major endogenous ligands (Corton et al. 2000). In contrast to the selective 
expression of both PPARa and PPARy, PPARp/ô is expressed ubiquitously (Inoue et 
al. 1998). The exact role of PPARp/ô is still a matter of debate, although a role in 
embryo implantation has been postulated (Lim et al. 1999).
Rodents exposed to peroxisome proliferators are subject to hepatocarcinogenesis in 
long term studies, suggesting a role for this receptor in regulating liver growth 
(Corton et al. 2000). Peroxisome proliferators are still used today, and in fact human 
exposure is relatively frequent: How can this be with a known effect of carcinogenesis 
in rodents? The high levels of PPARa in rodents compared to humans may be 
responsible for species differences in peroxisome proliferation and cancer (Gonzalez 
2002), with humans expressing much lower levels (Palmer et al. 1998). There has 
also been shown to be species difference in the effect of PPARa-activation, with 
increased fatty acid oxidation but not peroxisome proliferation occurring in humans 
(Francis et al. 2003).
In addition to stimulation of p-oxidation, PPARa has also been implicated in the 
regulation of the human SULT2A1 gene (Fang et al. 2005), human UGT2B4, murine 
UGT2B (Barbier et al. 2003a), and cholesterol 7a-hydroxylase (CYP7A1) and sterol 
27-hydroxylase (CYP27) (Post et al. 2001). Taken together, it is clear that PPARa 
regulates several endogenous processes, including bile and cholesterol metabolism, 
and in doing so its functions overlap with those of the pregnane X receptor (section 
1.2 .2 .8)
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1.2.2.5 Vitamin D Receptor (NRlIl)
The vitamin D receptor (VDR) receptor is a member of the super family of steroid 
receptors and forms a heterodimer with RXRa in response to its endogenous ligand 
la,25-dihydroxy vitamin D3 (Pascussi et al. 2003). This receptor shows high 
sequence similarity with the PXR in the DNA binding domain (DBD) (64%) but not 
the ligand binding domain (LBD) (37%), suggesting similar target genes, but different 
activating ligands. Indeed, activated VDR has been shown to bind to the same 
response element as PXR and CAR in the CYP3A4 (ER6, DR3), CYP2B6 (DR4) and 
CYP2C9 (DR4) gene promoters (Schmiedlin-Ren et al. 2001; Drocourt et al. 2002; 
Pascussi et al. 2003). Due to this shared use of binding sites, VDR may induce the 
expression of the drug metabolising enzyme CYP3A4 in caco-2 cells and in human 
hepatocytes in the presence of its ligand la,25-dihydroxyvitamin D3 (Schmiedlin- 
Ren et al. 2001), through binding to the ER-6 element in the proximal promoter 
(Thummel et al. 2001). These show that the VDR may regulate drug metabolising 
enzymes, constituting a potential drug-drug interaction, with altered first pass 
metabolism of a co-administered drug in the intestine limiting its bioavailability.
Although the active form of the vitamin D is not metabolised by CYP3A4, a recent 
report showed that CYP3A4 is involved in the 25 hydroxylation of vitamin D (Gupta 
et al. 2004a), demonstrating an important role for CYP3A4 in synthesising the active 
form for the vitamin D.
Although the LBD of VDR is different from that of the PXR, both receptors are 
activated by lithocholic acids, and regulate the expression of the CYP3A enzyme, an 
enzyme involved in the hydroxylation of the bile acids (Makishima et al. 2002;
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Pascussi et al. 2005), suggesting that these two receptors may have some functional 
redundancy.
Long-term treatment of patients with phénobarbital causes osteomalacia, a bone 
demineralisation disease (Dent et al. 1970): This effect may be mediated by PXR. 
Indeed, PXR induces the expression of the 25-hydroxy vitamin D-24-hydroxylase 
(CYP24) by binding to its promoter (Pascussi et al. 2005).
Taken collectively, homeostasis of vitamin D is partly under the regulation of the drug 
metabolising enzyme CYP3A4 and the PXR, whereby CYP3A4 increases the active 
form of the vitamin D, and the PXR induces its hydroxylation.
1.2.2.6 Constitutive androstane receptor (NR1I3)
The constitutive androstane receptor (CAR) is a LATF that can be termed an orphan 
receptor, in that, like PXR, no endogenous ligand has been identified to date 
(Honkakoski et al. 1998b). However, in contrast to PXR, and indeed almost every 
other LATF, CAR is constitutively active in cell lines, and is therefore alternatively 
known as the Constitutive Active Receptor (Sueyoshi and Negishi 2001). The cellular 
location of CAR is a matter of debate, with both nuclear and cytoplasmic locations 
having been suggested (Kawamoto et al. 1999). However, it is clear that CAR can 
bind and activate target genes, as a heterodimer with RXRa, in the absence of any 
ligand; this is usually prevented by the presence of bound androstane, a CAR 
antagonist (Baes et al. 1994). CAR has been shown to be expressed in liver, intestine, 
heart, muscle, kidney, and lung (Baes et al. 1994).
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CAR is activated by a diverse range of xenobiotics, including 1,4-bis (2-(3,5- 
dichloropyridoxyloxy)) benzene (TCPOBOP) and phénobarbital, as well as 
endogenous chemicals such as bilirubin (Saini et al. 2005). Interestingly, whereas 
TCPOBOP activates CAR via a traditional binding mechanism, both phénobarbital 
and bilirubin have been shown to not physically bind to CAR, but can activate the 
receptors and cause nuclear translocation (Saini et al. 2005).
CAR binding to regulatory regions of target genes appears to occur at a number of 
different sites. Activation of CYP2B genes occurs through binding to an imperfect 
DR-4 site within the phénobarbital response element (PBRE) (Honkakoski and 
Negishi 1997; Honkakoski et al. 1998b). However, CAR has also been shown to be 
capable of binding to the ER6 normally bound by PXR within the proximal promoter 
of CYP3A4 (Sueyoshi et al. 1999; Tzameli et al. 2000; Xie et al. 2000b). The DNA 
binding domain (DBD) of CAR has 66% identity with the DBD of the PXR, 
presumably allowing promiscuity with respect to target response elements (Blumberg 
et al. 1998).
In addition to the ability of CAR to show promiscuity in its choice of DNA response 
elements, binding to sites usually associated with PXR binding, CAR has also been 
shown to share some ligands with PXR. Both phénobarbital and clotrimazol are 
ligands for both PXR and CAR (Moore et al. 2000b), although it should be noted that 
this is not always true, with CAR knockout mouse being refractory to the effects of 
TCPOBOP, suggesting that this latter ligand is CAR-specific (Wei et al. 2000).
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1.2.2.7 The glucocorticoid receptor alpha (GRa, NR3C1)
The glucocorticoid receptor alpha (GRa) is a steroid receptor, and like the AhR is 
sequestered in the cytoplasm, associated with heat-shock protein 90 when inactive 
(Leo and Chen 2000). Upon binding of a ligand, heat-shock protein dissociates from 
the receptor and GRa translocates to the nucleus. However, in contrast to AhR, GRa 
functions as a monomer, with no equivalent of ARNT binding to the activated 
receptor (Freedman 1992). Interest in GRa with respect to target genes involved in 
chemical ADME has existed because of a seeming paradox: No consensus binding 
site for GRa has been identified in the CYP3A4 regulatory regions, despite the fact 
that treatment of hepatic cells with dexamethasone induces the expression of CYP3A4 
(Pascussi et al. 2000a), and the cotransfection of the expression plasmid for GRa 
increases the expression of CYP3A4 (El-Sankary et al. 2000). Several lines of 
evidence showed that the CYP3A enzymes were induced in vivo by glucocorticoids:
The assessment of the ratio of urinary 6 beta hydroxycortisol to cortisol permitted to 
show that CYP3A4 expression follows a diurnal activity mirroring the levels of 
hydrocortisone (reviewed in (Pascussi et al. 2003)), and the metabolic ratio also 
increased in the presence of rifampicin (Kovacs et al. 1998). The eiythromycin breath 
test has also been used to detect the induction of CYP3A by rifampicin and 
dexamethasone and inhibition by ketoconazole and troleandomycin (Wrighton et al. 
2000).
Further confusion was provided by the fact that CYP3A gene activation by 
glucocorticoids was not inhibited by the classical antiglucocorticoid PCN. Also, the 
induction of CYP3A expression by glucocorticoids was maintained in GRa null mice 
(Schuetz et al. 2000). These two latter pieces of evidence suggested a non-GRa 
mediated activation of CYP3A genes by glucocorticoids. The identification of another
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LATF, the pregnane-X-receptor (PXR; section 1.2.2.8) has resolved this apparent 
paradox (Bertilsson et al. 1998; Kliewer et al. 1998).
A role for GRa in transcriptional activation of CYP3A genes still exists however, 
although via an indirect mechanism. GRa may activate transcription of several 
LATFs, including PXR, RXRa and CAR, in the presence of sub micro molar 
concentrations of dexamethasone, increasing the levels of these receptors, and thus 
also the level of their target genes, including CYP3A4, CYP2B6 and CYP2C8/9 
(Pascussi et al. 2000a; Pascussi et al. 2000b). This effect of GRa on the expression of 
PXR, CAR and RXRa occurs at low concentrations of glucocorticoids, with higher 
concentrations being required to activate PXR molecules, and in turn CYP3A gene 
expression (Pascussi et al. 2003).
1.2.2.8 Pregnane x receptor PXR (NR1I2)
The Pregnane X receptor (PXR) also termed the pregnane activated receptor (PAR) or 
steroid X receptor (SXR), is a LATF activated by naturally occurring pregnanes and 
was initially identified in mouse liver (Blumberg et al. 1998; Kliewer et al. 1998). The 
PXR has subsequently been identified in a range of mammals including human, rabbit 
and rat (Bertilsson et al. 1998; Lehmann et al. 1998; Zhang et al. 2001) and most 
recently in the non-human vertebrate teleost fish Takifugu rubripes (pufferfish) in gut, 
heart, liver and ovary (Maglich et al. 2003). PXR is initially expressed at very low 
levels in the mid-foetal liver, and this expression increases during perinatal and adult 
life (Masuyama et al. 2001). In addition to the liver, PXR is also highly expressed in 
the intestine as well, mirroring the expression of its target genes, such as the CYP3A
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family members (Blumberg et al. 1998; Kliewer et al. 1998; Lehmann et al. 1998; 
Nishimura et al. 2004).
PXR is a central mediator of CYP3A gene expression, being activated by many of the 
xenobiotics that induce CYP3A expression, and which are substrates for CYP3A 
(Blumberg et al. 1998; Kliewer et al. 1998). This role as a central mediator of CYP3A 
activity is further confirmed by studies in the PXR knock out mouse, which is non- 
responsive to the CYP3A inducers dexamethasone and PCN (Xie et al. 2000a; 
Staudinger et al. 2001; Xie et al. 2001).
Interestingly, PXR is also highly expressed in the human stomach, some parts of the 
brain, and to a lesser extent in the heart and bone marrow (Lamba et al. 2004), 
regions, that are not usually considered CYP3A-rich. This suggests that the PXR is 
involved in the regulation of other biochemical pathways, which are CYP3A- 
independent. For instance, in the brain PXR is activated by neurosteroids, which may 
have a role in mediating the neurosteroid pathway, involved in memory, anxiety and 
depression (Lamba et al. 2004). It could also be a protective effect in the brain against 
drug accumulation by stimulating CYP3A4 and MDR-1 gene expression under 
physiological and stress situations (Lamba et al. 2004). PXR and CYP3A1 are 
increased in mouse liver and ovaries during pregnancy suggesting that the PXR may 
regulate steroid hormone metabolism during pregnancy (Masuyama et al. 2001). 
Taken collectively, the above data show that the role of PXR is extended to other 
tissues, where it could play important roles in mediating different metabolic pathways 
and providing protective measures for these organs.
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In a similar fashion to CAR, PXR may bind to a number of different DNA response 
elements. Firstly, PXR may bind (as a heterodimer with RXRa) to an ER6 within the 
CYP3A4 proximal promoter (Kliewer et al. 1998; Lehmann et al. 1998). Secondly, 
PXR binds a DR3 element within the CYP3A4 enhancer, the xenobiotic-responsive 
enhancer module (XREM) located approximately 8 kb upstream of the transcription 
start site (Goodwin et al. 1999). Thirdly, PXR may bind to a DR4 element within the 
CYP2B6 proximal promoter, sharing this site with CAR/RXR (Goodwin et al. 2001). 
The proximal ER6 element in the CYP3A4 promoter coordinates the distal-mediated 
activity of the DR3 for maximum response (Goodwin et al. 1999; Goodwin et al. 
2002), regulating both basal and xenobiotic-mediated gene expression of CYP3A4 
(Bombail et al. 2004).
PXR has been shown to be located in cytoplasm in the absence of ligand, bound to the 
constitutive active/androstane receptor retention protein (CCRP) and HSP90 in 
HepG2 cells (Squires et al. 2004). This latter group showed that removal of CCRP in 
HepG2 cells with siRNA attenuated activation of a reporter gene assay after exposure 
to PCN or rifampicin, showing that this factor plays a central role in the activation of 
the mouse and the human PXR (Squires et al. 2004). Localization of PXR is, as with 
CAR, equivocal with differing results seen in mouse liver, mouse primary hepatocytes 
and cell lines. In mouse liver and primary hepatocytes, unliganded PXR is retained in 
the cytoplasm as a complex with CCRP and hsp90, but in cell lines, PXR appears to 
exist in the unliganded state in the nucleus (Squires et al. 2004). What is clear 
however is that in human PXR protein, a nuclear localisation signal is important for 
the nuclear translocation of PXR, as is seen for CAR (Kawana et al. 2003).
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1.2.2.8.1 Targets genes for PXR
PXR activates transcription of approximately 40 genes whose products are 
responsible for the metabolism and elimination of both endo- and xenobiotics. 
Foremost amongst these target genes is CYP3A4, the major drug metabolising 
enzyme in human liver, and PXR is regarded as a central regulator of CYP3A4 
expression (Bertilsson et al. 1998; Xie et al. 2000a).
In addition to the CYP3A family, PXR has been reported to be involved in the 
expression of other phase I metabolism enzymes, phase II drug metabolism enzymes 
as well as enzymes involved in the metabolism of endobiotics. Table 1.5 shows target 
genes for PXR.
Another important aspect of ADME is access to cells through membrane transporter 
proteins, and PXR has been shown to regulate the expression of a number of these. 
These include the liver sinusoidal transporter sodium-independent organic anion 
transporter 2 (OATP-2), which mediates the hepatic uptake of endogenous and 
exogenous compounds (Guo et al. 2002; Frank et al. 2005), the multidrug resistance 1 
gene (MDR-1) which encodes the P-glycoprotein (Geick et al. 2001), and the 
multidrug resistance-associated protein MRP2 (Kast et al. 2002).
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PXR is an important regulator of endogenous metabolites, including bile acid 
homeostasis. This is achieved by suppressing their synthesis, inducing their uptake, 
their metabolism and their elimination. To this end, lithocholic acid (LCA) has been 
reported to be an activator of the human and mouse PXR (Staudinger et al. 2001; Xie 
et al. 2001). Once activated, the receptor represses the expression of CYP7A1, an 
enzyme responsible for the synthesis of bile acids and induces CYP3As responsible 
for their hydroxylation (Staudinger et al. 2001; Xie et al. 2001). The uptake of bile 
acids is mediated via the 0ATP2, which is a target gene for PXR (Guo et al. 2002) 
and their elimination is via MRD-1, also a target gene for PXR (Geick et al. 2001). 
The small heterodimer partner-1 (SHPl) gene has also been reported to be a target 
gene for PXR, contributing to the down-regulation of CYP7A1, adding a second 
PXR-dependant pathway by which PXR can suppress expression of CYP7A1 (Frank 
et al. 2005). PXR may also negatively regulate gene expression under normal 
physiological conditions, as the protein products for CYP7A1 and CYP8B1, both 
enzymes regulating the bile acids synthesis, are up regulated in PXR knock out mice 
(Stedman et al. 2005). Taken collectively, PXR plays the role of a sensor for 
endogenous bile acids in human and mouse, and regulates their homeostasis in the 
body, giving an important role for PXR in monitoring the changes in homeostasis in 
both normal health and disease.
PXR protects the hepatocytes from increased levels of bilirubin in blood suppressing 
the expression of the organic anion transporting polypeptide-C (OATP-C) (Stedman 
et al. 2005).
PXR target genes not only include enzymes and membrane transporters, but may be 
involved in the regulation of the other receptors like the AhR receptor (Maglich et al.
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2002), thereby providing an indirect role for PXR in the metabolism of the polycyclic 
aromatic hydrocarbons and polychlorinated biphenyls.
The above information demonstrates the complexity of the body system for 
interpreting and responding to changes in chemical levels. Interactions between 
LATFs, both in the presence and absence of, often shared ligands may activate/repress 
a large number of target genes, often shared by several receptors. This provides great 
flexibility in the system, with, for example, PXR activating expression of the drug 
transporter gene MRP2 in the presence of rifampicin, to increase its excretion, but 
repressing the expression of the same gene during cholestasis as a protective effect 
(Stedman, Liddle et al. 2005).
Although, the role of PXR is known to detoxify chemicals and regulate endogenous 
homeostasis, it may be a source of mediating toxicity. The fact that PXR responds to a 
large range of molecules, and induces a substantial number of genes involved in the 
metabolism and elimination of drugs may lead to drug-drug interactions, which can 
result in the loss of therapeutic effect or an increase in toxicity. The antidepressant 
herbal St John’s wort, an activator of the PXR and inducer of the CYP3A4 enzyme, 
increases the metabolism of CYP3A4 substrates, including oral contraceptives, the 
HIV protease inhibitor indinavir and cyclosporine A (Moore et al. 2000a) leading to 
the loss of effect of their therapeutic effects. Aflatoxin B1 (a fungal metabolite) 
metabolism by CYP3A4 may result in the generation of cancers, when the equilibrium 
between phase I and II metabolism is lost, by a co-adminstred drug resulting in over 
induction of CYP3A4 (Plant 2003). PXR and CAR share some ligands and activate a
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few common genes, including CYP3As (Sueyoshi et al. 1999; Xie et al. 2000b), 
MRP2 (Kast et al. 2002) , CY2B (Goodwin et al. 2001).
1.2.2.8.2 Ligand activation
Reporter gene assays have been used to investigate for potential activators of PXR. 
Stable transfections for the human PXR (Lemaire et al. 2004) and transient 
transfections (El-Sankaiy et al. 2001; Kobayashi et al. 2004) have been shown to 
detect potential activators of the PXR. Goodwin et al, used an expression plasmid 
containing the mouse PXR LBD fused to the DBD of the GAL4 yeast transcription 
factor, and co-transfection into CV-1 cells with the reporter plasmid containing five 
copies of the GAL4 DBD linked to chloramphenicol acetyltransferase (CAT) reporter, 
thereby identifying activators for the mouse PXR (Goodwin et al. 2002).
In our laboratory, experiments using reporter gene assays with the human PXR co­
expressed with a CYP3A4 promoter construct, has shown that different drugs possess 
different inductive ability. For instance, simvastatin has been shown to be a strong 
activator of the CYP3A4, with the activation ability of 200, rifampicin as a medium 
activator with activation ability of 32, compared to phénobarbital with activation 
ability of only 4 (El-Sankary et al. 2001).
Table 1.6 shows some activators for the PXR, they include, drugs, endogenous 
compounds and environmental chemicals.
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Table 1-6 Ligands activators of the PXR and their functions
Drug Function Reference
Pregnenolone,pregnanes Natural steroid (Bertilsson et al. 1998)
Cortisol Natural steroid (Bertilsson et al. 1998)
Pregnenolone Natural steroid (Kliewer et al. 1998)
Progesterone Natural steroid (Kliewer et al. 1998)
Progesterone ,17(3-estradiol Natural steroid (Bertilsson et al. 1998)
Lithocholic acid Emulsifiant (Staudinger et al. 2001)
Rifampicin Antibiotic (Bertilsson et al. 1998)
Clotrimazole Antifungal (Bertilsson et al. 1998)
Dexamethasone Synthetic steroid (Pascussi et al. 2000a)
Hyperforin Antidepressant (Moore et al. 2000a)
SR12813 Hypolipideamic (Moore et al. 2000a)
Lindane, DDT Pesticides (Lemaire et al. 2004)
PCN Antiglucocorticoids (Kliewer et al. 1998)
Phénobarbital Antiepileptic (El-Sankary et al. 2001)
EDC Estrogen like (Masuyama et al. 2000)
Eiythromycin Macrolide antibiotic (Kobayashi et al. 2004)
Vitamin E Antioxidant (Landes et al. 2003)
Dehydroepiandrosterone Neurosteroid (Lamba et al. 2004)
Nicotine Tobacco constituent (Lamba et al. 2004)
Pesticides Kills insects (Coumoul et al. 2002)
Nifedipine Calcium channel bloker (van Giersbergen et al. 2002)
Ritonavir,amprenavir Protease inhibitor (van Giersbergen et al. 2002)
Phenytoin, carbamazepine Anticonvulsive (Vignati et al. 2004)
Lovastatin Hypocholesterolemic (Landes et al. 2003)
Troglitazone Antidiabetic (Landes et al. 2003)
Vitamin K2 Bone mineralisation (Tabb et al. 2003)
Spironolactone Diuretic (Vignati et al. 2004)
PCBs Envirenmental toxicant (Tabb et al. 2003)
Guggulsterone, Hypolipidemic (Brobst et al. 2004)
Mifepristone (RU486) Antiprogesterone
antiglucocorticoid
(Brobst et al. 2004)
Paclitaxel Anticancer drug (Synold et al. 2001)
Efavirenz Anti HIV (Landes et al. 2003)
Glucocrticoids Steroid hormone (Vignati et al. 2004)
Omeprazole Anti ulcer (Brobst et al. 2004)
Troleandomycin Macrolide antibiotic (Brobst et al. 2004)
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In addition to xenobiotics, PXR may be activated by a number of endogenous 
chemicals, including bile acids and epoxycholesterol (Sonoda et al. 2005). In PXR 
null mice, a diet high in cholesterol and cholic acids, leads to premature death, 
compared to the wild type, showing the importance of PXR in cholesterol metabolism 
(Sonoda et al. 2005). The mechanism by which PXR could protect against the high 
levels of cholesterol is not clear yet, the continuous research on novel PXR target 
genes could answer the question. PXR is capable of maintaining the body’s 
homeostasis by inducing genes for the uptake, metabolism, conjugation, and 
elimination, making a PXR a central sensor for, both the endobiotics and xenobiotics, 
to ensure their normal levels in the body. Figure 1.3 shows the different roles of PXR 
in the body, and how it can act as a central metabolic/xenobiotic sensor.
Figure 1-3 Diagram highlighting the role of PXR.
Regulatory elements?
PXR gene
Receptor
Phase I enzymes
Phase II enzymes
Receptors
Ligands: exogenous: drugs, pollutants etc 
endogenous: bile acids 
steroids derivatives,etc...
Endobiotic metabolising enzymes
SHPl
Membrane 
tran snorters
PXR upon activation by ligands induces or represses the expression of target genes for 
phase I and phase II drug metabolising enzymes and membrane transporters. This 
results in a synchronised response to a chemical insult and helps maintain cellular 
homeostasis.
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1.2.2.8.3 Transcriptional activation of PXR
Pascussi et al. reported that micromolar concentrations of dexamethasone increases 
the mRNA for both PXR and RXRa (Pascussi et al. 2000a). The increase in these two 
receptors was shown to be via the glucocorticoid receptor, as the induction was 
ablated by the anti-glucocorticoid RU486 (Pascussi et al. 2000a). In addition, pre­
treatment of human hepatocytes with an inhibitor of protein synthesis cycloheximide, 
did not affect the increase of the PXR mRNA in response to the dexamethasone, nor 
did treatment with actinomicyn, an inhibitor of transcription, influence the decay of 
the PXR mRNA, demonstrating that dexamethasone does not influence mRNA 
stability. These observations have led to the conclusion that PXR is regulated at the 
transcriptional level, in part by GRa (Pascussi et al. 2000a). Zhang et al reported an 
induction in rat PXR mRNA by two non-CYP3A4 inducers, isoniazid and 
perfluorodecanoic acid (PFDA) (Zhang et al. 1999). These observations suggested 
that not all activators of PXR are capable of increasing the mRNA levels for PXR. 
Interestingly however, rat hepatocytes exposed to clofibrate or PFDA, two 
peroxisome proliferator chemicals, produced increased levels of PXR mRNA and 
protein levels. Treatment of rat hepatocytes with actinomycin D and puromycin, 
which inhibit mRNA synthesis and protein translation respectively, showed an 
abolition of the PXR mRNA and protein levels, demonstrating that PXR is not 
increased via increasing protein stability (Ma et al. 2005). This data is particularly 
interesting in light of the fact that neither clofibrate nor PFDA are PXR ligands, but 
PPARa ligands, suggesting a more complex relationship between LATFs than was 
previously thought.
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1.2.2.8.4 Structural characteristics of the human PXR
The LED for the PXR is unusual, and is responsible for the ability of PXR to be 
activated by a wide-range of ligands. For example, the PXR LED contains a flexible 
loop, allowing alterations in the LED cavity size to accommodate different sizes of 
molecules (Watkins et al. 2001). PXR contains two additional P strands, which 
together with the three other p strands form a wall that frame one side of the ligand 
binding cavity, making the PXR structure unique (Watkins et al. 2003b). The hPXR 
LED pocket is hydrophobic, conferred by the presence of multiple polar residues in 
the LED. These polar residues are important not only in creating the correct 
environment for ligand binding in general, but also appear to confer the specificity 
between human and mouse PXR ligands (Watkins et al. 2001). Watkins et al, reported 
that mutation of four polar residues in the LED of the mouse PXR to those seen in the 
human PXR LED resulted in activation of mouse PXR by the human PXR-specific 
ligand rifampicin (Watkins et al. 2001).
Unlike the LED, the DED of PXR is highly conserved between species (Honkakoski 
and Negishi 2000). The NLS (nuclear localization sequence) located in the DED and 
the XRS (xenochemical response sequence) located in the LED of PXR are required 
for the nuclear translocation of the mouse PXR (Squires et al. 2004). Human PXR 
requires only the NLS for nuclear translocation, with the NLS being recognised by the 
nuclear import protein importin a , leading to transport of PXR to the nucleus 
(Kawana et al. 2003).
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1.2.2.8.5 Splice variants of PXR
Alternative splice variants for nuclear receptors can be due to either alternative 
promoter usage or exon splicing, with the latter being the more common mechanism 
(Keightley 1998). Splice variants can result in altered patterns of expression, gene 
targets, biological functions (gain or loss of function), DNA-binding, intracellular 
binding interactions with other proteins, and sub cellular localization (Keightley 1998) 
of the LATF in question.
In normal human and cancerous breast tissue, the wild type PXR is expressed in 
addition to the splice variant, PXR2, the latter containing a deletion of 111 nucleotides 
resulting in the deletion of 37 amino acids in the ligand binding domain (Dotzlaw et 
al. 1999). This PXR2 variant is most likely generated by alternative splicing in exon 
5, is the most abundant splice-variant for PXR, and has been detected in 73 human 
livers screened, but representing only 6.7% of total wild type PXR mRNA, suggesting 
it may have little biological impact (Lamba et al. 2004). This variant, which has also 
been detected in the liver and small intestine, demonstrates a decreased basal and 
xenobiotic-activated expression of CYP3A4 (Hustert et al. 2001) and does not 
mediate induction of CYP3A7 or UGT lAs (lA l, 1A3, 1A4) genes after exposure to 
rifampicin (Gardner-Stephen et al. 2004). A similar, but not identical, variant exists in 
mice, with a deletion of 123 nucleotides resulting in a 41 amino acid deletion in the 
ligand binding domain, resulting in a reduced activation profile for the receptor, 
responding to only constitutive pregnane 5P-pregnane-3,20-dione and a reduced 
response to dexamethasone (Kliewer et al. 1998). Human pregnane activated receptor 
2 (hPAR2), identified by Bertilsson et al, in intestine and liver, contains 39 extra 
amino acids at the amino terminal probably due to an alternatively spliced first exon 
(Bertilsson et al. 1998). It was activated to the same extent by the drug rifampicin and
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the natural occurring pregnane 3a-hydroxy-5 (3-pregnane-
ll,20,dione,methanesulfonate, and was capable of inducing expression of both 
CYP3A7 and the UGT lA  isoforms lA l, 1A3 and 1A4 in HepG2 cells (Gardner- 
Stephen et al. 2004).
Seven splice variants reported by Fukuen et al, were differentially expressed in 15 
human liver samples resulting from the cryptic splice of exon 2, 3 or 5, together with 
the previously reported hPAR2 and hPXR2 (Fukuen et al. 2002). The functionality of 
these variant is not known, but it is believed that the interindividual variability of 
CYP3 A4 response is due, in part, to PXR variants, however, the functional impact of 
these splice variants on gene expression in vivo or there frequency of expression are 
unknown at present (Gibson et al. 2002).
1.2.2.8.6 Genetic polymorphisms of PXR
The human PXR contains 9 exons, and is localised on chromosome 3qll-13 (Zhang 
et al. 2001). Single nucleotide polymorphisms (SNPs) in the PXR are thought to be 
potential sources for variation in CYP3A4 induction (Koyano et al. 2004), especially 
since no SNPs in PXREs within the proximal and distal promoter of CYP3A4 have 
been identified to date (Zhang et al. 2001).
Thirty eight single nucleotide polymorphisms have been identified by Zhang et el, but 
the frequency of these were all less than 1%, suggesting that their impact on inter­
individual variation in expression of PXR-target genes may be minimal (Zhang et al. 
2001). Of the identified SNPs, the latter group identified three non-synonymous 
changes in exons 2 and 4 of PXR, named PXR*2, PXR*3 and PXR*4. The PXR*2 
and PXR*3 polymorphisms are located in the activation domain-1 (AF-1) region of 
the PXR, whereas PXR*4 is a R122Q substitution in the DBD. PXR*2 and PXR*3
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polymorphisms do not affect the ability of PXR to activate CYP3 A4 expression, but 
PXR*4 has a significant impact on the CYP3A4 induction by rifampicin resulting in 
decreased DNA binding. However, this latter variant was found only in one Caucasian 
out of twenty, and hence its classification as a true SNP must be questioned. Eleven 
SNPs have been identified in the Japanese population, with being four non- 
synonymous, consisting of the substitution of one amino acid with another one. 
However, the allele frequencies of these SNPs are very low, questioning their overall 
functional importance (Koyano et al. 2002). One variant of potential interest contains 
a substitution of amino acid Arg98 in the DBD to Cyt98, and demonstrates a complete 
loss of binding to the ER-6 and loss of ability to transactivate CYP3A4. This amino 
acid is conserved in human, mouse, rat, and rabbit, and is closely related to the human 
vitamin D receptor and the constitutive androstane receptor, suggesting it plays a 
critical role in protein:DNA interactions for these related LATFs (Koyano et al.
2004).
Hustert et al, screened a group of Caucasian (209) and Africans (37) for PXR 
variations, and reported six mis-sense mutations (Hustert et al. 2001). Three of the 
variants were located in the LBD, and three located in the N-terminal region of the 
PXR. The variants located in the N-terminal did not have an impact on the basal 
activity and drug induction of CYP3A4 activity. The variant located within the LBD 
has a defect in both the basal and/or the induced expression of the CYP3 A4.
Zhang et al have calculated that nucleotide diversity for the PXR is 1 in 15984 base 
pairs of coding sequence in Caucasians: This low frequency, combined with the fact 
that no polymorphisms have been found in the PXR binding site of CYP3A4, 
underlines the strong pressure to maintain functionality of PXR, and hence the 
importance of this receptor (Hamzeiy et al. 2002).
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1.2.2.8.7 Species differences in PXR expression
There are known differences in the induction of rat CYP3A1 and its human 
orthologue CYP3A4 by xenobiotics. For example, rifampicin causes a large induction 
of human CYP3A4 compared to rat CYP3A1, where the response is very weak 
(Kocarek et al. 1995; Barwick et al. 1996). The opposite situation has been observed 
with the synthetic steroid 5-pregnen-3 p-ol-20-one-16a-carbonitrile (PCN), a strong 
inducer of CYP3A1 but not CYP3A4. Obviously such differences in response to 
xenobiotics is of great importance during the process of drug development, 
complicating extrapolation of effects from animal models to the human situation. 
These differences in response to xenobiotics observed between species has been 
shown to be due, at least in part, to differences in PXR activation profiles (Lehmann 
et al. 1998). Xie et al produced humanized mice through a combination of knocking 
out the murine PXR and knocking in the human PXR; humanized mice responded to 
the human-specific PXR ligands, showing induction of PXR target genes such as
 ^ f
CYP3A1 (Xie et al. 2000a). Mutation of important polar amino acids in the mouse 
LBD to those contained within the human LBD also results in activation of the mouse 
PXR by human-specflc ligands, further suggesting that PXR is a central determinant 
in the species-specific response to xenobiotics (Watkins et al. 2001).
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1.2.2.9 Role of co-activators and co-repressors in mediating the transcriptional 
activity of LATFs
Co-activators and co-repressors act as bridging proteins between nuclear receptors 
and the transcriptional machinery, and may enhance or decrease transcriptional 
activation respectively (Gorton et al. 2000).
Co-activators are recruited by nuclear receptors upon binding a ligand, refining the 
action of the activated LATF (McKenna and OMalley 2002). Co-activators bind to 
receptors via a conserved short motif represented by the amino acid sequence LXXLL 
(Heeiy et al. 2001) and they stimulate acétylation of lysine tails on histones, opening 
chromatin structure.
A class of co-activator, the p i60 proteins, possess acetyl transferase activity, and 
comprise the steroid receptor co-activator 1 (SRC-1), transcription intermediary factor 
2 (T1F2) and a gene amplified in breast cancer (AlBl). These factors recruit other co­
activators including CBP/p300, which have the same function of acétylation 
(McKenna et al. 1999). These co-activators function by acetylating lysine residues in 
histone and thus disrupting the interaction between the positively charged histones 
and the negatively charged DNA (McKenna and O'Malley 2002). The link between 
nuclear receptors and the general transcription factor complexes is mediated to a large 
degree by TRAP (thyroid receptor-associated proteins) and DRIP (vitamin D 
receptor-interacting proteins) (Rachez et al. 1998). Another mechanism for chromatin 
remodelling involves the adenosine triphosphate (ATP)-dependent DNA unwinding 
mediated by the complex Swi/Snf (Khavari et al. 1993).
The unligated receptors recruit co-repressors to repress gene expression. There are 
two major co repressors, the nuclear receptor co-repressor (N-CoR) and the silencing 
mediator for retinoid and thyroid receptors (SMRT). These co-repressors recruit
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histone deacetylase to the target gene, resulting in a condensed form of chromatin and 
also interact with general transcription factors to inhibit their action (Watkins et al. 
2003b). Nuclear receptors are repressed in the absence of ligands with the nuclear co­
repressors SMRT and NcoR (Leo and Chen 2000) and have different affinities 
towards there nuclear receptors. For instance, SMRT binds preferentially to the VDR, 
whereas NcoR binds preferentially to the thyroid receptor (TR) (Takeshita et al. 
2002).
SRC-1 binds to and activates the transcriptional activity of the mouse (Kliewer et al. 
1998) and the human PXR (Lehmann et al. 1998). Upon activation of PXR, SRC-1 
binds to the receptor and interacts with histone acetyltransferase (HAT) complexes 
CREB-binding protein CBP/p300 (Watkins et al. 2003a). The interaction of PXR 
with the SRC-1 is ligand dependent (Lehmann et al. 1998; Takeshita et al. 2001; 
Mikamo et al. 2003) and has been shown to be dose dependent (Masuyama et al. 
2000). Another co-activator, the receptor interacting protein 140 (RIP 140) could bind 
to the mouse PXR (Masuyama et al. 2001).
The co-activators play a role in mediating the transcriptional regulation of the PXR 
towards its target genes. PXR mediates the gene transcription of CYP3A4 reporter 
gene, in response to endocrine disrupting chemicals (EDC), steroids, and to a lesser 
extent with the anticancer drugs cisplatin and paclitaxel in endometrial cell cancer. In 
contrast, the anticancer drugs highly induced the MDRl compared to the other 
compounds in the same cell line (Masuyama et al. 2005). This difference in induction 
of CYP3A4 and MDRl in response to PXR ligands is due to differences in 
recruitment of co-activators. The SRCl has been detected on CYP3A4 bound to the
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PXR response element, whereas the amplified breast cancer 1 was detected on the 
MDRl with PXR/RXR (Masuyama et al. 2005). The transcription factor FOXO-1, an 
activator of the gluconeogenesis, is a co-activator of the CAR and PXR mediated 
transcription (Kodama et al. 2004). Interrestingly, the CAR and PXR can be co­
repressor of the FOXO-1 mediated transcription (Kodama et al. 2004).
SMRT binds to the LBD of the PXR and represses its transcriptional activity towards 
human CYP3A4 in the presence or absence of rifampicin (Takeshita et al. 2002). The 
relative balance of the interaction of PXR with SRC-1 and SMRT may well determine 
the activity of this receptor towards its target genes (Takeshita et al. 2002).
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1.2.3 Summary
The ligand-activated transcription factor PXR is a nuclear receptor that is rapidly 
becoming regarded as a central regulator of the body’s response to fluctuating levels 
of both endo- and xenobiotics. It was first identified as the major regulator of the most 
abundant and important human liver drug metabolising enzyme, CYP3A4. PXR has 
been shown to regulate a large range of other enzymes, involved in both phase I and II 
of drug metabolism as well as drug transporters, which may alter drug disposition 
within the body. A large range of chemicals activate PXR, allowing it to respond to 
both endogenous substrates, thus playing a role as a regulator of homeostasis, and 
xenobiotics playing a role in detoxifying/clearing these chemicals from the body.
In the past few years this stimulus-response system has been demonstrated to be 
extremely refined, with PXR activating expression of genes under certain conditions 
and repressing the same genes expression in others. In addition, more and more 
interactions are being discovered between members of the LATF family, which may 
also serve to refine biological responses to chemical stimulii. Perhaps the best 
example of this is interactions between CAR, VDR, GRa and PXR, where overlap 
exists for both target genes and ligands.
Only by understanding how the interaction network of LATFs functions to respond to 
chemical stimulii will it be possible to accurately predict body responses to chemical 
exposure. Such knowledge would be important not only in the development of novel 
therapeutics, but also in the prevention/reduction of adverse drug reactions.
43
1.2.4 Aims of the project
Evidence that PXR is transcriptionally regulated has been well-established (Pascussi 
et al. 2000a), but the actual molecular mechanisms underlying this regulation is not 
well understood. The aim of my project is to delineate the molecular mechanisms of 
the human PXR gene expression to produce a more comprehensive understanding of 
this important transcription factor.
I will achieve this by
• Firstly, in silico analysis of the proximal promoter of the PXR, to identify 
putative binding sites for potential regulatory factors
• Secondly, by the use of reporter gene assay to investigate the functionality of 
these putative binding sites in Huh7 cells
• Thirdly, mutating binding sites for putative factors to investigate their 
biological functionality
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2 CHAPTER: Materials and Methods
2.1 Materials
2.1.1 General chemicals and plasticware
Table 2.1 shows the list of specialised chemicals and materials used and their supplier. 
All other chemicals were purchased from Sigma-Aldrich (USA) and were of 
molecular biology standard.
The radioactivity work was undertaken following the ‘Local Rules for Protection 
Against Ionising Radiation’ published by the University of Surrey Safety Office.
2.1.2 Plasmids
Maps of the plasmids used in this project are shown in appendix. The SEAP basic 
plasmid was purchased from BD Biosciences (USA). The pGR2.1-TOPO was 
purchased form Invitrogen (USA). The hepatocyte nuclear factors (HNF) 3a/3p were 
a gift from Dr Hung Fan (University of California, Irvine, USA). The vitamin D 
receptor (VDR), HNF l a  and HNF4a were a gift from Dr Richard B. Kim (Vanderbilt 
University, Tennessee, USA). Estrogen receptor alpha (ERa), peroxisome proliferator 
activated receptor alpha (PPARa) and glucocorticoid receptor alpha (GRa) were a 
gift from Dr J. Tugwood (Astrazeneca, Macclesfield). Retinoid X receptor alpha 
(RXRa) was a gift from Professor P. Chambon (INSERM, Strasbourg, France), and 
the constitutive activated receptor (CAR) form Professor M. Negishi (NIEHS, USA).
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PXR was a gift from Dr Steven Kliewer (GlaxoSmithKline, Research Triangle Park, 
NC, USA).
Table 2-1 Suppliers of items used in this study
Item Supplier
DNA modifiying enzymes Promega (USA)
Bacterial agar, phosphate buffer saline (PBS) tablets,! Oxoid (UK)
Tryptone, Yeast extract J
Agarose Boehinger Mannhein (Germany)
Bis-acrylamide stock solution 2% w/v,! Scotlab (UK)
Acrylamide stock solution 40% w/v J
DNA oligomer for PCR and EMSA MWG (Germany)
y-32P ATP triethylammonium salt (370 MBq/ml, Amersham Biosciences (USA)
approx 220 TBq/mmol)
Eugene 6 Roche (USA)
DH5a E.coli competent bacteria cells Invitrogen (USA)
96 well Optiplate Canberra Packard (Austria)
Aurora Alkaline Phosphatase Chemiluminescent MP Biomedical (Canada)
Reporter gene Assay Kit
DNA purification (gel extraction, plasmid extraction Qiagen (UK)
Mini and maxi preps)
Disposable pipette tips Alpha Laboratories (UK)
DMEM, Trypsin-EDTA, fetal bovine serum. Invitrogen (USA)
Streptomycin, Penicillin, L-glutamine,
non-essential amino acids
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2.2 Methods
2.2.1 Polymerase chain reaction
2.2.1.1 Primer design
The promoter for PXR was identified using NCBI (National Center for Biotechnology 
Information); Primers were designed using the Vector NTI program to amplify the 
1100 or 2200 kilobases of the 5’ flanking region of the PXR promoter, directly 
upstream of the transcription start site.
Table 2.2 shows the primers used and their characteristics.
Table 2-2 Primers for PCR.
The forward and reverse 1100 primers were used to amplify 1100 base pairs of the 
PXR proximal promoter. The forward and reverse 2200 primers were used to amplify 
the 2200 base pairs of the PXR proximal promoter.
Amplicon Homology Tm Sequence
Forward 1100 1100 bp 100% 54.4 5 ’ CCTTGGGAAGTGCAAATTGG-3 ’Reverse 1100 100% 55.3 5 ’ -AACACTTGGCTTGC AGGCTG-3 ’
Forward 2200 2200 bp 100% 51.6 5’-CCTAGCTGGGCTTGAGAGTG-3’Reverse 2200 100% 55.3 5’-AACACTTGGCTTGCAGGCTG-3’
2.2.1.2 Polymerase Chain Reaction
For initial cloning of the PXR proximal promoter, human genomic DNA that had 
been previously isolated from a blood sample (Dr N.Plant) was used at a stock 
concentration of 51 ng/pl. Primers were used at a concentration of 10 pmol/pl. To
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enhance the PCR product 5.5 M Betaine was added to a working concentration of 
0.55 M.
PCR reaction contained:
1 Ox Guy’s buffer 5 pi
BSA (lOpg/pl) 1 pi
20 mM dNTPs 1.5 pi (0.6mM)
5.5 M betaine 5 pi (0.55M)
Taq polymerase 5 U
DNA 1 pi (equivalent to approximately 50 ng DNA)
Water to 50 pi
Guy’s buffer is composed of 670 pi of 670 mM Tris pH:8.8(lM), 160 pi of 160 mM 
(NH4)2S04(1M), 67 pi of 67 mM MgCl2(lM), 69 pi P-mercaptoethanol (IM) and 34 
pi water.
Samples were placed in the PCR machine (MJ PTC-200 Thermal Cycler, GMI, USA) 
and processed as
94^C for 4 minutes
94^C for 1 minute 
55°C for 30 seconds 
72®C for 4 minutes >
72^C for 10 minutes
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2.2.1.3 Agarose gel electrophoresis
PCR reactions were checked by running agarose gel electrophoresis. Two microliters 
of the PCR product were mixed with 1 pi loading buffer (50% glycerol and 1% w/v 
Orange G dye) and run on 1% w/v agarose gel made in IX TAB buffer (0.04M Tris 
Acetate, 0.0 IM EDTA pH 8.3) containing 0.5pg/ml ethidium bromide at 4-5 V/cm 
until sufficient separation had been achieved. Photographic records were taken under 
UV light with GeneGenius Bio Imaging System, controlled by GeneSnap version 4.01 
software (Syngene).
2.2.1.4 DNA purification from agarose gels
DNA from the band corresponding to the correct size was gel purified using a 
QIAGEN kit for gel purification (Promega), according to the manufacturer’s 
instructions. Briefly, the band was cut from gel with a scalpel, and heated at 50^C in 
buffer QG, (solubilisation buffer, contains guanidine thiocyanate a powerful protein 
dénaturant) to melt the gel. This solution contains a pH indicator to allow optimum 
binding (pH 5). The pH needs to be less than 7.5 and is characterised by a yellow 
colour. This solution was then passed through an affinity column with a silica 
membrane. DNA binds to the silica membrane in the presence of high salt. Traces of 
agarose were removed by another wash with buffer QG and centrifugation. Salts were 
removed by washing with buffer PE containing ethanol, and purified DNA was eluted 
under basic conditions and low salt concentrations using 50 pi H2O.
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2.2.1.5 DNA quantitation
DNA was quantified with a Genequant II RNA/DNA spectrophotometer (Pharmacia 
Biotech). The spectrophotometer was zeroed with a relevant blank (usually water), 
and absorbance at 260 nm was measured.
2.2.1.6 Dephosphorylation of the 5’-ends
If a single-enzyme digest of a vector was carried out that generated compatible Sp­
ends, the terminal phosphate groups were removed using alkaline phosphatase to 
prevent religation of the vector.
1 Unit of alkaline phosphatase and lOX buffer were added to the vector. The reaction 
was left for 30 minutes at 37®C, then another unit of enzyme was added and the 
reaction was left for another 30 minutes at 37^C.
2.2.1.7 Ethanol precipitation
DNA was mixed with 1/10 volume of 3M sodium acetate (NaOAc) and 1 pg tRNA 
and 3 volumes ethanol (stored in freezer). The mixture was centrifuged for 15 
minutes at 16,000xg and the resultant pellet washed with 200 pi of 70% EtOH. 
Following a second centrifugation at I6,000g for 5 minutes, the supernatant was 
removed and the pellet left to air dry at room temperature, and finally resuspended in 
5 pi of TE.
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2.2.2 Cloning
2.2.2.1 Ligation
Ligations were carried out by running a gel with 1 pi of the insert and Ipl of the 
vector to check for the ratios. 1 pi of T4 DNA ligase was added to the vector and 
insert, 2 pi lOX buffer (30mM Tris-HCL pH 7.8, lOmM MgCb, lOmM DTT and 
ImM ATP) and nuclease free water was added to a final volume of 20 pi. The 
reaction was left at 16^C overnight.
2.2.2.2 Transformation of bacteria
Transformations were carried out using the competent E.coli strain DH5a. These cells 
reduced occurrence of unwanted recombination in cloned DNA due to recAl 
mutation, and allowed clean DNA preparation by eliminating non-specific digestion 
by endonuclease due to endAl mutation. Cells were liquated in 50 pi and stored at -  
80^C. Cells were left on ice to thaw. Five pi of the ligation reaction or unligated, but 
digested, plasmid (as a negative control) were added to the cells and incubated on ice 
for 30 minutes. This was then heat shocked for 40 seconds at 42®C and allowed to 
recover on ice for 2 minutes. Next, 450 pi of the LB-Broth (5 g of tryptone, 2.5 g 
yeast extract, 5 g NaCl, in 500 ml of water) were added to the reaction and incubated 
with shaking (250 rpm) for 1 hour at 37°C. Following incubation, cells were collected 
by centrifugation at 7000 g for one minute, and the pellet resuspended in 200 pi of 
LB-Broth. The cells were then spread onto an LB-Agar (as LB-Broth but with 7.5 g of 
Agar added) plate containing ampicillin (50 pg/ml) and incubated at 37^C overnight.
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2.2.2.3 Rapid selection of recombinants
Overnight colonies were selected with a toothpick and cultured in LB-Broth 
containing ampicillin (50 pg/ml) overnight at 37®C with shaking. An equal volume of 
culture medium was added to phenol/chloroform (1:1) (60 pi), vortexed briefly and 
centrifuged (2 minutes at 18,000 g) to separate the phase containing of proteins 
(bottom layer) to the phase containing plasmids and all bacterial nucleic acids (top 
layer). 20 pi of the top layer was run on a 1% agarose gel, mixed with 4 pi loading 
buffer. A DNA marker was also run as well as the blank vector as a control.
2.2.2.4 Glycerol stocks
Once the correct clone was identified a glycerol stock was prepared for long-term 
storage by the addition of 150 pi of glycerol to 850 pi of culture in a sterile 1.5 ml 
eppendorff. Tubes were then vortexed briefly and stored at -80^C. When the clone 
was needed, small amount of the glycerol stock was spread onto LB-Agar for growth.
2.2.2.S Minipreparation of plasmids
High quality DNA minipreparations were carried out using the QIAGEN miniprep kit, 
an affinity column based system, according to the manufacturer’s instructions. 
Briefly, after overnight culture of the required plasmid in LB-broth (37°C with 
shaking), 3 ml of culture was centrifuged and the pellet resuspended in 250 pi of lysis 
buffer PI. 250 pi of buffer P2 were added and mixed by inversion 6 times until the 
solution became clear and viscous. After addition of 350 pi of buffer P3 a fluffy white 
precipitate formed containing genomic DNA, proteins and cell debris. The tube was 
centrifuged for 10 minutes at 10,000g and the supernatant containing the plasmid
52
DNA was transferred to a QIAprep column and centrifuged for a further 1 minute at 
10,000g. The flow-trough volume was discarded and 750 pi of buffer PE was added 
to the column. After 5 minutes incubation, the column was centrifuged for 1 minute 
twice to remove any residual ethanol. 30 to 50 pi of water was applied to the column, 
placed in a clean tube, and centrifuged for 1 minute at 10,000 xg. The yield was 
increased by leaving the column incubating for at least 1 minute at room temperature 
prior to the elution step.
2.2.2.6 Endofree maxipreparation
For transfection reactions, larger quantities of DNA are required and free of 
endotoxins, hence a maxipreparation of DNA is required. A fresh colony was picked 
from an LB-Agar plate and cultured in 5 ml LB-Broth with 50 pg/ml of ampicillin 
and left for 8 hours in a shaker at 37®C. The culture was diluted 1/1000 with 250 ml 
of LB-Broth and left in shaker at 37®C overnight. The culture was centrifuged at 
6000xg for 15 minutes, and then lysed with buffer PI (as part of the kit). Buffer P2 
was added (10 ml), mixed gently and left for 5 minutes at room temperature. Chilled 
buffer P3 was added, and the mixture poured into a QIAfilter Cartridge, and left for 
10 minutes. The lysate was filtered into a 50 ml tube, and the bacterial endotoxins 
were removed by adding 2.5 ml of buffer ER added and incubated on ice for a further 
45 minutes. After equilibrating the QlAGEN-tip with 10 ml of buffer QBT, the lysate 
was applied and allowed to enter by gravity flow. The column was washed with 
2X30 ml of buffer QC. The DNA was eluted with 15 ml of buffer QN and 
precipitated with 10.5 ml of isopropanol and centrifuged after mixing at 15,000g for 
30 minutes at 4®C. The supernatant was removed carefully and pellet was washed 
with 5 ml of endotoxin-free, room temperature 70% ethanol, and centrifuged at
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15,000xg for 10 minutes. The pellet was dried and redissolved in 250 pi to 500 pi of 
endotoxin-free buffer TE.
2.2.2.7 Diagnostic restriction digest
Plasmids were confirmed by digesting with enzymes cutting at the edges of the insert 
{EcoRl). The size of the insert was confirmed by running the digest reaction with a 
molecular weight marker on a 1% agarose gel. The screening for orientation was 
performed by choosing one enzyme cutting within the insert (Apal) and the other 
within the vector SEAP (Acc65I). Restriction digests were performed on empty 
vectors as a negative control. One unit of enzyme cuts 1 pg/hour of DNA using the 
right buffer and the right temperature (most enzymes cut at 37®C).
Restriction digest contained:
DNA 1 to 5 pi 
BSA 1 pi 
lOxBuffer 2 pi 
Enzyme 10 U 
Water to 20 pi ^
y  Reaction left for 1 hour at 37^C
2.2.3 DNA sequencing
All the inserts were confirmed by sequencing. The sequencing method used was the 
“Termination reaction”, with the primers used being the 5’ and 3’ multiple cloning 
site SEAP primers. The sequence of the SEAP 5’ primer was 
CTAGCAAAATAGGCTGTCCC, and the 3’ primer was
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CCTCGGCTGCCTCGCGGTTCC. 200 ng of DNA in a volume of 12 pi water were 
mixed with 3.2 pmol of either primer and sequenced in-house using a CEQ 2000 XI 
DNA analysis system (Beckman Coulter) by Dr K. Plant. Sequence identity to the 
target sequence was then confirmed by interrogating the human genome using 
BLAST (Basic Local Alignment Search Tool) algorithm 
(www.ncbi.nlm.nih.gov/BLAST) (Altschul et al. 1990).
2.2.4 Cell based techniques
2.2.4.1 Culture conditions
The human hepatoma cell line Huh? (a gift from Dr Steve Hood, GlaxoSmithKline 
UK) were cultured in 15 ml Dubelcco’s modified Eagle medium (DMEM) 
supplemented with 10%(v/v) foetal calf serum, 1 % (v/v) non-essential amino acids, 2 
mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin in 75 cm^ flasks 
with vented lids (Nunclon surface from Nalge Nunc International) in 5% CO2 at 37^C. 
The cells were sub cultured every 4 or 5 days (-90% confluence) depending on the 
growth rate. The passage number was initially 11 and they were subjected to a 
maximum of 10 further passages to maintain phenotype.
2.2.4.2 Subculture of cells
The medium was removed by aspiration, the cells washed with 5 ml of PBS and 1 ml 
of trypsin-EDTA was added. The flask was gently rocked to ensure coverage of the 
cells by the protease and was incubated for 2-3 minutes at 37^C. The cells were 
detached by tapping the sides of the flask, and 4 ml of medium were then added to
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inhibit the enzyme activity of the trypsin. The suspension was divided into 5 flasks 
(1ml into each flask) and 14 ml of fresh medium were added.
2.2.4.3 Storage of cells in liquid nitrogen
To assure the availability of the cells, and for long term storage, they were stored in 
liquid nitrogen. When cells reached approximately 90% confluency, they were 
washed with PBS, trypsinised and centrifuged at 1300 xg for 5 minutes. The cells 
were resuspended in 91% FBS and 9% DMSO to a final concentration of 4x10^ 
cells/ml, and aliquoted into cryovials, frozen in -80^C overnight, and then stored in 
liquid nitrogen. When the cells were required, they were thawed at 37°C for 5 
minutes, transferred into a 20 ml tube with 10 ml medium, then centrifuged at 1300 xg 
for 5 minutes. The pellet was resuspended into 7 ml of fresh medium and put into 25 
cm^ vented flasks to allow rapid growing. Once the cells had grown to about 90% 
confluency, they were sub-cultured in 75 cm^ vented flasks.
2.2.4.4 Counting of the cells
An approximately 90% confluent flask was tiypsinised the cells resuspended in 4 ml 
of fresh medium. An improved neubauer haemocytometer was covered with a cover 
glass, drops from the cell suspension were applied to the edge of the cover glass until 
the counting surface was covered by capillary flow. Cells were counted manually 
from 4 squares; this result was divided by 4 and multiplied by 10,000, giving the 
concentration in cells/ml.
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2.1.4.5 Transient transfection protocol for the reporter gene assay
2.2.4.5.1 Plasmids
The basic vector SEAP (secretory alkaline phosphatase) was used as a negative 
control, with all the test inserts being cloned into this vector. Expression plasmids for 
the transcription factors (HNF la , 3a/3p, 4a) as well as ligand-activated receptors 
(VDR, ERa, PPARa, GRa, RXRa, CAR, and PXR) were used for co-transfection 
assays. Plasmid maps are given in the appendix.
2.2.4.5.2 Cell seeding
A flask with cells reaching approximately 90% of confluency was trypsinised as 
described in section 2.6.2. Dubelco modified eagle medium (DMEM) contains four 
fold higher amino acids and vitamin compared to the basic Eagle media, and also 
contains, salts, glucose and a pH indicator. It contains sodium bicarbonate as buffer 
and needs to be in an environment containing CO2 to maintain the pH between 7 and
7.4 (Invitrogen).
DMEM was added to the cells (4 ml) and counted using a haemocytometer. The cells 
were diluted and seeded in 96 well tissue culture plates at 10, 0000 cells/ml (100 
pl/well). The outside wells were not used because of potential evaporation of medium 
from these wells that could cause variation in the results (Dr V. Bombail personnel 
communication); these wells were filled with PBS (100 pl/well) instead. The plate 
was incubated at 37^C and 5% CO2 overnight to allow cell attachment.
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2.2.4.5 3 Transfection
DNA was introduced into the cells using the lipid-based reagent Fugene 6 (Roche). 
The Fugene and DNA were incubated in serum free medium. The order of the 
addition of the reagents was critical with Fugene 6 added first to a sterile tube 
containing the required amount of serum free medium, and then DNA was added and 
left to incubate for 30 to 45 minutes.
2.2.4.5.4 Optimisation of transfection
In order to define the optimum conditions for transfections, several ratios of 
Fugene/DNA were used as well as several cell concentrations. The starting DNA 
concentration used was constant at 0.05 pg/well and the ratios of Fugene/DNA used 
were 3:1, 3:2, 6:1, 6:2 and 6:3. Cell concentrations used were 20,0000, 10,0000, 
50,000, 25,000, 10,000, 5,000 and 1,000 cells per well. The best conditions for 
transfection was a Fugene:DNA ratio of 6:2 and a seeding cell concentration 10,000 
cells/well.
DNA transfections were carried out when the cells were between 50 to 80% confluent 
within the wells. The transfection mixture was added to the seeded cells without 
removing the existing medium, to avoid disrupting the cells. For basal expression 
experiments, cells were incubated 48 hours till SEAP activity determined.
2.2.4.5 5 Cotransfection of expression plasmids
The final DNA amount transfected per well was 0.1 pg in all single co-transfections; 
the amount of the co-transfected plasmid was 0.025 pg and that of the reporter 
construct at 0.075 pg. For multiple co-transfections (e.g. PPARa and RXRa) this was
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increased to incorporate 0.1 pg of each co-transfected expression plasmid. Figure 2.1 
highlights the steps for the transfeetions and the SEAP measurement.
Figure 2-1 Transient transfections steps
P X R
Eugene +
SEAP assay
S E A P
+/- Expression plasmid Micelles
SEAP secreted into 
culture medium
<^uh7 cells
Huh? cells were plated into 96 well plate and left over night to attach. The reagents: 
Eugene, DNA were added in this order to serum free media, and left to incubate for at 
least 30 minutes at room temperature. 100 pi of the mixture was added to the cells, and 
left till the enzyme assay was nerformed.
2.2.4.5.6 Chemiluminescent detection of SEAP protein activity
Following incubation of cells for the requisite time, medium was assayed for the 
amount of the alkaline phosphatase secreted in the cells using a chemiluminescent 
alkaline phosphatase assay (Aurora kit, MP Biomedical). The solutions were left to 
equilibrate at room temperature. To 10 pi of medium, 18 pi of Ix dilution buffer was 
added into a 96-well optiplate (polystyrene microplates) and left at 65®C for 30 
minutes in order to destroy any endogenous alkaline phosphatase activity. The plate 
was cooled on ice for 2 minutes and left to equilibrate at room temperature for 15
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minutes. 24 pi of assay buffer was added and left for a further 5 minutes at room 
temperature. Then 24 pi of reaction buffer (containing the substrate CSPD disodiumS- 
(4-methoxyspiro [l,2-dioxetane-3,2’-(5’-chloro)tricyclo(3.3.1 .l)decan -4-yl)phenyl 
phosphate.]) were added and left at room temperature for 10 minutes. The 
dephosphorylation of the substrate by SEAP emits light, which may be measured at 
477 nm. The plate was read in a Lumicount plate reader (Packard), with optimal gain 
and photomultiplier settings automatically determined by the machine after screening 
the plate for the maximum and minimum luminescence values.
2.2.5 Nuclear protein extraction
The nuclear proteins were extracted for both Western blotting and the electromobility 
shift assay. Cells were grown as described previously in section 2.6.1 and nuclear 
proteins were extracted and analysed as described below. The proteins were extracted 
from cells which has been transfected with the PPARa/RXRa expression plasmids, 
and from non-transfected cells.
2.2.5.1 Huh? nuclear protein extraction
The protocol was based on that of Dignam and co-workers (Dignam et al. 1983). The 
Huh7 cells were trypsinised when they had reached approximately 90% confluence.
Cells were pelleted by centrifugation (1300 xg for 5 minutes), washed in PBS, 
centrifuged again then resuspended in 5 packed cell volumes (PVC, the volume of the 
cell pellet) of PBS and spun (1300 xg for 5 minutes). After removal of the 
supernatant, a suspension was made in 2 PCV of cold buffer A (10 mM Hepes-KOH, 
pH 7.9, 1.5 mM MgCli, 10 mM KCl and 0.5 mM DTT) and the cells were left to
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swell on ice for 10 minutes. The cells were homogenised using 10 strokes of a dounce 
homogeniser and centrifuged at 2000 xg for 15 minutes. The difference between the 
volume of the supernatant and the initial volume was called the packed nuclear 
volume (PNV). The pellet was resuspended in 0.5 volumes of ice cold buffer C (25% 
glycerol, 20 mM Hepes-KOH, pH 7.9, 1.5 mM MgCli, 0.2 mM EDTA, 20 mM NaCl, 
0.5 mM DTT, 0.5 mM PMSF) and 0.5 PNV of high salt buffer C (buffer C containing
1.2 M NaCl) was added drop wise and with swirling, then homogenised using 10 
stroke of dounce homogeniser and then spun at 16000 xg for 30 minutes. The 
supernatant containing the nuclear proteins was aliquoted and stored at -80^C.
2.2.S.2 Protein electrophoresis
The integrity of the nuclear protein extract was checked by running a sodium dodecyl 
sulphate-polyacrylamide electrophoresis gel (SDS-PAGE) containing a 12% resolving 
gel and a 4% stacking gel (see table 2.4 for composition).
Samples (10 pi) were mixed with an equal volume of loading dye (4.8 ml Milli-Q 
water, 1.2 ml 0.5 M Tris-HCl pH 6 .8, 0.96 ml glycerol, 1.92 ml 10% SDS, 0.48 ml p- 
mercapto-ethanol, 0.6 ml 0.05% (w/v) Pyronin Y, stored in the dark for 2 weeks). The 
samples were denatured at 95^C for 5 minutes, were left to cool down and then loaded 
on to a gel containing a 5x pH 8.3 Running Buffer (15.5 g Tris base, 72 g glycine, 5 g 
SDS, dissolved in 1 litre milli-Q water) and run for 40 minutes at 200 V.
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Table 2-3 SDS-polyacrylamide Gel composition
Resolving gel (12%) Volume
Milli Q water 5.43 ml
2x Resolving gel buffer (181.6g Tris base 4g, SDS, Milli-Q 
water to IL, pH 8.8 with HCl)
4.5 ml
Acrylamide (40%) 5.62 ml
Bis-Acrylamide 2.95 ml
TEMED (N,N,N 1 ,N 1 -Tetramethylethylenediamine) 18 pi
Ammonium persulfate (10%w/v) 180 pi
Stacking gel (4%)
Milli Q water 7.15 ml
2x Stacking gel buffer (60.6g Tris base, 4g SDS,Milli-Q water 
to IE, pH 6.8 with HCl)
2.5 ml
Acrylamide (40%) 0.75 ml
Bis-Acrylamide 0.4 ml
TEMED 10 pi
Ammonium persulfate (10%w/v) 50 pi
2.2.S.3 Coomassie staining
After electrophoresis, the gel was stained with coomassie blue (0.25% Coomassie 
Blue R-250, 40% methanol, 10% acetic acid) for three to four hours at room 
temperature with gentle agitation. The gel was destained with gentle shaking, 
overnight, using a destain solution (12.5% isopropanol, 10% glacial acetic acid) that 
was changed at regular intervals.
2.2.S.4 Protein quantitation
The protein concentration was measured by the Lowry assay (Stoscheck 1990; 
Latchman 1995). The samples (20 pi) were diluted in 0.5 M NaOH (380 pi) and 
divided into 2 tubes (200pl each). Standard solutions of bovine serum albumin 
(BSA=250 pg/ml) were prepared in duplicate (Table 2.5).
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Table 2-4 Bovine Serum Albumin Standards for Lowry protein concentration 
measurement
BSAfuB NaOH 0.5Mtun BSA concentrationtps/mll
0 200 0
10 190 12.5
20 180 25.0
30 170 37.5
40 160 50
80 120 100
120 80 150
160 40 200
200 0 250
To all the samples 1 ml of a freshly prepared Lowry reagent was added (0.5 ml 1% 
CUSO4, 0.5 ml 2% NaK-Tartrate, 50 ml 2% NaCOs). The solution was mixed by 
vortexing and incubated at room temperature for 10 minutes. An equal volume of 
Folin-Ciocalteu’s phenol was mixed with water and 100 pi of this mixture was added 
to the samples and standards and mixed immediately and left for at least 30 minutes at 
room temperature. The absorbance was measured at 720 nm using a Kontron 
spectrophotometer. The standard curve was used to calculate the unknown protein 
concentration by interpolation.
2.2.6 Western blotting
Western blotting was performed to check for the presence of the PPARa protein in 
Huh7 cells, using an antibody against this transcription factor.
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2.2.6.1 Sample preparation
The protein concentration used was 2 mg/ml in PBS. An equal volume of loading 
buffer (described in section 2.2.5.2) was added and heated for 5 minutes at 95®C, then 
allowed to cool and briefly vortexed and centrifuged for few seconds. 10 pi of the 
sample were loaded (equivalent to 5 pg protein). One microliter of molecular weight 
marker solution (Santa Cruz sc-2035) was loaded.
2.2.6.2 Gel electrophoresis
Proteins were run on an SDS-polyacrylamide gel (12% resolving gel and 4% stacking 
gel) as previously described in section 2.2.S.2. The gel was run at 0.04 amperes and 
120 volts for about 1 hour until the pyronin Y band had reached the bottom of the gel.
2.2.6.3 Blotting
Nitrocellulose membrane, 2 blotting papers and 2 scotchbrite pads were cut to the size 
of the gel. The membrane was placed in methanol for 10 seconds then washed with 
distilled water for 5 minutes. The blotting papers and scotchbrite pads were soaked for 
10 minutes into transfer buffer (160 ml 5x transfer buffer (0.1 M Tris base, 0.74 M 
glycine into 1 L milli-Q water) 200 ml methanol, 640 ml milli Q water). The gel was 
removed from the rack and the stacking gel removed. The placement of the 
sehotehbrite pads and the blotting papers and the gel is shown in figure 2.2. The tank 
was filled with transfer buffer, the cassette placed into the transfer tank and 
transferred at 0.1 amperes, 120 V overnight. The blotted gel was stained in coomassie 
blue (0.25% Coomassie Blue R-250, 40% methanol and 10% acetic acid) to show that 
no proteins were detectable on the gel and had hence not been transferred.
64
Figure 2-2 Assembly for electrophoretic transfer of protein
Black (negative)
Scotchbrite pad 
^  Filter paper
Gel
Nitrocellulose membrane 
^  Filter paper 
Scotchbrite pad
Red (positive)
2.2.6.4 Blocking of the nitrocellulose membrane
The membrane was removed from the cassette, and non-specific binding blocked with 
10 ml of blocking agent (5 % w/v dried milk in TBSiTween). TBS was composed of 
2.42 g Tris base, 8 g NaCl, pH to 7.6 with hydrochloric acid in a volume of 1 litre of 
water, and Tween was added to give a 0.1% solution. The blocking stage was left for 
1 hour at room temperature roller. The blocking buffer was discarded and the 
membrane was washed once for 10 minutes with TBSiTween and twice for 5 minutes 
with rolling.
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2.2.6.S Immunodetection
2.2.6.5.1 Incubation with antibodies
A primary polyclonal anti PPARa antibody, raised in rabbit (Sigma, P0369), was 
used to detect PPARa. The antibody was diluted at 1:2000 in diluent (0.2 g of milk 
powder in 10 ml of TBSitween). The membrane was incubated with the primary 
antibody for 1 hour at room temperature on a Denley Spiramix 5 roller. The 
membrane was washed with 10 ml TBSitween three times. The secondary antibody, 
raised in goat IgG-HRP (Santa Cruz sc-2301), was diluted at 1:5000 into 10 ml of 
diluent and incubated for 1 hour at room temperature. The membrane was washed 
three times with 10 ml of TBSitween.
2.2.6.5.2 Chemiluminescent detection
A Lumigen PS-3 based kit, ECL+Plus Westen blotting reagents (Amersham Life 
Science) was used for the detection of horseradish peroxidase (HRP). The bound 
horseradish peroxidase catalyzes the oxidation of luminol in the presence of hydrogen 
peroxide. The light was captured on a Type 667 Polaroid film (SIGMA). Figure 2.3 
shows the principle for the detection.
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Figure 2-3 Diagram summarising the chemiluminescent detection
MW stds
Protein
Secondary Ab
Film
Epitope
HRP
Lumigen PS-3 + Peroxide
, . .  Buffer peroxide
Acridinium------------------ ^
HRP
Primary Ab Secondary Ab
2.2.7 Site directed mutagenesis
PCR with primers containing a unique restriction site within the PXR promoter and 
SEAP, were used for the mutation of the PPARa/RXRa response element (PPRE). 
Two mutations of the PPRE were generated (mutation A and mutation B), to ensure 
ablation of the site, and for each mutation two sets of primers were designed. 
Mutation A was designed to mutate three bases, and mutation B was aimed to mutate 
three bases and delete four within the core element of the PPRE. One set amplified the 
fragment upstream of the site PPARa/RXRa putative binding site on the PXR 
promoter and the other amplified the region downstream of this site (Figure 2.4). The 
putative PPRE was mutated to an Agel restriction site (see table 2.6 for primers 
sequences).
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Figure 2-4 Strategy followed for the generation of the site directed mutagenesis
Sense a 
 ►
Sense b
L
PPARa/RXRa
Antisense a 
<-----------
Antisense b
Sense
Upstream fragment
PXR SEAP
Antisense
Downstream fragment
A unique restriction digest was generated within the PPRE for the enzyme AgeL The 
upstream and downstream fragments were amplified with primers generated from the 
2200 bp construct. The upstream fragment was ligated with the downstream fragment, 
and the fragment was amplified with PCR using nested primers. The resulting 
fragment was digested and cloned into the SEAP plasmid.
The antisense primer of the upstream fragment was designed to overlap with the sense 
primer of the downstream fragment. The fragments were ligated and used as 
templates to amplify using nested primers giving a fragment of 1.5 kb (see table 2.7). 
The forward primer contained a restrietion site for the Acc65I cutting site; the 
resulting fragments were digested with the later enzyme and EcoRI, and cloned into 
SEAP.
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Table 2-5 Primers sequences for PXR promoter mutants.
Fragments Sequence Tm
Upstream
Sense a 5’-ATAAGGGATTTTGCCGATTTCGG-3’
Agel
59.1
Antisense a 5 ’ -CC ATAGAGACCGGTCCTTTTTCC A-3 ’ 59.3
Sense b 5 ’ -ATAAGGGATTTTGCCGATTTCGG-3 ’ 
Agel 
1
59.1
Antisense b 5’-c a g c c a t Æ c g g t c t g t c c t t t t t -3’ 59.3
Downstream
Agel
Sense 5’-a g g a c a g À : c g g t a t g g c t g t g g -3’
60.9
Antisense 5 ’ -C ACAGGTAGGCCGTGGCTGTG-3 ’
60
Table 2-6 Nested primers sequence used to amplify the 1.5 kb fragment of the 
PXR promoter
Primers Sequence Tm
Sense Acc65I
5’- TCCACT(^GTACCGAAATCCAGT-3’
54.9
Antisense 5’- TCAACTGGGATGATGCCCAG-3’ 55.5
The letters shown in bold are the ones, which have been mutated.
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2.2.8 Electromobility shift assay (EMSA)
This method investigates protein-DNA interactions, and is informative on the 
investigation of the functionality of the putative binding site for the PPARa/RXRa on 
the PXR proximal promoter using a probe containing the putative binding site and the 
mutated site. The electromobility shift assay is a powerful method for the detection of 
factors binding to a specific DNA sequence (Latchman 1995). The protein bound to a 
radio labelled probe would be separated from the unbound probe by electrophoretic 
separation on a non-denaturing polyacrylamide gel.
2.2.8.1 Probe preparation
The probes used for the electromobility shift assay were radio labelled at their 
dephosphorylated 5’ end. 1 pi of probe (100 pmol) was incubated with 2 pi ^^P ATP 
(7.4x10^ Bq) and 10 U of T4 polynucleotide kinase (Promega) and the reaction 
mixture incubated at 37^C for 60 minutes. To denature the enzyme, 80 pi of Tris 
EDTA buffer were added and temperature increased to 68°C for 10 minutes. The 
probes were stored at -20®C for a maximum of two weeks.
Table 2-7 Oligomer sequences for the EMSA studies.
Bases indicated in bold were altered by mutagenesis, whereas those indicated in red 
were deleted via mutagenesis.
Oligomer name Sequence
Wild type sense 
Wild type antisense
5 ’ -GGAAAAAGGAC AG AGCTÇTATGGCT-3 ’ 
5 ’ -CCTTTTTCCTGTCTCGAGATACCGA-3 ’
Mutant A sense 
Mutant A antisense
5 ’-GGAAAAAGGACAGACCGGTATGGCT-3 ’ 
5 ’ -CCTTTTTCCTGTCTGGCC ATACCGA-3 ’
Mutant B sense 
Mutant B antisense
5 ’-CTGGAAAAAGGA//CCGGTATGGCTGT-3 ’ 
5 ’ -GACCTTTTTCCT//GGCC ATACCGAC A-3 ’
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2.2.S.2 DE-81 test protocol for radiolabelling efficacy
The efficiency of radiolabelling was examined using DE-81 ion-exchange filters. 
These filters have a high affinity for nucleotide chains but a low affinity for single 
nucleotides. 0.5 pi of the probe was applied to each half of the filters and left to air- 
dry for approximately 30 minutes. One half of the filter was washed four times with 
0.5 M Na2HP04 for two minutes and allowed to dry. The count per seconds were 
measured with Mini-monitor GM for both the washed and unwashed halves. The 
incorporation efficiency was measured as follows
Washed filter
------------------------------ X 100
Unwashed filter
Greater than 60% incorporation efficiency was acceptable; below this probes were re­
synthesised.
2.2.8.3 Binding reaction
The binding reaction mixture consisted of 10 pi of 2x binding buffer (40mM Tris- 
HCl, pH 7.9, lOOmM NaCl, 20% glycerol and 0.2 mM DTT), 1 pg of poly-dI:dC, 20 
pg of nuclear proteins and nuclease free water to a final volume of 20 pi. The reaction 
was left to incubate for 10 minutes at room temperature, 2 pi of the labelled probe 
were then added and the reaction was left to incubate for a further 30 minutes. In 
order to identify if the binding was specific and reversible, xlO, x30, x50 and xlOO 
excess unlabelled probe were added to the reaction, maintaining a consistent final 
volume 20 pi.
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2.2.S.4 Gel electrophoresis
To the binding reaction 2 pi of loading buffer were added (0.5x TBE, 10% glycerol, 
0.25% bromophenol blue and 0.25% xylene cyanol FF) and 10 pi of the mixture were 
loaded on a 8% polyacrylamide gel (10.75 ml 30% acrylamide, 25.25 ml water, 4 ml 
5x TBE, 400 pi 10% ammonium persulfate, 40 pi TEMED freshly prepared). The gel 
was then placed into a cassette and the phosphor screen was left on the gel for 2 to 4 
hours. The phosphor screen was placed in a Molecular Imager Personal FX 
(Molecular Dynamics) avoiding contact with light, and picture was examined using 
the Quantity One software program (Molecular Dynamics).
2.3 Statistical analysis
The results were analysed for significant differences, using one factor ANOVA with 
Bonferonni all means post hoc test (GraphPad Prism Software version 4.00, San 
Diego,CA).
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3 CHAPTER: Presence of putative binding sites for liver-enriched 
and ligand-activated transcription factors within the PXR 
proximal promoter: An in silico analysis
3.1 Introduction
My initial investigation on the regulation of PXR gene expression involved in silico 
studies of its promoter. Through the use of in silico analysis it is possible to identify 
putative transcription factor binding sites within the PXR proximal promoter. 
Whereas such identification is equivocal, as computer prediction does not necessarily 
equate to biological function, it does provide initial data for the planning of in vitro 
experimentation. However, in silico analysis are useful in pre-selecting potential 
regulatory sites for experimental studies (Quandt et al. 1995)
Although it is undisputed that PXR plays a central role in the body’s response to 
xenobiotic exposure, little work has been undertaken on the regulation of PXR gene 
expression itself. The majority of previous work has studied the activation profile of 
PXR, and the target genes that it interacts with to promote transcription (Vignati et al. 
2004). However, another important potential control point is the level of PXR 
expression, and this has not been fully investigated to date. The potential for PXR to 
be regulated at the transcriptional level was first demonstrated by Pascussi et al, who 
reported that glucocorticoids are capable of producing an in vivo increase in the level 
of several transcription factors including PXR (Pascussi et al. 2000a).
Whereas this previous work demonstrated that PXR could be regulated at the pre- 
translational level, it did not demonstrate if such control was at the level of 
transcription or transcript stability.
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Previous work from other groups, have reported that the PXR in mouse foetal cells 
contains a binding site for HNF4a in the first 100 base pairs (Kamiya et al. 2003).
In order to further investigate the molecular mechanisms of regulation of PXR gene 
expression, it was important first to correctly identify the PXR promoter in silico, and 
identify putative transcription factor binding sites within this region. The complete 
sequencing of the human genome and its annotation with the NCBI (National Centre 
for Biotechnology Information) database makes identification of proximal promoter 
sequences relatively straightforward. In addition, online databases such as 
TRANSFAC act as a repository for transcription factor interactions motifs, with tools 
such as Matlnspector or Match being used to interrogate the TRANSFAC database to 
identify putative binding sites for transcription factors within DNA sequences. 
TRANSFAC is database that collects data which are relevant for gene expression at 
the transeriptional level (Wingender et al. 1996) and provide information on genomic 
binding sites of eukaryotic transcription factors and the related binding proteins 
(Heinemeyer et al. 1999).
The TRANSFAC approach has already been used to detect a putative binding site for 
the FXR/RXR heterodimer in the ABCBll promoter, which was additionally shown 
to be functional (Plass et al. 2002).
3.2 Identification of the PXR promoter
The PXR proximal promoter was identified from the NCBI database using the 
following protocol. A cDNA for the complete PXR cDNA (AF364606) was identified 
and its corresponding region within the human genome located using the BLAST tool
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(www.ncbi.nlm.nih.gov/BLAST/). The DNA region immediately upstream of the first 
exon was designated the PXR proximal promoter.
It should be noted that since this project was undertaken the NCBI database has been 
further annotated to include the genomic location of PXR in several species, including 
human. The identified location agrees with the assignment produced during this first 
analysis.
3.2.1 Putative binding sites
The matrix search was first proposed by Quandt et al, where the seareh for putative 
binding sites relied on the matrix similarities, which consider the frequency of each 
single nucleotide at each position within the response element (Quandt et al. 1995). 
Putative transcription factor binding sites were identified for 2200 bp 5’ to the 
putative transcription start site, initially using Matlnspector and Match (gene- 
regulation.com) to interrogate the TRANSFAC database. The putative binding sites 
were identified using a high match setting with the core similarity at >0.85 and matrix 
score at >0.75 in order to minimise missing of true positives sites, or identification of 
false positives sites. The MATRIX represents the DNA binding profile for individual 
or groups of transcription factors (Wingender et al. 2000). The matrix similarity 
describes the quality of a match between the matrix and the input sequence. The core 
similarity describes the quality of a match between the core sequence of a matrix (the 
four most conserved position within a matrix) and a part of the input sequence 
(Quandt et al. 1995).The search starts with only matches to the core region taken into 
consideration. The matrix similarity is calculated only if the core similarity reaches 
the pre-defined threshold. The results of my TRANSFAC analysis will be compared 
with the experimental data, which allows assessment of false positive matches.
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Such a screen produced > 300 putative transcription factor binding sites and these 
were sorted by two methods. A manual screen of the sites was undertaken, with each 
putative interaction site reviewed critically. Sites were selected/discarded from the 
final map based upon the following criteria,
1. Accept sites identified by both the Matlnspector and Match interrogations of 
the TRANSFAC database.
2. Discard sites for transcription factors known not to be expressed in the liver, 
and accept sites for transcription factors known to be expressed in the liver.
Whereas such an approach will by it self discard many putative sites of interest (and 
indeed identify false positives as well) this was deemed acceptable for two reasons. 
First, the aim of the in 5/7/co analysis was to identify potential interactions sites for 
future analysis and, second, any interaction sites of interest would be tested in vitro 
for biological functionality.
Following this screening procedure, 64 putative interaction sites were identified: 
These sites are presented in Table 3.1, with their location in the PXR proximal 
promoter indicated in Figure 3.2
The identified putative binding sites included interaction sites for factors involved in 
the general transcription process, most notably the TATAA binding protein. In 
addition, putative binding sites were identified for transcription factors associated 
with maintaining the basal expression of genes. The factors identified in this group 
were the hepatic nuclear factors (HNF la , 4a, 3P), CCAAT enhancer binding protein 
(C/EBPa), CCAAT, tumor suppressor protein p53, octamer binding site, and
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specificity protein 1 (SPl). Finally, a selection of putative binding sites for ligand- 
activated transcription factors was identified. These included the vitamin D receptor 
(VDR), glueocorticoid receptor (GR), progesterone receptor (PR), BARBIE box, the 
peroxisome proliferator activated receptor alpha (PPARa), aryl hydrocarbon receptor, 
and the famesoid X receptor.
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3.3 Discussion
As stated in the section 3.1, assignment of the transcription start site for the PXR gene 
was based upon the alignment of transcript sequence to the human genome. However, 
as transcripts may not always be full length, this assignment is not equivocal. Several 
techniques could be carried out in vitro to assign the transcription start site, but these 
were outside the scope of the present project. I do however present some evidence to 
support this assignment. In >90 % of mammalian genes a TATAA-box is found 25-30 
bp upstream of the transcription start site, and is central to the efficient attachment of 
RNA polymerase II (Roeder 1996). I identified a putative TATAA-box located 30 bp 
upstream of the designated transcription start site, within the expected area. This 
therefore increases my confidence in the assignment of the transcription start site.
The organisation of eukaryotic DNA within chromatin may favour the recognition of 
TFs irrespective of the affinity to the binding sites. Hence, in silico analysis combined 
with in vitro and in vivo information can fully confirm the predictions made initially. 
Also, the binding of a protein may depend on the biological context. The TFs may 
bind to the DNA during its replication, if they possess a rapid kinetic association 
before chromatin proteins have reassembled on the DNA. So the binding of a TF does 
not necessarily depend on its affinity (Roulet et al. 1998).
3.3.1 Putative binding sites for general transcription factors
Several of the putative binding sites identified within the PXR proximal promoter 
included those for general transcription factors as well as ligand activated 
transcription factors, and a description of their functions follows.
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3.3.1.1 TATA box
The presence of a TATAA box defines the minimal DNA element for accurate 
transcription initiation and is bound by the TATA binding protein (TBP) (Roeder 
1996). The core promoter binds the basal transcription factors, the transcription is 
hierarchical and dynamic and starts with chromosomal de-repression with chromatin 
remodelling and nucleosomal disruption. The TF then binds, resulting in the initiation 
of transcription with the interaction with the upstream regulatory elements (Roeder 
1996). Genes that do not contain a TATA box majority are house keeping genes such 
as glyceraldehyde-3-phosphate dehydrogenase (GAPD), and oncogenes (Zhang
1998). The initiation of the transcription involves the binding of the TATA box 
binding protein with the TFIID, TFIIA, B, F, H and E, and RNA polymerase II 
(Zhang 1998). The RNA becomes activated by phosphorylation of its C terminal 
domain (Sudarsanam and Winston 2000). A TATA box in the PXR promoter has been 
identified at -30 bp from the transcription start site, suggesting assignment of the 
transcription start site was correct (table 3.1 and figure 3.2).
3.3.1.2 HNFs
The HNFs have been demonstrated to be involved in the regulation of CYPs gene 
expression: HNF l a  is reported to regulate the CYP4A and CYP7A genes (Cheung et 
al. 2003), as well as the membrane transporter OAPT-C (Jung and Kullak-Ublick
2003), binding as a homodimer to the perfect palindrome sequence 
GTTAATnATTAAC (Nolten et al. 1995). HNF3 has been reported to be involved in 
the drug mediated responsiveness of CYP3A4 gene (Bombail et al. 2004) with the 
isoform HNF3y having a synergistic effect with C/EBPa to mediate the CYP3A4 
gene expression (Rodriguez-Antona et al. 2003). HNF3 bind to the consensus
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sequence A(A/T)TRTT(G/T)RYTY in target genes (R=G or A and Y=T or C) 
(Cereghini 1996). Whether H N Fla and HNF3 regulate PXR gene expression needs to 
be explored with, for example, a reporter gene assay approach.
A functional binding site for HNF4a was identified in the XREM of the CYP3A4 
distal promoter, which enhanced both PXR and CAR mediated basal and drug 
induced of the CYP3A4 gene expression (Tirona et al. 2003). This factor is also 
reported to maintain PXR gene expression in mouse hepatocytes (Kamiya et al. 2004). 
HNF4a binds as a homodimer to a consensus binding site consisting of DRl of 
AGGTCA (Cereghini 1996). It would be interesting to show whether this factor is 
also important for human PXR gene expression, and would help to increase our 
knowledge of the mechanisms of regulation of rodent and human PXRs.
3.3.1.3 Specificity protein 1
Specificity protein 1 (SPl) is ubiquitously expressed, binding to a GC rich element 
(GGGCGG) in gene promoters, and is involved in cell growth, proliferation and 
differentiation as well as chromatin remodelling (Philipsen and Suske 1999). SPl has 
been shown to bind to both the proximal promoter and the enhancer of phénobarbital 
response element (PBRE) of the CYP2B1 gene, and enhancing basal and drug 
induced activity (Muangmoonchai et al. 2001). In our laboratory two putative binding 
sites have been identified for SPl within the proximal promoter of the CYP3A4 gene 
and mutation of the proximal Spl binding site reduces the drug mediated increase of a 
CYP3A4 reporter gene in response to metyrapone and phénobarbital (Bombail et al.
2004).
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3.3.1.4 CCAAT binding site
CCAAT binding sites are present in many eukaryotic genes. It is generally bound to 
CCAAT binding factor (CBF), also named nuclear factor Y (Coustry et al. 1995), a 
factor that is ubiquitously expressed and functions together with the C/EBP to achieve 
maximum transcriptional activation (Dooley et al. 1998). It is believed that the 
CCAAT box is important for the expression of genes constitutively expressed, as well 
as of genes active only in fully differentiated cells (Marziali et al. 1999).
3.3.1.5 C/EBP alpha
CAAT enhancer binding protein (C/EBP) is ubiquitously expressed and was named 
for its ability to bind to the CCAAT response element (Antonson and Xanthopoulos 
1995). The C/EBPa isoform has been implicated in CYP3A4 gene expression, by 
maintaining basal expression via binding to its proximal promoter (Rodriguez-Antona 
et al. 2003), and conferring the drug responsiveness of the CYP3A4 (Bombail et al.
2004). C/EBPa is also involved in adipocyte and hepatocyte differentiation (Shugart 
and Umek 1997) and the regulation of inflammation (Ramji and F oka 2002).
C/EBP can form homodimers or a heterodimers with factors from the same family in 
order to mediate their effects (Rodriguez-Antona et al. 2003). If C/EBPa is involved 
in the regulation of PXR, that would mean, together with the participation of HNF3 
and 4, that CYP3A4 and PXR are regulated by the same factors, which would explain 
their co-expression in the liver and intestine.
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3.3J.6 Octamer binding site
Octamer motif is bound by two octamer binding proteins Octl and Oct2, the Octl is 
ubiquitously expressed (Johnson and McKnight 1989), and binds to a consensus 
sequence octamer (ATTTGCAT) motifs (Terada et al. 1995). The octamer is found in 
house keeping genes like histone 2B (Schreiber et al. 1988) and in many other 
eukaryotic genes and result in their up or down regulation (Gibson et al. 2002). Either 
an increase or a decrease in PXR gene expression could be mediated by this factor, 
and reporter gene assays would be useful to investigate whether up or down regulation 
of the PXR gene results.
3.3.1.7 Tumour suppressor p53
The tumour suppressor p53 has binding sites in many genes, and its inactivation is 
found in over half of tumours (Miyashita and Reed 1995). It bind to a core sequence 
TGCCT in target genes (Scharer and Iggo 1992). It plays its role as a tumour 
suppressor, by inhibiting the cell cycle and induces apoptosis (Miyashita and Reed 
1995). It is believed that this factor interacts with the TATA binding protein to repress 
transcriptional activation (Farmer et al. 1996). PXR has not been previously linked to 
tumour inhibition or initiation; the binding site for this factor within the PXR 
promoter would suggest that this receptor could be involved in the tumour initiation or 
repression.
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3.3.1.8 COUP-TF
Chicken ovalbumin upstream promoter transcription factor (COUP-TF) is a 
transcription factor that binds as a dimmer to a direct repeat A/GGGTCA with various 
spacing. It is a member of steroid orphan nuclear receptor family, in that no ligand has 
been identified to date (Cooney et al. 1992). COUP-TF has the ability to repress or 
increase gene transcription, with the promiscuity in the DNA binding domain leading 
to the repression of the action of other receptors, by competing for the same response 
element. For example COUP-TF can compete with HNF4 for the same binding site on 
the human apoliprotein CIII gene (Mietus-Snyder et al. 1992). It can also repress the 
transcription, by forming a heterodimer with RXR, removing this heterodimer partner 
from other receptors such as VDR, TR and RAR (Cooney et al. 1993). In contrast, 
COUP-TF can also up regulate gene transcription by enhancing the HNF4 
transcriptional activity in target genes (Ktistaki and Talianidis 1997). Therefore, the 
role of this factor on the PXR could be either positive or negative regulation, as a 
putative binding site for the HNF4a has been detected on the PXR promoter. 
Therefore, would need to carry out experiments to further investigate this.
3.3.2 Putative binding sites for ligand-activated transcription factors
The presence of putative binding sites for several LATF may reflect the role of the 
PXR in the body, with a promiscuous LED, allowing response to many structurally 
unrelated chemicals.
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3.3.2.1 Glucocorticoid receptor
Previous work on PXR expression and that of its target gene CYP3A4, showed that 
the PXR mRNA is increased with micromolar concentration of dexamethasone in 
vitro, and this subsequently increased the levels of the CYP3A4 expression (Pascussi 
et al. 2000a). This effect is believed to be mediated by the OR. The presence of 
putative binding sites for the OR within the PXR promoter may suggest that the GR is 
interacting directly with the PXR promoter inducing transcriptional activation and 
hence mRNA levels.
3.3.2.2 Estrogen receptor
The estrogen receptor is a steroid receptor, and plays an important role in maintaining 
sex hormone homeostasis (Smith 1998). The estrogen receptor family comprises of 
two member in man, namely ERa and ERp (Smith 1998), with both receptors 
forming homodimers when activated by ligand, and binding to a consensus half site 
oriented as an inverted repeat, separated by three bases AGGTCANNNTGACCT 
(Freedman 1992). Both receptors are widely expressed in the body, but have some 
organ and cell specificity of expression, suggesting that they have different 
transcriptional activities (Dechering et al. 2000). Both receptors exhibit high sequence 
similarity in their DBDs (96%) but only 60% in their LBDs, suggesting slightly 
different ligand profiles (Mosselman et al. 1996). There is some discrepancy in the 
literature for their affinity towards 17p estradiol, with some reports showing that this 
ligand shows a higher affinity for ERa (Mosselman et al. 1996), and other reports 
concluding similar affinities for both receptors (Dechering et al. 2000).
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The ERa may be involved in the regulation of drug metabolising enzymes: It may act 
indirectly on the positive expression of the CYPlAl and CYPIBI, as no putative 
binding sites have been identified in the latter promoters (Reviewed by (Honkakoski 
and Negishi 2000)).
The relationship between PXR and ERa is at two levels, namely through sharing 
some ligands, and through their joint action for the metabolism of estrogens. Both 
endogenous estrogens (Kliewer et al. 1998; Schuetz et al. 1998), and environmental 
estrogens (e.g. bisphenol-A) (Takeshita et al. 2001) are activators of the human and 
mouse PXR and are substrates for CYP3A4 (Quattrochi and Guzelian 2001). 
Interestingly, the anti-estrogenic drug tamoxifen, used for the treatment of breast 
cancer, is also a substrate for the CYP3A enzymes (Mani et al. 1993). This could lead 
to the impaired metabolism of gonadal steroids. An inverse relationship between the 
PXR and ER exists, which in breast cancer could lead to the drug resistance (Dotzlaw 
et al. 1999) , as well as in the endometrial cancer, where the co-expression of PXR 
together with CYP3A4 could lead to drug resistance (Masuyama et al. 2003).
PXR and CYP3A4 have been reported to be expressed in the normal endometrium 
(Williams et al. 2004) and the presence of putative ER binding sites may suggest that 
the ER is an inducer of PXR, the latter being activated by the ER ligand. This could 
be of help when designing drugs for the treatment of breast cancer specifically, to 
predict the adverse side effects of anti estrogen drugs.
3.3.2.3 Vitamin D receptor
The vitamin D receptor (VDR) forms a heterodimer with RXRa upon activation and 
induces target genes (Pascussi et al. 2003) via binding to a direct repeat consensus 
sequence separated by three nucleotides AGGTCANNNAGGTCA (Freedman 1992).
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However, it may also bind to the same response elements as the PXR and CAR 
(Pascussi et al. 2003). Recently it has been shown that PXR induces the expression of 
the CYP24 enzyme, an enzyme involved in the hydroxylation of the vitamin D, 
probably through direct binding of the PXR to the CYP24 promoter (Pascussi et al.
2005). CYP3A4 has also been reported to be involved in the 25 hydroxylation of the 
vitamin D (Gupta et al. 2004b). The presence of a putative binding site for the VDR in 
the proximal promoter (table 3.1, figure 3.2) suggests that VDR may regulate PXR 
expression, which could result in the induction of the PXR target gene CYP24 and 
CYP3A4 for the inactivation or the activation of the vitamin D respectively Thus 
giving a role for PXR in regulation of the vitamin D, which could impact on bone 
mineralization.
3.S.2.4 Farnesoid x Receptor
The farnesoid X receptor (FXR) is known as a bile salt sensor, and forms a 
heterodimer with RXRa (Makishima et al. 1999) to bind to a consensus AGGTCA 
oriented as IR in target genes (Pineda Torra et al. 2003). FXR down regulates the 
expression of the enzyme involved in bile salt biosynthesis (cholesterol 7a 
hydroxylase CYP7A1) via the activation of SHP (Grober et al. 1999). PXR is also 
known to be involved in the regulation of bile acid homeostasis, down regulating the 
CYP7A1 (Xie et al. 2001). The presence of a putative binding site for FXR within the 
PXR proximal promoter suggests that there is some functional redundancy between 
these two nuclear receptors, as PXR is also activated by lithocholic acid, making a 
double safety mechanism against potentially toxic increases in the levels of bile acids.
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3.3.2.S Barbie box
The barbie box was originally identified in Bacillus megaterium, and shown to confer 
responsiveness to barbiturate via an important cw-acting elements in the promoter of 
the P450 BM-1 and 3 genes consisting of the core AAAG (Liang et al. 1995). It has 
since been identified in several other species including the proximal promoter of 
mammalian CYP2B1/2 and CYP2C1 (He and Fulco 1991). Although no specific 
protein was found to bind to the Barbie box, and the deletion of this site did not affect 
the responsiveness of P450BM, CYP2B1, CYP2B2, and CYP3A2 genes to 
phénobarbital (reviewed by (Sueyoshi and Negishi 2001)). The responsiveness to 
phénobarbital and phenobarbital-like drugs in mammalians is conferred to a PREM 
(phénobarbital responsive enhancer module), consisting of two nuclear receptor 
motifs (NRl and NR2 represented by DR4), which bind the CAR/RXRa heterodimer 
(Honkakoski et al. 1998b). These two sites have been reported to be important for 
phénobarbital responsiveness and the PBREM does not contain a Barbie box 
(Honkakoski et al. 1998a). Whether this factor confers responsiveness to 
phénobarbital for the PXR needs to be clarified using phénobarbital, but was not the 
aim of the current study.
3.3.2.6 Progesterone receptor
Progestérones are important in maintaining pregnancy in mammals, and for the 
female reproductive functions, and their effects are mediated through the nuclear 
progesterone receptor (PR). PR is induced by estrogens via ER (Lydon et al. 1996) 
and progesterone is known to down regulate the expression of the estrogen receptor to 
modulate the menstrual cycle (Okulicz et al. 1993). PR binds to an inverted repeat as 
a homodimer, separated by three nucleotides AGAACAnnnTGTTCT (Lucas and
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Granner 1992). This is the same as the GRE and this response element is often 
referred to the P/GRE. Progesterone is an activator of the PXR (Kliewer et al. 1998), 
and a substrate for the CYP3A4 enzyme (Gibson et al. 2002). The presence of a 
putative binding site for the PR on the PXR promoter (table 3.1, figure 3.2), may 
suggest that the PXR in addition to being activated by progesterone, is 
transcritpionally induced by the hormone itself, through the PR, to increase the 
expression of the CYP3A4 enzyme for the metabolism of the Progesterone.
S.3.2.7 Androgen receptor
Androgen receptor (AR) is a ligand-dependent nuclear receptor member of the steroid 
receptors, activated by androgens, and induces transcription in target genes which are 
involved in development and growth (Chang et al. 1995). The AR binds as a 
homodimer to a consensus sequence organised as an inverted repeat 
AGAACAnnnTGTTCT, identical to that utilized by GR and PR (Lucas and Granner 
1992). High levels of AR are expressed in the male reproductive organs, and also in 
the uterus, urinary bladder, liver, gastrointestinal tract, kidney, and pancreas (Takeda 
et al. 1990). Androgens have been implicated in prostate cancer, and anti-androgen 
therapy is the basis for treatment. In men, the primary circulating androgen is 
testosterone, and is produced mainly in leydig cells, and partly in adrenal glands. 
They are also converted to estrogens in fat tissues (Debes and Tindall 2002). With 
testosterone being a substrate for CYP3A4 (Gibson et al. 2002) the presence of a 
putative binding site for this receptor in the PXR promoter may suggest that the 
androgens are able to induce the expression of PXR gene, thus increasing the 
expression of the CYP3 A4 and hence metabolism of testosterone.
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3.3.2.S Peroxisome proliferator activated receptor alpha
The peroxisome proliferator activated receptor alpha (PPARa) forms a heterodimer 
with the RXRa and binds to an imperfect DR separated by one nucleotide 
AGGTCANAGGTCA (Johnson et al. 2002). The PPARa ligands clofibrate and 
perfluorodecanoic acid have been shown to induce the expression of rat PXR mRNA, 
although these ligands for PPARa are not considered ligands for PXR (Zhang et al.
1999). The presence of the PPARa/RXRa binding site in the human PXR promoter at 
1335 base pairs from the transcription start site, suggests that this effect is not only on 
the rat PXR but also on human PXR and the induction is probably at the 
transcriptional level. Further analysis will help to investigate the functionality of this 
binding site. This will be discussed in chapter 5.
3.3.2.9 Nuclear factor kappa B
Nuclear factor kappa B (NF-kappa B) is a nuclear transcription factor (Giri and 
Aggarwal 1998) and plays a role in the anti apoptotic process and confers resistance 
to Tumor Necrosis Factor (Zhou et al. 2000). Tumour necrosis factor is an anti­
inflammatory cytokine that induce apoptosis (Van Antwerp et al. 1998) and is 
activated by chemotherapeutic drugs and stress stimuli, such as X rays (Giri and 
Aggarwal 1998). NK-kappa B binds to the consensus sequence, GGGRNNYYCC 
(where R indicates A or G, Y indicates C or T, and N indicates any base) (Parry and 
Mackman 1994). The presence of a putative binding site for this factor in the PXR 
promoter may suggest that the PXR could be involved in the apoptosis process by 
either inducing or inhibiting it.
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3.3.2.10 Aryl hydrocarbon receptor
The aryl hydrocarbon receptor (AhR) forms a heterodimer with the aryl hydrocarbon 
translocating factor (Amt) (Gonzalez and Femandez-Salguero 1998) and binds to a 
consensus DNA sequence called the dioxin response element (DRE), namely 
TNGCGTG (Masten and Shiverick 1995). The presence of a putative binding site for 
the AhR/Amt in the PXR promoter may suggest that this heterodimer induces the 
expression of PXR in response to its ligands, thus implicating the PXR in the 
metabolism of the PAHs and related carcinogens. In fact, Maglich et al, showed that 
rifampicin-activated PXR induced the AhR receptor and its target gene CYPlAl 
(Maglich et al. 2002). These results suggest that the nuclear receptors regulate each 
other’s expression in order to condition the cells to respond to the best way to over 
come any potential disturbance to normal homeostasis.
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3.4 Conclusion
My in silico analysis has allowed to identify the PXR proximal promoter region, and 
putative transcription factor sites present therein. The putative binding sites identified 
in the PXR proximal promoter suggest the interaction of many transcription factors 
with this promoter, and several ligand-activated transcription factors are of particular 
interest. This suggests that PXR is potentially under the transcriptional regulation of 
many different factors, which may underly the ability of PXR to respond to a wide 
range of different chemicals. Of some surprise to me was the identification of binding 
sites for ligand-activated transcription factors such as PPARa and AhR, whose 
ligands are not traditionally thought of as targets for genes whose expression is 
activated by PXR.
In vitro analysis is now required to further investigate the regulation of PXR gene 
expression and to confirm the functionality of these interaction sites.
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4 CHAPTER: TRANSCRIPTIONAL REGULATION OF PXR BY 
LIVER ENRICHED AND LIGAND-ACTIVATED 
TRANSCRIPTION FACTORS
4.1 Introduction
PXR regulates a large set of genes involved in many different biological functions, 
and it responds to structurally unrelated drugs and environmental contaminants. 
Enzymes regulated by PXR include those involved in phase I drug metabolism, such 
as CYP3A4, CYP3A7 (Gibson et al. 2002), phase II enzymes, such as the GST-A2 
and drug transporters, such as 0ATP2, MDRl (Maglich et al. 2002). The structural 
characteristics of the PXR LBD, allows it to accommodate and bind a wide range of 
chemicals, meaning it has the ability to be activated by, and respond to, a large 
number of extend stimulii (Watkins et al. 2001). In addition, the importance of this 
receptor in maintaining cellular homeostasis is being increasingly recognised. Indeed,
PXR is regarded as a master regulator of body homeostasis as it has been shown to 
respond to endogenous ligands such as bile acids (Staudinger et al. 2001), and it is 
though to be a sensor for the body’s over-load of cholesterol (Sonoda et al. 2005).
Previous work on the PXR promoter has demonstrated that HNF4a may regulate 
mouse PXR in foetal hepatocytes (Kamiya et al. 2003). The inactivation of the 
HNF4a in mouse fetal hepatocytes, using a Cre-lox technique resulted in the 
suppression of expression of PXR and its target gene CYP3A11. The identification of 
a functional binding site for the HNF4a within the first 200 base pairs of the PXR 
proximal promoter, showed that the effect conferred by the HNF4a was though direct
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binding to PXR promoter (Kamiya et al. 2003). Whether the human PXR is regulated 
by this factor additionally needs to be explored. The glucocorticoid ligand 
dexamethasone induces mRNA for PXR, suggesting that the glucocorticoid receptor 
may regulate PXR gene expression (Pascussi et al. 2000a), although whether 
glucocorticoid receptor binds directly to the PXR regulatory regions is not known.
PXR is also regulated at the protein level, where the small heterodimer partner (SHP) 
interacts with the PXR receptor and suppresses its activity (Ourlin et al. 2003). This is 
important for the bile acids homeostasis, where the PXR has also been shown to 
regulate the expression of the SHP, and reduces bile acids synthesis (Frank et al.
2005). Hence, PXR is regulated at both the transcriptional level and protein levels.
The in silico data described in chapter 3 showed that the PXR proximal promoter 
contains several putative binding sites for general and ligand-activated transcription 
factors. This opened the opportunity to further explore the role of several putative 
PXR activating factors. My initial investigation of the molecular mechanisms of PXR 
gene regulation, involved the generation of deletion constructs of the promoter and 
identification of the effects of each of the fragments generated. Initially, the activity of 
both, the whole 2200 bp PXR proximal promoter construct, and the deletion 
constructs were examined in Huh7 cells. Following this, expression plasmids for 
general transcription factors and ligand-activated transcription factors were co­
transfected, and their effect on the PXR reporter gene examined.
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4.2 Generation of PXR proximal promoter deletion constructs
2200 bp of the PXR proximal promoter was amplified from human genomic DNA and 
cloned into SEAP reporter gene. This 2200 bp construct was used as a template for 
the generation of nine smaller daughter constructs. Figure 4.1 shows the steps 
undertaken to generate the deletion constructs. Table 4.1 shows the primers used to 
amplify the fragments, the length of the fragments, and the cutting sites for enzymes. 
Table 4.2 shows the enzymes used for the generation of the 900, 600 and 400 base 
pairs fragments.
Figure 4-1 Strategy followed for the generation of the deletion constructs.
I Stage 1 I 
/  \
PCR with nested primers containing restriction 
sites for enzymes (Table 4.1), using 2200 bp 
construct as template.
2200 bp construct digested with enzymes to 
generate 400, 600 and 900 bp fragments 
(Table 4.2)
\  /
Stage 2
Gel purification o f 1600, 1500, 1300, 1200, 
900, 600,400,200 and 76 bp fragments
Stage 3
Ligation into SEAP
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Table 4-1 Primers used to generate deletion constructs.
The mutated restriction site is shown in bold. The diagnosis for insert was checked 
with double restriction digest and confirmed by sequencing.______
Length Forward primer Reverse primer Enzymes for 
insert diagnosis
1600
bp
B fa l
cctttca^gctttccaccc 
— ► Hind III
atgatgcccagggagagctg Hind III + EcoR I
1500
bp
tccact^taccgaaatccagt 
Rsa I  ► Acc651
tcaactgggatgatgcccag Acc651 + EcoR I
1300
bp
aggacaygctttatggctgtgg 
Sac I  ► Hnid III
atgatgcccagggagagctg Hind HI + EcoR I
1200
bp
tcaacc^tagcaaatcccagc gatgatgcccagggagagctgt Nhe I  + EcoR I
B fa l  ► N h e l
200 bp tcattt^ctagctcaagtgctgg 
Bfa Nhe I__________
tccgggttctcctcctcaac Pst I  + Not I
76 bp ctatg^ctagcacgggaagaggaa 
B fa l—^Nhe I____________
tggcagctgtcaccgtagacacc PCR
Table 4-2 Enzymes used for the generation of the 900, 600 and 400 base pairs 
constructs.
Fragments Enzymes generating insert Enzymes for insert diagnosis
900 bp Acc 651+ Apa I EcoR I  + Not I
600 bp Xho I EcoR I  +Acc651
400 bp B g lll EcoR I  +Acc651
Figure 4.2 shows the digested clones with the respective enzymes. For the 76 base 
pair insert, PCR was used to check for the presence of the insert due to its small size. 
All the inserts were confirmed by sequencing. Sequencing was done with the forward 
and reverse SEAP primers, to confirm for the orientation of the insert.
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Figure 4-2 Agarose gel electrophoresis analysis of the deletion constructs.
Ladder 2.2 1.6 1.5 1.3 1.2 1.1 900 600 400 200
B
5kb
2kb
Ikb
2kb
Ikb
76bp
A: Each construct was double digested to liberate the insert from the SEAP basic 
plasmid. The double digest cut the plasmid into two, giving the blank plasmid SEAP, 
of 4.7 kb, and the inserts 2.2, 1.6, 1.5, 1.3, 1.2, 1.1 kb, 900, 600, 400 bp. The construct 
for the 200 bp fragment was digested with enzymes giving fragment of the size of 
500bp. B; The analysis of the insert for the 76 bp fragment was carried out by PCR, 
with the primers used to amplify the fragment. The reactions were run on a 1% 
agarose gel together with the 1 kb step ladder, and electrophoresed for 20 minutes.
4.3 Optimisation of the reporter gene assay
In order to determine the optimum conditions for the reporter gene assay, and to 
ensure robust, reproducible experiments the time for optimum SEAP production and 
the effect of culture age needed to be examined. The SEAP activity was measured at 
24, 48 and 72 hours post transfection (figure 4.3). It can be seen that at 24 hours there 
is no significant SEAP activity compared to the control vector (empty vector), but a 
significant increase is observed after 48 and 72 hours. Examination of the deletion 
constructs suggested that 48 hours exposure produced the most reproducible effects.
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Also for time saving, a 48 hours reading was chosen as the time for SEAP activity to 
be measured.
Figure 4-3 Determination of the best time for the expression of the PXR reporter 
gene assay.
50000-
Fc
40000-
=
I 30000-
Ico 20000-
2
S 10000-
gg
* * *
* * *
24 h 
48 h 
72 h
Control 2200
The 2200 bp construct was transfected into Huh? cells with the empty vector 
representing the negative control. SEAP activity was measured at 24, 48 and 72 hours 
post transfection. The experiment was undertaken on two separate occasions. Each 
data point represents the mean, plus SEM, for three biological repeats (n=3), Ns= not 
significant, ***=p<0.001 by one-way ANOVA with Bonferoni post hoc analysis.
From previous work undertaken in our lab, it was suggested that the Huh? cells lost 
their ability to respond to drugs with extensively passaged cells and it was suggested 
that the loss of cell phenotype was responsible of this phenomenon. Accordingly, the 
2200 bp construct was transfected into Huh? cells at different passage numbers, from 
passage 12 till passage 20 (with passage 11 being freshly recovered cells from liquid 
nitrogen). Figure 4.4 shows that PXR expression dropped markedly between passages
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17 and 20, suggesting a loss of transcriptional activity towards PXR. Fututre 
experiments were thus limited to passage number 12 through to 17.
Figure 4-4 Loss of the celFs responsiveness to the reporter gene assay with highly 
passaged numbers
ns
45000
40000
_  35000- 
|  |  30000 
I l  25000
0 i  20000
1 I  15000
10000
12 13 16 17 20
Huh7 cells passage number
The 2200 bp construct was transfected into Huh7 cells at different passage number. 
SEAP activity was measured 48 hours postransfections. The experiment was 
undertaken on two separate occasions. Each data point represents the mean, plus 
SEM, for three biological repeats (n=3). *=p<0.05, **=p<0.01, ns= not significant by 
one-way ANOVA with Bonferoni post hoc analysis.
4.4 Determination of the PXR activity of each deletion construct
The activity of each reporter gene construct, compared to the next smaller one gives 
the activity of DNA binding elements contained within the unique region of the larger 
construct: The 2200 bp full construct represents the net activity of all other constructs. 
Using this system, it is possible to identify positive and/or negative regulatory regions
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within the PXR promoter. The next step would then be to identify which of these 
DNA binding elements mediate the positive or the negative effects observed.
Figure 4.5 shows PXR the activity of each construct when transfected into Huh? cells. 
All constructs showed some activity; although it can be seen that a wide variation in 
the activity of the fragments can be seen, this is indicative of the unique regulatory 
elements contained with each fragment. Fragments 400, 900 and 1600 base pairs 
showed a net negative regulation of PXR gene expression when compared to the next 
smaller fragment, whereas the 600, 1200 and the 2200 showed a positive regulation of 
the PXR gene expression relative to the previous smaller construct. The highest 
response was with the 1200 bp fragment, and the overall effect with the 2200 bp 
fragment was, as expected, a positive regulation of the PXR.
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Figure 4-5 Positive and negative transcriptional elements in the PXR proximal 
promoter
eOOOOn
_ S  50000- 
o c
8 Z  400004
<D £
Q. 300004 
LU o 
OC 20000 -  
X JS
2  10000 -
2200 ts s
Transfection of a deletion constructs series from the parent 2200 bp PXR reporter 
gene construct. SEAP activity was measured 48 hours postransfection as described in 
materials and methods. SEAP activity of each fragment was compared to its smaller 
daughter construct, and regions of the PXR proximal promoter designated as 
containing positive (+) and negative (-) basal regulatory elements, tss = putative 
transcription start site. Each data point represents the mean, plus SEM, for three 
biological repeats (n-3). **=p<0.01, ***=p<0.001 relative to previous construct by 
one-way ANOVA with Bonferoni post hoc analysis.
102
4.5 PXR is differentially affected by liver enriched and ligand activated 
transcription factors
The in silico analysis gives only a hypothesis on potentially functional binding sites 
within a promoter. To delineate the molecular mechanisms of PXR gene expression it 
was necessary to investigate the role of transcription factors, including the liver- 
enriched transcription factors (LETFs) and the ligand-activated transcription factors 
(LATFs) to confirm their involvement in PXR gene regulation.
In silico analysis showed the existence of several putative binding sites for LETFs, 
including HNFla, HNF3a/p and HNF4a, and also for LATFs including GRa, ERa, 
VDR and PPARa. Initially, the full 2200 bp PXR proximal promoter reporter gene 
construct was co-transfected with expression plasmids for these transcription factors 
to examine their effects on PXR gene expression. Figure 4.5 shows the effect of the 
co-expression of these factors, the LETFs (figure 4.6 A) and LATFs (figure 4.6 B) on 
the 2200 base pairs (bp) construct.
As PXR is highly expressed in the liver, relative to the other organs, it is perhaps not 
surprising that the LETFs would have a role in the regulation of PXR gene expression. 
The results show that the HNF3p and 4a  factors down regulate the expression of the 
PXR. By contrast, LATFs were, in general, activators of PXR gene expression, with 
the exception of PXR and CAR, which were shown to significantly repress PXR gene 
expression. This suggests that regulation of PXR gene expression is complex, with 
many factors having positive and negative effects; this is consistent with the complex 
regulatory regions observed under basal expression (figure 4.5).
As many of these transcription factors appear to alter PXR gene expression to some 
extent, and taking into account the complexity of the proximal promoter, a logical
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next step would be to examine the effect of these transcription factors on different 
reporter gene fragments, further refining their interaction sites. The effect of PPARa 
will be discussed in chapter 5.
Figure 4-6 Transcriptional regulation of the basal expression of PXR by LEFTs 
and LATFs.
100t
B Control hnf1 a  hnfSa hnfSp hnf4a 
Co-transfected LETF
s{c ^
300-r
***
Control ERa GRa RXRa PXR CAR VDR PPARa 
Co-transfected LATF
The 2200 bp construct was co-transfected with either LETFs (A) or LATFs (B) into 
Huh? cells. SEAP activity was measured 48 hours post-transfection. Data are 
representative of experiments undertaken on three separate occasions, representing 
three biological repeats (n=3). Variation between repeat measurements was less than 
10% for all data points. *=p<0.05, **=p<0.01, ***=p<0.001 ns=not significant 
relative to no co-transfected control by one-way ANOVA with Bonferoni post hoc 
analysis.
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4.6 Effects of the hepatic nuclear factors
Hepatic nuclear factors are liver enriched transcription factors and are involved in the 
constitutive expression of hepatic genes (Akiyama and Gonzalez 2003). Of particular 
interest is that several hepatic nuclear factors (HNFs) family members (HNFl, HNF3 
and HNF4) have been reported to play important roles in the regulation of P450 gene 
super family members (Gonzalez and Lee 1996), several of which are also regulated 
by PXR. HNFs, in particular HNFl and HNF3, are not described as traditional 
ligand-activated TFs, they do not respond to ligands, they do not possess a ligand 
binding domain, and these factors are reported to regulate genes involved in liver 
functions (Cereghini 1996). It should be noted that the HNF4 is classified as a 
member of the nuclear receptor superfamily, as it contains a LBD, but the ligands for 
this factor are not known (Sladek et al. 1990). However, in contrast to PXR, this 
activation probably acts to programme the tissue specific expression patterns elicited 
by HNFs, rather than the ability to respond to fluctuating levels of chemical stimulii. 
The HNFs regulate genes involved in diverse functions, and appear to regulate each 
others expression. For example, HNF3p regulates the expression of H N Fla, HN3a 
and HNF4a (Duncan et al. 1998). HNF4a has also been shown to regulate the 
transcriptional activity of H N Fla (Tian and Schibler 1991).
The facts that PXR is highly expressed in the liver and my preliminary in silico data 
suggested that the PXR promoter probably contains several binding sites for the 
HNFs, is supportive of the hypothesis that PXR is under the regulation of some, if not 
all, of the HNFs.
Previous work carried out on the PXR promoter, reported that HNF4a controls the 
expression of PXR gene expression in mouse foetal hepatocytes. This was probably
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through binding to the proximal promoter, where a binding site for HNF4a was 
identified in the first 200 base pairs, relative to the transcription start site (Kamiya et 
al. 2003). But whether this factor or other HNFs play the same role towards the 
human PXR needs to be investigated. The in silico data showed the presence of 
several putative binding sites for the HNFs, supporting such a hypothesis. 
Co-transfection of the whole 2200 base pairs construct with the HNFs showed that the 
HNF3p and HNF4a down regulate the expression of PXR (figure 4.6 A). Next, the 
effects of these factors were therefore now examined on shorter fragments of the PXR 
proximal promoter, in order to compare my data with the findings done by Kamiya et 
al (2003). This latter group demonstrated that the positive effect of the HNF4a on the 
PXR gene expression was through direct binding to PXR proximal promoter in foetal 
mouse hepatocytes, and the deletion of the HNF4a allele with Cre-lox, caused a 
suppression of PXR expression in fetal mouse hepatocytes (Kamiya et al. 2003). The 
reporter constructs 200 and 76 were co-transfected with expression plasmid for these 
HNFs. These shorter constructs were specifically chosen because of the presence of a 
putative binding site for HNF3p at 67 and another one for the HNF4a at 186 base 
pairs from the transcription start site. An H N Fla putative binding site was identified 
with the in silico analysis at about 93 base pairs from the transcription start site. As 
HNF3a binds to the same response element as HNF3p (Duncan et al. 1998) it was 
interesting to investigate effect of this HNF as well. Figure 4.7 shows the effect of the 
different HNFs on the 76 base pairs construct (A) and on the 200 base pairs construct 
(B).
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Figure 4-7 Effect of hepatic nuclear factors on PXR gene expression.
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Huh7 cells were transfected with the SEAP constructs for the 76 (A) and 200 (B) base 
pairs of the PXR promoter. They were co-transfected with the expression plasmid for 
the hepatic nuclear receptor la , 4a, 3a, and 3p. Positions of the HNFla, HNF3p and 
HNF4a within the PXR promoter and their relative positions are shown. Data is 
representative of experiments undertaken on three separate occasions representing 
three biological repeats (n=3). Variation between repeat measurements was less than 
10% for all data points. SEAP activity was measured 48 hours post transfections. 
**=p<0.01,***=p<0.001 relative to no-cotransfected control by one-way ANOVA 
with Bonferroni post hoc analysis.
The results of the co-transfection of expression plasmids for the HNFs showed that 
the HNF3p and HNF4a increased PXR gene expression, which suggests that the in 
silico predictions are correct. The results obtained with the HNF4a shows that the 
PXR gene expression between human and mouse is maybe similar. However, the 
effect of the HNF4a on the entire construct showed that this factor represses the PXR
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gene expression (Figure 4.6(A)). This could be due to a difference between the adult 
and foetal gene regulation of PXR, or simply a difference between human and rodent 
gene regulation of the PXR. The effect of HNF3a on the PXR gene expression is 
probably through binding to the same binding site as HNF3p. Whereas the in silico 
predictions for the HNF3P and HNF4a are probably correct and functional, that of the 
H N Fla may not be correct or not functional.
4.7 Steroid receptors mediated transcriptional activation of the PXR gene 
expression
The steroid hormone nuclear receptor family comprises several LATFs, including ER, 
GR, VDR, RXR, and PR (Tsai and O’Malley 1994). They all seem to be connected to 
the PXR or CYP3A4 in one way or another: For instance, estrogen, progesterone and 
cortisol, are all known to be substrates for the CYP3A4 enzyme (Gibson et al. 2002), 
and are reported to be activators of PXR receptor. In addition, the active form of the 
vitamin D induces the CYP3A4 gene expression (Drocourt et al. 2002).
To further understand the molecular mechanisms by which PXR is regulated, it was 
important to investigate the potential role of these factors that could have in PXR gene 
regulation. The role of GRa, ERa and VDR will be examined as putative binding 
sites were identified with the in silico search.
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4.7.1 The estrogen receptor regulates PXR gene expression
The estrogen receptor is a steroid hormone receptor that bind to the consensus 
sequence AGGTCA (oriented as inverted repeat) as a homodimer (Tsai and O’Malley 
1994), although it has been shown to form a heterodimer with ERp and bind to the 
same response element (Cowley et al. 1997). Estrogen receptor target genes are 
generally those involved in the metabolism (both anabolism and catabolism) of 
estrogen and its derivatives, and thus plays an important role in maintaining levels of 
these important sex hormones (Smith 1998).
Overall, four putative binding sites for ERa were identified with high match 
similarity within the PXR proximal promoter. In order to identify whether the 
estrogen receptor has an effect on PXR gene expression, and to identify which of 
these putative binding sites was likely to show biological activity, an expression 
plasmid for ERa was co-transfected with several PXR deletion constructs and any 
alterations in activity examined. No exogenous ligand for the estrogen receptor was 
added to the system on the presumption that levels of endogenous estrogens within 
Huh7 cells are sufficient to activate the ER.
As can be seen from Figure 4.8 increased expression of the estrogen receptor resulted 
in an increased level of SEAP expression for most of the constructs. The fragment 
between 2200 and 1600 showed an increase in PXR expression; this is probably 
through the direct binding of the ER to the putative binding site found at -1855. The 
increase in expression with the. fragment between 1200 and 600 is likely to be due to 
the direct binding of the ER to the response elements found within the PXR promoter 
at 987 and 618. No putative binding sites were identified within the first 400 base 
pairs of the proximal promoter, where a strong activation of gene expression was 
noted: This suggests an indirect mechanism, probably be involving a second factor.
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which needs to be further investigated. These net effect of these coordinated response 
is an up regulation of PXR gene expression in response to endogenous estrogen 
receptor ligands, as evidence by the increase seen for the full length construct (Figure
The repression of the 1500 bp construct following the over expression of the ER, 
could be a regulatory effect against an over expression of PXR by the ER. This effect 
could be through binding of the ER to a non-consensus binding site, or involving 
another factor. This repression of the 1500 bp construct could be produced in another 
tissue like for instance breast tissue, where there is an inverse relationship between 
PXR and ER levels of expression (Dotzlaw et al. 1999).
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Figure 4-8 Transcriptional activation of PXR gene expression by the ERa
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Huh7 cells were transfected with SEAP reporter gene constructs containing 2200, 
1600, 1500, 1200, 1100, 600 or 400 base pairs of the PXR promoter. The positions of 
the putative binding sites for the ER are represented. The constructs were co­
transfected with the expression plasmid for the ERa. SEAP activity was measured 48 
hours later with the chemiluminescence reporter gene assay as described in material 
and methods. Data is representative of experiments undertaken on three separate 
occasions, representing three biological repeats (n=3). Variation between repeat 
measurements was less than 10% for all data points. For each promoter fragment 
tested, the respective fragment minus co-transfected expression plasmid was used as 
control; these values were normalized to 100%. *=p<0.05, ***=p<0.001 relative to no 
cotransfected control by one-way ANOVA with Bonferroni post hoc analysis.
I l l
4.7.2 The glucocorticoid receptor a  regulates PXR gene expression
The glucocorticoid receptor (GR) is a ligand activated transcription factor, binds as a 
homodimer to the consensus sequence AGGTCA, oriented as an inverted repeat (Lee 
et al. 1993). GR exists in two isoforms, GRa and GRp, as a result of a splice variant, 
which differ in their carboxyl terminal (Encio and Detera-Wadleigh 1991). GRp is 
located mainly in the nucleus, and does not bind the glucocorticoid agonist 
dexamethasone nor the glucocorticoid antagonist RU38486 in vivo (Oakley et al.
1996). GRp is expressed mainly at low levels, in all human tissues (Dahia et al. 1997), 
and functions mainly to inhibit the GRa, by forming a non-functional heterodimer 
(Oakley et al. 1996). In comparison, GRa is widely expressed and is involved in 
different functions, such as the regulation of protein and lipid metabolism, and 
inflammation (Dahia et al. 1997). Dexamethasone, which is a GRa ligand, increased 
the levels of the PXR mRNA with sub-micro molar concentrations (Pascussi et al. 
2000a), demonstrating that the nuclear receptors interplay to modulate the body 
response to xenobiotics. It is, however not known whether the GR is directly 
mediating the activation of PXR by binding to its promoter or involving other, 
unknown factors.
Five putative binding sites were identified for GRa in my in silica analysis, with high 
match similarity. Figure 4.9 shows the input of different constructs into the overall 
activation of PXR by the GRa protein. No significant effect was seen on the 
expression of the 1600, 1200, 1100 and 600 PXR deletion constructs. These fragments 
containing putative GREs (at -1571, and -613) this would suggest that in this case the 
putative binding sites for the glucocorticoid receptor may have been an incorrect in 
silico assignment, or that the binding site is present but non-functional in vitro.
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Finally, it is possible that the site is theoretically functional, but that an unknown 
transcription factor may inhibit the action of the GRa at this site.
Figure 4-9 Transcriptional regulation pf PXR gene expression by GRa.
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Huh? cells were transfected with SEAP reporter gene containing 2200, 1600, 1500, 
1500, 1200, 1100 or 600 base pairs of the PXR promoter. The positions of the 
putative binding sites for the GRa are represented. The constructs were co transfected 
with the expression plasmid for the GRa. SEAP activity was measured 48 hours later 
with the chemiluminescence reporter gene assay as described in material and 
methods. Data is representative of experiments undertaken on three separate 
occasions, representing three biological repeats (n=3). Variation between repeat 
measurements was less than 10% for all data points. For each promoter fragment 
tested, the respective fragment minus co-transfected expression plasmid was used as 
control; these values were normalized to 100%. **=p<0.01 relative to no 
cotransfected control by one-way ANOVA with Bonferroni post hoc analysis.
The fragment between 1500 and 1200 bp may contain an important GRE regulatory 
element, causing a decrease in the expression of the PXR gene in response to 
glucocorticoid receptor ligands. The in silico data mining predicts a putative binding
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for the GR at 1453 with high match similarity. However, it is known that GRa ligands 
such as dexamethasone actually increase the level of PXR gene expression (Pascussi 
et al. 2000a), suggesting that further levels of control are required. GRa caused an 
increased in the PXR expression levels, as the co-transfection of the GRa with the 
whole construct resulted in the induction. This suggests that the 1600-2200 base pairs 
region contains positive elements for GRa. In silico analysis suggests a putative 
binding sites at 1918, and 1785 between the 2200 and the 1600 base pairs from the 
transcription start site. It is possible that these latter elements could interact with the 
downstream element to coordinate the net response of the PXR proximal promoter to 
GRa activation; this latter interaction would then explain the final positive action of 
glucocorticoid receptor ligands on PXR gene expression previously observed 
(Pascussi et al. 2000a).
Pascussi et al showed that the pre-treatment of the primary hepatocytes with 0.01 pM 
of dexamethasone showed an increase in the PXR mRNA levels (Pascussi et al. 
2000a). Pre-treatment of Huh? cells with 0.01 pM dexamethasone produced an 
increased in the expression of the basal expression of the PXR when the 2200 
construct was transfected consistent with activation of PXR gene expression by 
glucocorticoids (figure 4.10). These results combined with that obtained by Pascussi 
et al (Pascussi et al. 2000a), show that the induction of the PXR is probably at the 
transcriptional level. This also shows that the reporter gene assay behaves as observed 
in vivo, where the treatment of animals with dexamethasone resulted in an increase in 
the PXR mRNA levels (Zhang et al. 1999).
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Figure 4-10 Effect of the pre-treatment of Huh? cells with submicromolar 
concentrations of dexamethasone on PXR expression
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Huh? cells were transfected with SEAP reporter gene containing 2200 base pairs of 
the PXR proximal promoter. Huh? cells were pre-treated with 0.01 pM of 
dexamethasone overnight or with 0.1% DMSO. SEAP activity was measured 48 hours 
later with the chemiluminescence reporter gene assay as described in material and 
methods. Data is representative of experiments undertaken on two separate occasions, 
representing three biological repeats (n=3). Variation between repeat measurements 
was less than 10% for all data points. **=p<0.01, ns: not significant, relative to non 
treated cells by one-way ANOVA with Bonferroni post hoc analysis.
4.?.3 Transcriptional activation of the PXR by the retinoid X receptor a
The retinoic X receptors (RXR) belong to the superfamily of nuclear receptors, and 
consist of three isoforms, namely RXRa (NR2B1), RXR(3 (NR2B2) and RXRy 
(NR2B3), which show some functional redundancy, where the triple mutant mouse
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RXRa +/-, RXRp RXRy are normal with no obvious congenital or postnatal 
abnormalities (Krezel et al. 1996), this suggests that RXRa alone is sufficient for 
completion of a number of RXR functions. For example, in RXRa knock out mice, 
treated with the CAR ligand TCPOBOP or the PXR ligand PCN, CYP3A1 mRNA 
was still induced, suggesting RXRp or RXRy was capable of functionally replacing 
the missing RXRa (Cai et al. 2002).
RXRa can form a heterodimer with several other nuclear receptors, including the 
thyroid receptor (TR), VDR, PPARs, CAR and PXR (Mangelsdorf and Evans 1995; 
Bertilsson et al. 1998; Lehmann et al. 1998). The fact that RXRa is a heterodimer 
partner for many transcription factors means that it could act as a rate-limiting factor 
for the transcriptional activity of these nuclear receptors. However, as RXRa is highly 
expressed in both adult liver and the human hepatoma cell line Huh7, this was initially 
thought not to be the case (Phillips et al. 2005). However, as many of the ligand 
activated transcription factors examined in my study heterodimerise with RXRa prior 
to interaction with DNA, I felt it was important to examine the effects of RXRa over 
expression on the test system I have developed for analysis of PXR expression. 
Although RXRa is highly expressed in Huh? cells, co-transfection of this factor 
caused a significant increase in PXR gene expression (figure 4.11). This effect was 
observed for all the fragments examined, consistent with the role of RXRa as a 
heterodimer partner for several factors thought to influence PXR gene expression
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Figure 4-11 Positive regulatory effect of RXRa on PXR gene expression.
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Huh7 cells were transfected with the 2200, 1600,1500, 1100 and 600 base pairs 
constructs of the PXR promoter. All constructs were cotransfected with the expression 
plasmid for the RXRa and SEAP activity was measured 48 hours post transfections. 
Data representative of experiments undertaken on three separate occasions, 
representing three biological repeats (n=3). Variation between repeat measurements 
was less than 10% for all data points. For each promoter fragment tested, the 
respective fragment minus co-transfected expression plasmid was used as control; 
these values were normalized to 100%. ***=p<0.001 relative to the no cotransfected 
control by one-way ANOVA with Bonferoni post hoc analysis
Because the over expression of RXRa produced an enhanced response, it was 
important to investigate whether RXRa increased the activation of PXR gene 
expression in response to other nuclear receptors. Figure 4.12 shows that over 
expression of RXRa elicited an increase in VDR mediated activated of PXR 
expression. Hence, the heterodimerisation of the VDR with the RXRa may be
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dependent on RXRa availability. Such a result is consistent with the observation that 
RXRa knock out mice, the basal expression of CYP2A5 and CYP2B mRNA are 
down regulated, suggesting that RXRa-mediated pathways control the basal 
expression of these genes (Cai et al. 2002).
Figure 4-12 Role of the RXRa in mediating the VDR transcriptional expression 
of the PXR expression.
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The 2200 bp construct was co transfected with VDR either alone or with the RXRa 
expression plasmid in Huh? cells. SEAP activity was measured 48 hours post 
transfections. Data are representative of experiments undertaken on three separate 
occasions, representing three biological repeats (n=3). Variation between repeat 
measurements was less than 10% for all data points. ns= not significant,***=p<0.001 
relative to the no-cotransfected control by one-way ANOVA with Bonferoni post hoc 
analysis
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4.7.4 Vitamin D receptor positively regulate the PXR gene expression
As mentioned in the introduction (section 1.2.2.5), l,25-(OH)2-D3, the active form of 
vitamin D, induces CYP3A4 expression in caco-2 cells and to a lesser extent, in 
human hepatocytes (Schmiedlin-Ren et al. 2001). This action is probably mediated via 
the PXR and CAR response elements contained within the promoter of this gene.
In addition, PXR ligands have been reported to induce CY24, an enzyme involved in 
the catabolism of l,25(OH)2D3; this is achieved through binding of activated PXR to 
the promoter of CY24, and prolonged stimulation may result in osteomalacia 
(Pascussi et al. 2005). Taken together, these finding suggest that VDR might play a 
role in regulating PXR gene expression to maintain the equilibrium between the 
synthesis and catabolism of the vitamin D.
As figure 4.12, had demonstrated the requirement for expressing RXRa to achieve 
measurable VDR-mediated effects on PXR gene expression, expression plasmids for 
this nuclear receptor were included in all experiments in this section.
Figure 4.13 shows the effect when constructs 2200, 1500, 900 and 400 were co­
transfected with expression plasmids for both VDR and RXRa. Interestingly, the 
expression of the 1500, 900 and 400 fragments were higher than the whole construct, 
suggesting the presence of a regulatory element between the 2200 and 1500 base pairs 
that reduces the response to the VDR/RXRa heterodimer: The response of the 2200 
base pairs constructs is probably through the identified putative binding site for VDR 
a t -1564.
The response of the 1500, 900 and 400 base pairs constructs to the VDR/RXRa could 
be through a non-regulatory element as no putative binding site were identified 
beyond the 1500 base pairs.
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Figure 4-13 Vitamin D receptor mediated increase in PXR gene expression.
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Huh? cells were transfected with SEAP reporter gene constructs containing 2200, 
1500, 900,and 400 base pairs of the PXR promoter. The position of the putative 
binding site for the VDR is represented. The constructs were co-transfected with the 
expression plasmids for VDR/RXRa. SEAP activity was measured 48 hours later 
with the chemiluminescence reporter gene assay as described in material and 
methods. Data is representative of experiments undertaken on three separate 
occasions, representing three biological repeats (n=3). Variation between repeat 
measurements was less than 10% for all data points. For each promoter fragment 
tested, the respective fragment minus co-transfected expression plasmid was used as 
control; these values were normalized to 100%. ***=p<0.001 relative to no 
cotransfected control by one-way ANOVA with Bonferroni post hoc analysis.
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4.8 Repression of PXR expression by the PXR and CAR proteins
PXR and CAR are believed to have diverged from same ancestral gene, the chicken X 
receptor (CXR) (Handschin et al. 2004). PXR and CAR share structural and 
functional features, namely 66% similarity in their DBDs (Moore et al. 2003), and 
binding to the same response elements in several genes, including CYP3A4, CYP2B6, 
MRP2 and CYP2C9 (Xie et al. 2000b; Goodwin et al. 2001; Kast et al. 2002; Pascussi 
et al. 2003). In addition, the two receptors share some ligands such as phénobarbital 
(Lehmann et al. 1998).
However, PXR is not constitutively active in the cells, the opposite of CAR. The 
promiscuity of the PXR, being capable of inducing a big range of genes, and 
responding to unrelated xenobiotics and endobiotics, make PXR a highly inducible 
receptor, capable of responding to changes in cellular status. The need for tight 
regulation of PXR, is probably necessary in order to maintain the basal levels of its 
target genes required for the metabolism of the endogenous compounds.
It was interesting to note that the co-transfection of either PXR or CAR expression 
plasmids down-regulated expression of the PXR receptor plasmid (figure 4.14).
No putative binding sites for the PXR or CAR were identified with the in silico 
search. However, PXR/RXR or CAR/RXR could bind to the VDRE found at -1564, 
thus conferring the down regulation seen with the 2200 and the 1600 bp constructs. 
But the effect on the rest of the constructs could be explained by the binding of these 
two heterodimer to non-regulatory element, or involve an indirect pathway, in which 
other factors are involved in the down regulation which have been previously induced 
by PXR and CAR proteins. The down regulation could be only the fact that these two 
receptor compete all over the promoter with other transcription factors, thus inhibiting 
their binding to their response elements.
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Figure 4-14 Down-regulation of PXR expression with the (A) PXR and (B) CAR 
proteins
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Huh7 cells were transfected with SEAP reporter gene containing 2200, 1600, 1500, 
1300, 1200, 1100, 900, 600, 400 and 76 base pairs of the PXR promoter. The 
constructs were co transfected with either the expression plasmid for PXR (A) or 
CAR (B). SEAP activity was measured 48 hours later with the chemiluminescence 
reporter gene assay as described in material and methods. Data is representative of 
experiments undertaken on three separate occasions, representing three biological 
repeats (n=3). For each promoter fragment tested, the respective fragment minus co­
transfected expression plasmid was used as control; these values were normalized to 
100%. Variation between repeat measurements was less than 10% for all data points. 
**=p<0.01, ***=p<0.001 relative to no cotransfected control by one-way ANOVA 
with Bonferroni post hoc analysis.
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4.9 Discussion 
4.9.1 Basal expression
PXR expression levels in Huh? cells are very low compared to in vivo tissue, as 
demonstrated previously in our lab (Phillips et al. 2005). This may explain to some 
extent the low level expression of CYP3A4 in human hepatoma cell lines, as a major 
role of constitutive PXR expression in maintaining the basal expression of several 
drug metabolising enzymes, including members of the CYP3A family (Phillips et al. 
2005). One mechanism for increasing expression of these drug metabolising enzymes 
is to increase PXR expression levels, either through over-expression (Phillips et al 
2005), or through stimulation of the expression of the chromosomal copy of PXR. To 
perform the latter it is therefore necessary to understand the control mechanisms 
underlying regulation of this gene expression. The overall activity of the proximal 
promoter of the PXR gene in the Huh? hepatoma cell line is positive, as demonstrated 
using the 2200 bp reporter gene construct, and further dissection was undertaken to 
identify sub-regions that confer this positive effect.
An in silico search of the PXR proximal promoter revealed many factors that could be 
involved in maintaining the basal expression of PXR, and hence deletion constructs 
were produced to further refine important areas of regulation: negative and positive 
regulation of these different fragments of the PXR promoter may be indicative of the 
role of specific transcription factors binding to their cognate sites on the PXR 
proximal promoter. Taken collectively, these factors coordinate the final response of 
the PXR to different transcription factors, and interactions between them are very 
likely central to determining the final PXR expression level.
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An important finding of my initial data is the presence of both positive and negative 
regulatory regions within the PXR proximal promoter. The deletion construct series 
suggested that the regions between 2200-1600, 1500-900 and 600-76 contained 
positive elements, whereas regions between 1600-1500 bp and 900-600 contain 
negative elements. The fragment between 2200 and 1600 contain putative binding 
sites for C/EBP, CCAAT, Octamer, SPl, Barbie box, COUP-TF, AhR/Amt, p53 and 
PR, these factors could have a positive effect on PXR expression, combined with the 
positive effect of the GR and ER. The fragment between 1500 and 900 contained 
putative binding sites for the HNFla, Octamer, CCAAT, C/EBPa, SPl, COUP-TF, 
P53, PPARa, NFKB, ERa, and GRa. The positive effect could be due to any of these 
factors, except GRa, as it was shown to down regulate expression of the 1500 bp 
construct. The positive effect produced between 600 and 400 bp could be due to 
HNF4a, CCAAT, ERa and/or PR. The negative regulation of the fragment between 
1600-1500 could be conferred by the AhR or by CCAAT. The negative regulation of 
the 400 bp could be due to the FXR, PR, COUP-TF, SPl or CCAAT. As the net effect 
of the proximal promoter is positive this would suggest that the negative regulatory 
element(s) and their effect in suppressing PXR expression is negated by the positive 
regulatory elements present in the upstream fragment(s).
Overall, my data suggests that the PXR proximal promoter is complex, with several 
positive and negative regulatory regions that interact to produce the net expression 
level of PXR. Within these regions, in silico analysis identifies several putative 
transcription factor interaction sites: To further delineate which factors are important, 
the functionality of these putative binding sites was examined by co-transfection with 
expression plasmids for the factors known to bind at these sites.
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4.9.2 Role of the HNFs
Liver enriched transcription factors such as the HNFs are reported to be reduced in 
hepatoma cell lines to 30-60% of those levels seen in primary hepatocytes (Jover et al.
2001). Such a marked decrease in expression may have important consequences for 
the overall pattern of gene expression observed in these cell lines, potentially resulting 
in the loss of liver-specific characteristics. As PXR is responsible for regulating the 
expression of many of the genes preferentially expressed in liver, then it is a logical 
hypothesis that decreased HNF levels may result in reduced PXR, and hence PXR- 
target gene expression. To test this, the ability of HNFs to stimulate PXR gene 
expression was tested through over-expression studies. Interestingly, the effects of the 
HNFs on the PXR promoter were the opposite to what was expected from the above 
discussion, and resulted in the down regulation of PXR expression.
H N Fla has previously been reported to both up-regulate expression of some genes 
(CYP1A2, CYP2C29 and CYP2E1) and down-regulating the expression of others 
(CYP2A5, CYP2B10 and CYP2D9) (Cheung et al. 2003). My studies suggest that 
PXR gene expression is not significantly altered by H N Fla, a result that is perhaps 
not surprising when one considers that PXR up-regulate genes that are down- 
regulated by H NFla. This would suggest that the action of H N Fla in regulating the 
expression of genes mentioned earlier is not at the level of controlling ligand- 
activated transcription factor expression, but via interactions directly with the target 
gene regulatory elements.
There are three HNF3 genes in mammals (a,(3,y). They are all expressed early in 
mouse embryos (Monaghan et al. 1993), suggesting that these factors are important
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during development. HNF3 proteins are involved in controlling the expression of 
many genes (Darlington 1999), predominantly through their ability to modify 
nucleosomal organization (Cirillo et al. 1998). HNF3y has been implicated in the 
regulation of the CYP3A4 gene expression (Rodriguez-Antona et al. 2003). 
Unfortunately, I was not able to test the effect of HNF3y on PXR gene expression, 
due to the lack of a suitable expression plasmid. Putative binding sites for HNF3p 
were identified at approximately -67 bp and -137 bp relative to the PXR transcription 
start site, suggesting a direct effect of HNF3p on PXR gene expression. No binding 
sites were found for the HNF3a within the PXR proximal promoter, however, it has 
been reported that both HNF3a and 3P may interact with the same response element 
in target genes (Duncan et al. 1998). It is not clear yet whether such an interaction 
would be competitive or additive/synergistic in its net effect, and further in vitro work 
would be required to confirm this. It is interesting to note that HNF3P down regulated 
the expression of PXR with the 2200 base pairs construct; the up regulation of the 
HNF3p of the 76 and the 200 constructs could therefore be attenuated by upstream 
elements, thus preventing over expression of PXR and hence the unwanted induction 
of its target genes, which could disrupt the homeostasis.
HNF4a has also been demonstrated to be an important factor in regulation of the PXR 
target gene CYP3A4 (Jover et al. 2001). HNF4a mediates PXR and CAR gene 
activation of the CYP3A4 gene, probably through alterations in chromatin, resulting 
in increased access for PXR/CAR to their DNA binding sites (Tirona et al. 2003). 
Previous work on the PXR promoter carried out by Kamiya (Kamiya et al. 2003) 
demonstrated that HNF4a may bind to the PXR promoter and help to maintain its 
expression in murine foetal liver cells. I have demonstrated that this relationship also
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exists in human cells, but with HNF4a having a positive effect only on the proximal 
200 bp.
Co-transfection of the expression plasmid for HNF4a elicited increased expression 
with the 200bp PXR deletion construct, but not the 76 bp PXR deletion construct; this 
is consistent with the findings of the in silico data mining, with the identification of a 
putative binding site for HNF4a at approximately -186 bp relative to the transcription 
start site. Again the down expression of the whole construct (2200 base pairs) is 
probably a mechanism of regulation against the over expression of this gene, as it is 
the case with the HNFSp. Such a finding is entirely consistent with PXR being a 
complex promoter, under a complex mechanism of regulation as was suggested from 
the in silico data and the basal expression of each deletion construct, harbouring both 
negative and positive regulatory elements.
4.9.3 Role of the estrogen receptor in PXR gene expression
The estrogen receptor is a ligand activated transcription factor belonging to the 
nuclear receptor superfamily (Smith 1998) that binds as a homodimer to the estrogen 
receptor response element (Kushner et al. 2000). It exists as two isoforms, ERa and 
ERp, and are differentially expressed in the organs. For example, ERa is highly 
expressed in the uterus, whereas ERp is mostly expressed in the ovaries and prostate.
ERa is also expressed in liver, lung, testis, and both are expressed in some parts of the 
brain (Dechering et al. 2000). The two receptor isoforms can form a heterodimer, 
which exhibits the same affinity of binding to the ERE as the homodimer ERa, but 
the homodimer ERp, has less affinity, so induces target genes to a lesser extent 
compared to the ERa homodimer (Cowley et al. 1997). The respective roles of the
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two receptors is difficult to determinate as they have over lapping tissue distribution 
(Dechering et al. 2000). The natural ligand for the ER is estradiol, although it may 
also be activated by a wide range of synthetic estrogens, including Bisphenol A .
Estrogens are substrates for CYP3A4 (Gibson et al. 2002), and activate PXR in 
human, mouse and rat (Kliewer et al. 1998; Masuyama et al. 2003). In addition, PXR 
and ER share same ligands, with both receptors activated by Bisphenol A (Takeshita 
et al. 2001). Interestingly however, estrogen is not an inducer of CYP3A4, despite its 
ability to activate PXR; the reason for this is not yet clear. However, as estrogen is a 
ligand for PXR, it was pertinent to examine the effect of the estrogen receptor on PXR 
gene expression. I demonstrated that the estrogen receptor does have a stimulatory 
effect on PXR gene expression, probably through interaction with the ERE site in the 
first 1200 bp of the proximal promoter. Within this region, in silico analysis suggests 
the presence of three putative estrogen receptor binding sites at -987, -618 and -585, 
suggesting that these sites are active within this region of the promoter. As no ERa 
binding sites were identified between 1600 and 1500 base pairs, this suggests that the 
effect is through binding of the ER to a non-consensus binding site or involving 
another factor. The down regulation of the 1500 construct could also be through 
binding of the ER to a non-consensus binding site or involving another factor, which 
could in turn regulate the upstream effects of the 1600 and 2200 bp fragments. 
Between 2200 and 1600 bp, a putative binding site was identified at approximately 
1855 from the transcription start site, this suggest that the ER is binding directly to the 
promoter and inducing it. This data strongly suggests that PXR is a target gene for the 
estrogen receptor and that the endogenous estrogens induce PXR.
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An inverse relationship between expression in breast tissue of the estrogen receptor 
and PXR (Dotzlaw et al. 1999) and in endometrial cell cancer (Masuyama et al. 2003) 
has been reported. This later group showed that estradiol increased the expression of 
PXR in endometrial cells, and proposed that PXR/CYP3A4 pathways might play a 
role in human endometrial cancer; such a hypothesis is supported by the fact that 
tamoxifen, an anti-estrogen used in the treatment of breast cancer, is a substrate for 
CYP3A4 (Dotzlaw et al. 1999).
Whereas, in this scenario, the presence of elevated PXR in breast tumor tissue may be 
indicative of a poor prognosis for the anti-estrogen treatment, it should be 
remembered that elevated levels of PXR may in themselves be anti-estrogenic, 
representing an endogenous system to maintain the homeostasis of estrogens, which 
are metabolised by CYP3A4.
4.9.4 Role of the glucocorticoid receptor on the PXR gene expression
It has been shown previously that submicromolar concentration of the synthetic 
glucocorticoid dexamethasone induces the expression of PXR and RXRa mRNA 
(Pascussi et al. 2000a) and that dexamethasone is an activator of the PXR receptor at 
supramicromolar concentration (>10 pM). In addition, the increase in the levels of 
expression of PXR in the presence of over expressed GRa protein in my studies is 
likely to be through a putative binding site identified within the promoter. The 
endogenous ligands for the GRa are sufficient to maintain basal expression of the 
PXR.
The normal concentration of circulating glucocorticoids in human are in the range 0.1 
to 0.45 pM in human, a concentration that permits a full activation of GR (Pascussi et
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al. 2003). The pre-treatment of the cells with O.OlpM dexamethasone, resulting in 
extended PXR expression, suggests that this effect is probably through the action of 
the GR towards the PXR promoter. Pre-treatment with dexamethasone may result in 
induction and activation of several factors, such as the RXRa (Pascussi et al. 2000b), 
which could affect basal expression of the PXR.
Dexamethasone treatment of primary rat hepatocytes has been shown to result in the 
maintenance of phenotype and an increased expression of C/EBPa/p/y, HNF 1 a/p, 
HNF3a, HNF4a, RXRa and the liver specific markers albumin (Sidhu et al. 2004). 
Treatment with dexamethasone helps to maintain the phenotype in rat hepatocytes 
(Colbert et al. 1984) and induces the differentiation of human bone marrow 
osteoprogenitor (Cheng et al. 1994). Accordingly, pre-treatment of the Huh? cells 
with dexamethasone may induce factors that could be important in PXR expression.
4.9.5 Role of the VDR
Up regulation of PXR gene expression in the presence of co-transfected VDR shows 
that endogenous ligands for VDR are capable of activating PXR gene expression. This 
action is likely to be localised to the putative binding site found with the in silico 
search, at -1564 bp, relative to the transcription start site. However, a positive effect is 
also observed with the 1500, 900 and 400 bp PXR deletion constructs, although no 
putative VDRE was identified in these regions. This may be due to the presence of a 
non-consensus binding site for the VDR, or due to an indirect action where VDR 
activates a second factor, which then binds to the PXR proximal promoter and 
activates transcription.
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It has been reported that over-expression of RXRa increases the transcriptional 
activity of the vitamin D receptor (Weigel 1996) and that of thyroid hormone 
(Yamaguchi et al. 1999).My results obtained herein, show a similar finding, where 
over-expression of the RXRa enhanced VDR transcriptional activity.
My results obtained with the co-transfection of VDR with PXR reporter gene 
constructs suggest that there may be a direct interaction between VDR and the PXR 
proximal promoter. Thus, in addition to responding to changes in xenobiotics, such 
data would support a role for PXR in the physiological regulation of vitamin D.
4.9.6 Transcriptional activation of PXR by RXRa
My results obtained with the co-transfection of the PXR constructs with the 
expression plasmid for RXRa, indicate that RXRa could be an important factor in 
maintaining PXR basal expression. The biological importance of RXRa has been 
shown when knock out mice for RXRa and p resulted in malformations (Krezel et al. 
1996). RXRa can form a homodimer, when activated by 9-cis retinoic acid, and bind 
to DR-1 elements on target genes (Mangelsdorf and Evans 1995). Thus PXR could be 
responding to RXR ligands and may be involved in retinoic acid metabolism.
I have also demonstrated that RXRa could be a rate limiting factor in Huh? cells, as it 
is a heterodimer partner for many transcription factors (VDR, PPARa, TR, CAR, 
PXR, RAR), and competition could lead to the reduced availability of RXR
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4.9.7 Down-regulation of the expression of the PXR by PXR and CAR proteins
One surprising result from these studies was the marked inhibition of PXR gene 
expression by both PXR and CAR proteins. Such a phenomenon does however bear 
up to scrutiny as a potential feedback loop, where increased activation of PXR/CAR 
suppresses expression of these genes, ensuring that over expression of their target 
genes does not occur. Such over expression could easily occur in an unregulated 
system as exposure to xenobiotics is often for a chronic period, or a relatively high 
dose. As the consequences of such over expression could be altered homeostasis of 
endogenous metabolism.
However, as the PXR proximal promoter does not contain a readily identifiable PXRE 
it is important to address the molecular mechanism underlying such a phenomenon. 
PXR has been shown to mediate increases in GSTA2-mediated metabolism through 
activation of gene expression via binding to a sequence within the antioxidant 
response element of this gene (Falkner et al. 2001). No consensus binding sites for the 
antioxidant response element was found within the PXR promoter. Such data would 
suggest that, under at least certain circumstances, PXR might bind to a non-consensus 
binding site; we would hypothesise that this is the case in the context of the PXR 
proximal promoter as well.
An alternative explanation is that co-transfected PXR or CAR compete with other 
factors maintaining basal expression, ultimately giving a negative regulation of the 
PXR. The PXR or CAR bound to the PXR promoter could block the access for other 
factors. In addition PXR or CAR could activate factors, which have a role in down- 
regulating expression.
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It is known that the hormone la,25-(OH)2D3 auto-regulate vitamin D la-hydroxylase 
CYP27B1 by down-regulating it (Prosser and Jones 2004). The endogenous ligands 
for PXR could play a role in maintaining homeostasis for the PXR by down- 
regulating its expression. As the PXR is not constitutively active, this could be a self- 
defence mechanism against increased levels of the PXR to avoid perturbation the 
homeostasis.
The high levels of expression of CAR in Huh7 cells (Phillips et al. 2005) should result 
in reduced levels of PXR expression, but up regulation of the receptors discussed 
earlier (VDR, ERa, GRa, RXRa and PPARa) would bring PXR expression to the 
final basal levels seen in the Huh7 cells. This is again in concordance with the basal 
expression of the different fragments (Figure 4.5) where positive and negative 
regulatory regions within the PXR promoter have been suggested.
In addition CAR and PXR may recruit co-repressors to the PXR promoter, as these 
two factors can bind co-repressors and co-activators in the LBD. The amount of the 
co-repressors may be higher than co-activators, resulting in the observed down- 
regulation. Indeed, PXR has been shown to be able to bind the co-repressor SMRT 
and represses the basal as well as drug induced CYP3A4 gene expression (Takeshita 
et al. 2002).
Saini et al, suggested that PXR suppresses CAR activity. Because the PXR knock out 
mice showed an increase in the bilirubin clearance, a pattern similar to that found 
when CAR was activated, and also the presence of the PXR ligand PCN conferred a 
resistance to hyperbilirubinemia. Hence it has been proposed that the ligand free PXR
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confers the down regulation towards the CAR (Saini et al. 2005). These latter authors 
proposed that this is a regulatory mechanism as CAR is constitutively active. 
However, PXR is classified as a ligand activated transcription factor (Kliewer et al. 
1998; Lehmann et al. 1998; Takeshita et al. 2001), and hence a ligand free PXR 
activity is perhaps not the best way of describing the constitutive activity of this 
receptor. PXR may instead be activated by endogenous ligands, a process that would 
obviously depend upon the ligand concentration in the cell.
Maglich et al, reported that the treatment of mice with the PXR ligand PCN increased 
the levels of PXR and CAR mRNA levels in mouse liver and to a lesser extent in 
human hepatocytes after treatment with rifampicin (Maglich et al. 2002). In this later 
study however, they used a ligand for PXR, and increased the levels of PXR mRNA 
were seen in only one of the two donors used in the study, with the increase being 
slight. The data obtained in my study did not use any exogenous ligand, suggesting 
that PXR may down regulate its own expression as self-defence against PXR over 
expression when only endogenous/low levels of ligands are present.
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4.10 Conclusion
PXR plays a central role in mediating the body response to different stimuli, inducing 
many target genes. The ability of PXR to induce a range of genes and the fact that it is 
activated by a whole set of unrelated xenobiotics and endobiotics suggest that it is 
under a complex regulation, confirmed by the results obtained with the in vitro 
analysis and in silica data. My results also show that there is interplay between 
nuclear receptors.
The regulation of receptors by other receptors has been suggested by Maglich et al, 
whereby PXR activated by its ligand rifampicin, induces expression of AhR in human 
hepatocytes (Maglich et al. 2002).
Whereas ERa, VDR and GRa induce PXR expression, CAR, PXR, HNF3p, HNF4a 
decrease its expression. This shows that the regulation of the PXR gene expression is 
under the control of many factors and also suggests that the regulation of this receptor 
occurs at the transcriptional level.
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5 CHAPTER: Transcriptional regulation of the PXR gene by the 
ligand activated transcription factor PPARa
5.1 Introduction
My in silico analysis of the PXR proximal promoter identified putative binding sites 
for a number of liver-enriched transcription factors (LETFs) and ligand-activated 
transcription factors (LATFs). As PXR is highly expressed in the liver it would be 
expected that the promoter contained putative binding sites for LETFs such as 
hepatocyte nuclear factors (HNFs), C/EBPa, and COUPTFL However, the presence 
of putative binding sites for LATFs is very interesting, and I hypothesise that this 
reflects the role of the PXR as a promiscuous ligand activated transcription factor, 
capable of responding to a large array of chemical stimuli.
Little is known about PXR gene regulation and the function of its promoter. However, 
it has been shown that the liver-enriched transcription factor HNF4a binds to the 
proximal promoter of mouse PXR gene and regulates its expression in foetal mouse 
hepatocytes (Kamiya et al. 2003); to date, this is the only factor reported to bind to the 
mouse PXR promoter and regulate its expression. Indirect evidence does exist to 
suggest that LATFs can interact with the PXR regulatory elements: First, the 
transcriptional activity of PXR has been shown to be activated by dexamethasone, a 
GRa ligand (Pascussi et al. 2000a). Second, transcriptional activation of PXR by 
PPARa ligands (PFDA and clofibric acid) has also been reported, both in vivo and in 
vitro (Zhang et al. 1999).
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Whereas the rationale for activation by glucocorticoids is now becoming clear, with 
these GRa ligands also being ligands for PXR and substrates for PXR target genes, 
including CYP3A4 (Gibson et al. 2002), the activation by peroxisome proliferators is 
somewhat surprising as these PPARa ligands appear not to be ligands for PXR, nor 
are they substrates for PXR target genes (Zhang et al. 1999; Ma et al. 2005).
The identification of a putative binding site for the PPARa/RXRa heterodimer within 
the PXR proximal promoter, as detailed in Chapter 3, could provide a molecular 
rationale for this observed transcriptional activation. Accordingly, the functionality of 
this putative PPRE binding site was investigated using reporter gene and 
electromobility shift assays, and speculation as the biological consequences of such 
activation is presented.
5.2 Reporter gene assay for the assessment of the role of the PPARa on the 
PXR gene expression
5.2.1 Reporter gene assay for the transcriptional activation of PXR reporter 
gene assay by PPARa
A putative binding site for the PPARa/RXRa heterodimer was identified in the 
region from -1318 to -1338 base pairs upstream from the transcription start site 
(chapter 3).
In general, the PPARa/RXRa heterodimer binds to an imperfect DRl recognition site 
for nuclear receptors, namely AGGTCA (Johnson et al. 2002). Seven high affinity 
binding sites have been identified for the PPARa/RXRa, as annotated in 
TRANSFAC. The putative binding site found using Matlnspector to interrogate the
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TRANSFAC database was tggaaaaaggacAGAGctcta. Underlined bases are those that 
exhibit high conservation with the consensus binding sequence, and those in capitals 
show the core sequence used by Matlnspector and Match when interrogating the 
TRANSFAC database. The DRl unit present in the PXR promoter is 
AGGACAgAGCTCT, which is different from the consensus sequence at three 
locations (underlined). The 5’ extended half-site has been reported to increase the 
binding affinity for PPARa to imperfect DRl recognition sites (Palmer et al. 1995). 
The 5’ extended sequence representing the extended aaaa sequence is present in the 
predicted sequence.
To examine the effect of PPARa on transcription of the PXR gene, an expression 
plasmid for PPARa was co-transfected with the fragment containing 2200 base pairs 
(bp) of the PXR proximal promoter, in addition to examining the of 1500 and 1300 
base pairs fragments (figure 5.1).
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Figure 5-1 PPARa-mediated increases in PXR gene expression.
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Secretory alkaline phosphatase (SEA?) reporter gene constructs containing 2200, 
1500 or 1300 hp of the human PXR proximal promoter were transfected into Huh7 
cells, with or without an expression plasmid for PPARa, as described in materials and 
methods. SEAP activity was measured 48 hours post-transfection. Each data point 
represents the mean, plus SEM, for three biological repeats (n=3), and is 
representative of at least three independent experiments. Control representing the 
SEAP blanck vector. ***=p<0.001, ns= not significant relative to no-cotransfection 
control by one-way ANOVA with Bonferoni post hoc analysis.
PPARa expression positively influenced expression mediated by the 2200 bp 
construct, demonstrating that PPARa expression up-regulates PXR gene expression. 
Furthermore, the up-regulation of expression is localized to the region between the - 
1500 and -1300 bp constructs. This has two implications; first, this is consistent with 
the putative PPRE, identified at -1330 base pairs from the transcription start, second, 
the response seen for this fragment is not significantly different than that seen with the 
2200 bp construct, suggesting that the response conveyed by this unique area is the 
major determinant of PPARa -mediated responses.
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Because I had previously shown that RXRa over-expression resulted in increase in 
PXR expression and enhanced the VDR mediated gene expression of PXR, it was 
interesting to investigate if this effect was the same with PPARa (figure 5.2). Co­
transfection of the RXRa expression plasmid with PPARa resulted in an enhanced in 
the PXR expression, compared to PPAR alone (Figure 5.2).
Figure 5-2 Reporter gene assay showing increased expression of the PXR with 
cotransfection of the expression plasmid for PPARa and RXRa.
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SEAP reporter gene construct containing 2200 or 1500 bp of the human PXR 
proximal promoter were transfected in Huh? cells, with the expression plasmids for 
PPARa with or without RXRa. SEAP activity was measured 48 hours post­
transfection. Each data point represents the mean for three biological repeats (n=3), 
and is representative of at least three independent experiments. Variation between 
repeat measurements was less than 10% for all data points. For each promoter 
fragment tested, the respective fragment minus co-transfected expression plasmid was 
used as control; these values were normalized to 100%. ***=p<0.001, relative to no­
cotransfection control by one-way ANOVA with Bonferoni post hoc analysis.
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The increased expression of PPARa associated with the over expression of RXRa 
could be due to increased formation of the heterodimer of PPARa/RXRa, thus 
resulting in a further increase in the PXR expression (Figure 5.2).
It has previously been reported that the Wyeth and 9-cis-retinoic-acid ligands for the 
PPARa and RXRa, respectively, cooperatively induce the acyl-CoA oxidase gene 
(Keller et al. 1993), a PPARa target gene, and has been shown that the retinoic acid 
activates the PPARa/RXRa and that retinoids can act as peroxisome proliferators 
indirectly (Kliewer et al. 1992; Standeven et al. 1997). This could also be the case 
where PXR could respond to either to PPARa ligands or RXRa ligands, and the 
outcome would be increased level of expression of PXR.
5.2.2 Loss of PXR activation by PPARa following ablation of the putative 
binding site for the PPARa/RXRa located at -1330 bp
The above PXR reporter gene studies using over-expressed PPARa suggestes that the 
main interaction occurs between -1.5 kb to 1.3 kb of the PXR proximal promoter. As 
in silico analysis identified a putative PPARa/RXRa binding site within this region, 
further investigations were undertaken to examine the functionality of this binding 
site. Site-directed mutagenesis was carried out on the putative binding site, producing 
two mutant version of the putative PPARa/RXRa response element. Three bases 
from the 3’ half site were mutated to produce an initial mutant (A) 
(TGGAAAAAGGACAgACCGGTATGGC), and an additional four bases were 
deleted (indicated in red) to create the second mutant (B)
(CTGGAAAAAGGA//CagA//CCGGTATGGCTGT). The rationale for the selection 
of bases for alteration/deletion was that these bases represented the most highly
141
conserved bases within the putative binding site, following the in silico analysis. The 
effects of these mutations were then examined using the PXR reporter gene assay, as 
previously described (figure 5.3).
Figure 5-3 Mutation of the PPRE down regulates the expression of the PXR gene 
activation.
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SEAP reporter gene construct containing 1500 bp of the human PXR proximal 
promoter representing the wild type construct, site directed mutagenesis A (SDM) or 
SDM for mutant B, were transfected into Huh7 cells with or without co-transfection 
of the expression plasmids for PPARa and RXRa. SEAP activity was measured 48 
hours post-transfection. Experiments were undertaken of at least three times, with 
n=3. ***=p<0.001, ns= not significant, relative to no-cotransfected construct by one­
way ANOVA with Bonferoni post hoc analysis.
As can be seen from Figure 5.3, mutant A retained the ability to mediate PPARa- 
stimulated expression of the PXR gene, suggesting that cither the mutation was not 
sufficient to remove all activation via this site, or that the site was, in fact, not 
involved in PPARa-mediated responses. However, the reporter gene construct
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containing the more severe mutation (B) showed a complete loss of PPARa-mediated 
activation of the PXR gene. Together these data demonstrate that the identified 
putative PPARa/RXRa binding site is functional, and that complete ablation of it 
results in a loss of PPARa-mediated activation of PXR gene expression.
5.3 Functionality of the PPARa/RXRa putative binding site
The functionality of this putative binding site was further investigated using 
electromobility shift assay (EMSA) with the wild type probe and with the mutated 
ones. The EMSA is based on the observation that the complex protein:DNA migrates 
more slowly than free DNA, during electrophoresis in a non-denaturing 
polyacrylamide gel.
5.3.1 Binding reactions
Following demonstration that ablation of the putative PPARa/RXRa binding site 
identified in silico abolished PPARa-mediated activation of the PXR reporter gene 
construct, I next investigated whether DNAiprotein interactions occurred in this 
region. As described in materials and methods (section 2.2.8.1) 25mer oligo’s 
representing the wild-type, mutant A and mutant B sequences were prepared and 
binding examined using EMSA. Binding reactions were carried out with probes 
representing both the sense and antisense strands of the DNA (Figure 5.5) and 
demonstrated proteiniDNA interactions only occurred with the sense strand, 
consistent with the in silico predication from Matlnspector. EMSA done with protein 
extracts from transfected cells with the expression plasmids for PPARa/RXRa and
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non-transfected ones showed the same band (data not shown), it shows that the 
endogenous PPAR/RXR heterodimer is capable of binding the probe.
Figure 5-4 EMSA showing that binding occurs only on the positive strand.
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DNA oligos representing the positive strand (+) and the negative strand (-) for the 
wild type (W), mutant A (MA) and mutant B (MB), were radiolabelled at their 5’ end 
with ^^ P. Probes were incubated in presence ( '^  ) or absence (0) of nuclear proteins 
extracts from Huh7 cells, as described in materials and methods. The reactions were 
run on a 8% non-denaturing polyacrylamide gel. The experiments were carried out 
three times, and were reproducible. The doubke-headed arrow shows the bound probe, 
and t  shows the free probe.
144
Figure 5.5 shows the binding of the wild type, mutant A (sense) and mutant B (sense) 
ratios, showing that for mutant B the binding was much weaker than both wild type 
and mutant A.
Figure 5-5 EMSA showing reduced proteiniDNA interactions with the mutants 
probes compared to the wild type.
No DNA W MA MB
t
radiolabelled probes for the wild type (W), mutant A (MA) and mutant B (MB) 
for the positive strands were incubated with 20 pg of Huh? nuclear protein extracts. 
The reactions were run on a non-denaturing polyacrylamide gel (8%). Data 
representative of experiments undertaken on three separate occasions. The arrow 
shows the bound probe, *|* shows the free probe.
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5.3.2 Competition binding
Having demonstrated that a proteimDNA interaction occurrs within the putative 
PPARa/RXRa binding site, the specificity of this interaction was next examined via 
competition binding with an excess of either the wild type sense oligo or the mutant B 
sense oligo. Binding reactions were incubated with increasing amounts of unlabelled 
wild type (panel A) or mutant B (panel B) oligo, and EMSA undertaken as previously 
described. Figure 5.6 shows the results of the competition binding with the wild type 
(panel A) and mutant B (panel B). The results showed that the wild type showed near 
complete competition with 30 fold excess of cold probe, whereas there was still 
binding at 50 fold excess with the mutant cold probe. Furthermore, binding is specific 
as it can be competed by unlabelled cold oligo, and that the mutant B cannot compete 
as well as the wild type, confirming the poor affinity of the mutant B oligo.
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Figure 5-6 Specificity of the binding to the PPRE demonstrated by competition 
binding with the wild type and mutant probes.
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radiolabbelled oligos for the wild type (W) and mutant B (MB) probes were 
incubated with 20 pg of protein extracts from Huh? cells, in the presence of excess 
(xs) amounts of cold probe for wild type (panel A) or for mutant B probe (panel B) 
keeping the final volume of the reactions to 20 pi. Percentage of bound probe was 
calculated compared to the free probe, and plotted against excess cold competitor (C). 
Data shown are derived from three separate determinations.
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5.4 Discussion
The identification of a putative response element for PPARa using in silico analysis 
correlates with the reporter gene assay, suggesting that PPARa effects are mediated 
by element(s) located between 1300 and 1500 base pairs from the transcription start 
site.
The functionality of this site was investigated by site-directed mutagenesis and 
EMSA, showing that specific protein-DNA interactions that could be ablated by 
mutation of the putative binding site, resulting in a reduced activation of PXR by 
PPARa over-expression.
Having demonstrated a clear ‘how’ regarding the activation of PXR by PPARa, it is 
next important to consider the ‘why’ as PPARa ligands have not been shown to be 
PXR ligands or to be substrate for PXR target genes.
The activation of PXR gene expression by non-ligands for PXR would result in an 
increased expression of PXR protein, but with no increase in exogenous ligands. This 
could result in increased levels of activated PXR by its endogenous ligands, 
presuming that these endogenous ligands are normally in excess, or the activation of 
PXR by low affinity ligands that do not normally interact when PXR levels are 
limiting. Such increased activation of PXR by endogenous ligands could result in the 
increased metabolism of a range of endogenous chemicals, potentially disrupting 
cellular homeostasis -  a potential source of unwanted adverse drug reactions.
An alternate hypothesis is that PXR activation by PPARa could represent a “rescue 
mechanism” against increased levels of PPARa ligands, which could be eliminated by 
any of the large number of transporters under transcriptional control of PXR, 
including MDRl, OATP, and MRP2. Previous reports have shown that activation o f
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PXR can differentially activate target genes when responding to chemical stimuli. For 
example, activation of PXR by endocrine disrupting chemicals (EDC) and the 
anticancer drugs cisplatin and paclitaxel stimulate different target genes in 
endometrial cell cancer, where EDCs stimulate CYP3A4 expression but the anticancer 
drugs stimulate MDRl (Masuyama et al. 2005). This was subsequently shown to be 
due to differential interactions between the co-activators complexes caused by the two 
classes of chemicals. This could be the case in this study, whereby activation of PXR 
gene expression by PPARa ligands could aid in their clearance through the activation 
of a subset of PXR target genes specifically targeted to this end; activation of 
‘traditional’ PXR target gene such as CYP3A4 would not be observed however.
It should be noted that induction of PXR levels by PPAR ligands could result in 
increased protein levels but with no ultimate effect on target gene expression if levels 
of endogenous ligands are limiting. Although unlikely, this must be considered as a 
possibility.
Data reported previously have shown an increase in the transcriptional activity of PXR 
by the PPARa ligands clofibrate and PFDA in the rat (Zhang et al. 1999), and the 
results obtained in the current study show that the induction of PXR gene expression 
is via a direct binding of PPARa to the PPRE on the PXR proximal promoter. 
Furthermore, induction of PXR by PPARa ligands is also cross-species event, and the 
response of human and rodents PXR to ligands for PPARa is similar. The difference 
remains probably in the fact that the peroxisome proliferators do not induce 
peroxisomes and liver cancer in human (Palmer et al. 1998).
Interestingly, PXR and PPARa receptors do share some functional characteristics, 
suggesting common modes of action within the body. PPARa expression is dictated
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by diurnal variations in blood glucocorticoid levels, with glucocorticoids 
transcriptionally activating PPARa expression to achieve this effect (Lemberger et al.
1996). As it is known that the PXR is induced by submicromolar concentrations of 
dexamethasone (Pascussi et al. 2000a) it is likely that this also follows these diurnal 
variations in glucocorticoid levels. Indeed, many genes whose products are involved 
in drug metabolism show circadian variation in their expression, potentially at least in 
part to variations in glucocorticoid expression levels (Chiang et al. 1990; Belanger 
1996; Ohno et al. 2000).
PPARa and PXR both regulate genes involved in bile acids synthesis as PXR 
suppresses expression of cholesterol 7a-hydroxylase (CYP7A1) and induces CYPSAs 
(Staudinger et al. 2001), whereas PPARa suppresses CYP7A1 and sterol 27- 
hydroxylase (CYP27) (Post et al. 2001). As both PXR and PPARa regulate 
expression of CYP7A1 and also expression of SULT2A, which is implicated in the 
excretion of bile acids (Fang et al. 2005), this clearly demonstrates some cross­
compatibility of PPARa and PXR for their target genes. Such a cross-compatibility 
may partially explain the transcriptional interaction as well, with both receptors 
responding to similar chemical stimulii.
This is not the first example of nuclear receptor cross talk involving bile acid 
metabolism, as it has been reported that the PPARa promoter contains a functional 
FXR/RXRa binding site, responsible for increased PPARa expression in response to 
the FXR ligand chenodeoxycholic acid (CDCA) (Pineda Torra et al. 2003). In silico 
analysis of the PXR proximal promoter also showed the presence of a putative 
binding site for the FXR/RXRa at -364 bp relative to the transcription start site, 
although this was not further investigated in this thesis. This adds further weight to the
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hypothesis that PPARa and PXR may interact, suggesting a network of LATFs that 
interact in regulating bile acids.
Hence, these PXR and PPARa appear to regulate some common metabolic pathways 
through the regulation of an overlapping set of target genes. Despite responding to 
different ligands, PPARa and PXR are able to exhibit redundancy, a potential safety 
mechanism allowing cells to respond in a comprehensive way to chemical exposure. 
Such interactions are not limited to PPARa and PXR, with Maglich et al 
demonstrating that activation of human PXR by its ligand rifampicin resulted in 
increased expression of the AhR receptor, and its target gene CYPlAl (Maglich et al. 
2002).
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5.5 Conclusion
I have shown that the PPRE within the PXR proximal promoter is a functional site, 
conferring basal transcriptional activity to PXR. This has an important implication in 
term of species specific responses, as the response of the PXR to PPARa appears not 
to be species specific. This is in marked contrast to the hepatocarcinogenic activity of 
peroxisome proliferation- mediated by PPARa in rodents but not humans.
Due to a shortage of time, supershifi assays could not be completed to positively 
identify the interacting protein as PPARa, and this should be conducted in the future. 
Other techniques that could have been used to further examine the role of PPARa in 
regulating PXR gene expression include siRNA to ablate native PPARa within Huh? 
cells, or transgenic technology to examine these effects in whole animal systems.
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6 CHAPTER: General discussion and future directions
6.1 Discussion
PXR is regarded as a central regulator of body homeostasis. The promiscuity in its 
LBD and its ability to induce genes involved in the metabolism/disposition of 
endobiotics and xenobiotics provides this activity; however it could also lead to the 
problem of drug-drug interactions. Although in general PXR plays a beneficial role in 
the body, it does have some potential for adverse side effects, due to this pluripotent 
activity. It is the central regulator of the most abundant and important drug 
metabolising enzymes CYPSAs, regarding with their abundance and functions 
(Bertilsson et al. 1998; Lehmann et al. 1998). The study of the regulation of the PXR 
gene becomes an important matter to investigate due to this important role in the body 
and its place in the centre of the activation network of ligand-activated transcription 
factors.
The role of PXR as a master regulator of the body homeostasis is becoming more 
recognised, as in its ability to be activated by endogenous compounds. For instance, 
PXR is activated by lithocholic acid, which suggest that it may regulate bile acid 
production (Staudinger et al. 2001); also, P-carotene and retinol are reported to be 
activators of PXR, resulting in the induction of PXR target genes CYP3A4/7 MDRl 
and MRP2 in reporter gene assays (Ruhl et al. 2004). This is interesting, as these 
compounds are not metabolised by the CYP3A enzymes. This suggests that the PXR 
could be involved in the p-carotene and retinol metabolism pathway. PXR is also 
activated by vitamin E, and this activates the expression of CYP3A4 in a reporter
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gene assay (Landes et al. 2003). The activation of PXR by these endobiotics and 
xenobiotics shows that this receptor is an important endogenous sensor of changes in 
the homeostasis.
PXR is capable of maintaining cellular homeostasis by up regulating or down 
regulating the same genes, dependant on pathophysiological situations. For example, 
PXR up regulates MRP2 gene in the presence of the drug rifampicin (Kast et al. 
2002), but down regulates this gene during cholestasis to protect the cells from the 
toxic levels of bile acids (Stedman et al. 2005). Also, the involvement of PXR in the 
metabolism of cholesterol has been highlighted by the PXR knock out mice, when 
they were challenged with a high diet of cholesterol, resulting in the death of the 
animals by hepatotoxicity and renal failure (Sonoda et al. 2005). This study showed 
the role of the PXR in cholesterol metabolism, and its importance in the body’s 
response to high levels of cholesterol. However, the actual mechanism of regulating 
cholesterol metabolism is not known yet, again demonstrating the versatility of the 
receptor, suppressing the synthesis of the bile acids, presumably inhibiting the 
catabolism of cholesterol, and responding to high levels of cholesterol, presumably
I
via increasing its catabolism.
In my project the aim was to investigate the molecular mechanisms underlying the 
regulation of the PXR. There is some evidence showing that PXR is regulated at the 
transcriptional level, such as the increased levels of PXR mRNA following 
dexamethasone exposure of primary human hepatocytes (Pascussi et al. 2000a), but 
whether the glucocorticoid receptor induces PXR expression directly by binding to the 
promoter is not yet known. The role of the HNF4a in the regulation of the PXR is 
probably at the transcriptional level as HNF4a knock out mice repressed the
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expression of the PXR, and the transcriptional activation was mediated through 
binding of HNF4a to the PXR proximal promoter (Kamiya et al. 2003). Also, the 
increase in the levels of PXR mRNA levels in response to the PPARa ligands 
clofibrates and perfluorodecanoic acid in rat hepatocytes suggests a role for PPARa in 
regulating PXR expression (Zhang et al. 1999). The induction of the PXR by 
dexamethasone may be anticipated because GRa ligands are CYP3A4 substrates 
(Gibson et al. 2002), but the dependence of PXR induction on PPARa is an intriguing 
result as ligands of PPARa are not ligands for PXR nor they are metabolised by 
CYP3AS.
In silico analysis of the PXR promoter revealed several putative binding sites for 
general transcription factors and for ligand-activated transcription factors. The 
identification of putative binding sites for the LETFs is not surprising as PXR is 
highly expressed in the liver under basal conditions. More intriguing was the 
identification of several putative binding sites for LATFs, suggesting that the 
promoter of the PXR reflects the protein’s functions in the cell: PXR may accept 
multiple, diverse stimuli at the transcriptional level, and respond by inducing target 
genes. These results suggest that PXR is under complex transcriptional regulation, 
which is not surprising when one considers the promiscuity of PXR in its ability to 
respond to a variety of compounds and induce a variety of genes in different 
situations.
The use of reporter gene assays is a technique used by molecular biologists to 
investigate the transcriptional regulation of a gene of interest, this technique has been 
used in our lab to investigate the molecular mechanisms underlying the regulation of
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the CYP3A4 using hepatic cell lines (El-Sankary et al. 2000; El-Sankary et al. 2001; 
Bombail et al. 2004). The use of cell lines may be not the best way to investigate the 
mechanisms of regulation of genes, because the expression of the LEFT are reported 
to be reduced to 30 to 60 % of the normal hepatocytes, and also the expression of the 
CYP enzymes is reported to represent only 0.1 to 2% mRNA of the primary 
hepatocytes (Jover et al. 2001; Cheung et al. 2003). Indeed, work carried out in our 
group has demonstrated that the levels of some transcription factors are significantly 
reduced in Huh? cells compared to the primary hepatocytes, including PXR (Phillips 
et al. 2005), suggesting that the cells have lost important regulatory elements. 
However, these methods are important to investigate the molecular mechanisms of 
regulation of genes of interest, and the potential role of TFs in regulating the 
expression of target genes.
Preliminary results of the reporter gene assay using the construct containing the 2200 
base pairs of the PXR proximal promoter showed basal expression of the PXR was 
not as simple as it may have been hypothesised, with the deletion constructs showing 
that the PXR promoter contains regions of both positive regulation and negative 
regulation; the factors regulating each portion of the PXR proximal promoter would 
interact to modulate the final effect on the PXR.
The HNFs showed interesting results, as the HNF3P and 4a produce an important up 
regulation of the short fragment of the promoter (200 base pairs) construct, whereas 
they result in down regulation of the 2200 bp construct. This again shows the 
complexity of the system regulating this receptor and the existence of positive and 
negative regulation forces on the PXR promoter. Their role of down regulating PXR
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is may be regarded as a safety mechanism against the over expression of this 
transcription factor, and thus protect the cells from an unwanted up regulation of its 
target genes. The down expression of the PXR by HNF4a shows that the mechanisms 
underlying human PXR gene expression are probably different from that of the foetal 
mouse. HNF4a was shown to regulate the mouse foetal PXR by binding to its 
proximal promoter (Kamiya et al. 2003). The positive and negative forces may be 
balanced differently under different physiological conditions (for example, drug 
treatment, development), thus modulating the net effect of HNFs on PXR expression.
The reporter gene assay using over expression of LATFs proteins with the 2200 bp 
PXR construct showed that the PXR was positively regulated by GRa, ERa, VDR 
and RXRa. These factors would be activated by endogenous ligands that are 
apparently present in Huh? cells in concentrations high enough to confer activity of 
their respective receptors, thereby inducing PXR expression. This provides more 
evidence as to the ability of PXR to be maintained by a wide variety of endogenous 
ligands, and suggests that PXR could respond to the physiological or 
pathophysiological variations of these ligands and hence respond better to changes in 
homeostasis. As PXR is induced by these factors produces experimental support for 
the predictions of the in silico analysis.
An interesting finding of my studies was the down regulation of PXR gene expression 
by the over expression of PXR and CAR proteins. This shows that PXR, or in other 
words the endogenous ligands for this receptor, are capable of repressing its own 
expression to avoid over induction of target genes. The repression mediated by CAR 
may be secondary to the dissociation of its repressor androstane or is a response to an
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endogenous ligand, which is not known yet. In fact, down regulation of CAR by PXR 
has been suggested as a safety mechanism against the over activation of the CAR 
(Saini et al. 2005). The ligand-independent PXR suppressed the expression of the 
CAR by competing for the co-activator SRC-1 thus disrupting the interaction of the 
ligand-independent interaction between CAR and SRC-1 (Saini et al. 2005). This 
suggests that these two receptors regulate each other’s expression; PXR being a 
promiscuous receptor, and CAR being constitutively active, the requirement for the 
tight regulation of these two receptors becomes very important.
The results obtained with transgenic mice expressing a constitutively active human 
PXR, could explain the importance of maintaining this receptor at low levels as this 
chronic over expression caused hepatomegaly, growth retardation and histological 
liver disease (Xie et al. 2000a).
In this work, I have also shown that induction of PXR by PPARa is via interaction at 
a PPRE motif, and that this may be cross species event, as the initial observations 
were made in rat liver (Zhang et al. 1999). The increase in PXR expression with 
overexpression of PPARa was nontheless unexpected because ligands for this factor 
appear not to be ligands for PXR nor are they metabolised by PXR target genes. 
However, in this context, the levels of PXR mRNA are increased in caco2 cells after 
treatment with the PPARa ligand clofibrate (Fadheela Salman, University of Surrey, 
personnel communication). This suggests that PXR is induced by at least one ligand 
for PPARa, and that this probably occurs in both the liver and intestine.
Activation of PXR gene expression by non-ligands of the receptor could have 
important ramifications on metabolism. Specifically, it could represent a general 
protective mechanism against increased levels of xenobiotics by causing good scale
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induction of drug detoxifying enzymes, but eould also merely represent ‘friendly fire’ 
in the body’s response system to chemieal stimulii, with the potential to cause adverse 
side effeets through the disruption of eellular homeostasis.
Figure 6.1 shows a diagram representing the PXR promoter and the potential TFs 
implicated in its regulation, either by direct binding or involving another regulatory 
factor.
Figure 6-1 Representation of the potential factors involved in the direct or 
indirect transcriptional regulation of PXR.
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A ligand binds to its receptor and triggers the transeriptional activation or repression 
of the PXR. The positive regulation of some ligand activated transcription factors is 
counteracted by the negative regulatory aetion of the PXR itself, CAR, HNF3p or 4a.
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Although not directly nor extensively addressed in my studies, the role of co­
activators and co-repressors should not be minimised. The difference in expression of 
co-activators and their levels in different cell and tissue types may contribute to the 
differences in response to drugs or the response to a co-transfected plasmid in a 
reporter gene assay (Leo and Chen 2000). For example, the co-regulator amplified in 
breast cancer 1 (AIB-1) was highly expressed in breast cancer cell lines compared to 
the steroid receptor co-activator 1 (SRC-1), suggesting that the AIB-1 is involved in 
the pathogenesis of breast cancer (Anzick et al. 1997). In addition, the difference in 
induction of CYP3A4 and MDRl in response to PXR ligands, has been shown to be 
due to the difference in recruitment of co-activators to PXR, where the SRCl was 
detected with PXR bound to the PXR response element of CYP3A4, AIB-1 was 
detected with PXR on the PXR response element of MDRl (Masuyama et al. 2005). 
Also, the binding of the PPARa/RXRa to the PPRE in the SULT2A1 promoter was 
not increased by the treatment with the PPARa ligand ciprofibrate, but the co­
transfection of the co-activator CREB binding protein (CBP) lead to the binding of 
these co-activators to the PPRE, increasing activity of the reporter gene assay (Fang et 
al. 2005). The profile of these co-activators and co-repressors are not yet fully 
described in the Huh? cells, and this is an important research topic. This knowledge 
could help to understand to what extent co-activators or co- repressors influence PXR 
gene expression.
The body is capable of responding to different stimulii. The harmony in the response 
to one or more stimulii is achieved by interaction networks of the responding factors 
that result in the most effective adaptation of the body to the stimulii. The ligand-
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activated transcription factors are important for achieving this interaction. The 
outcomes of such interactions are three fold.
• First, it is possible for a single stimulus to elicit different responses in different 
tissues, activating different gene sets to produce the most effective response in 
each tissue (Hartley et al. 2004).
• Second, that redundancy in the response system allows for a metabolic safety 
net, ensuring correct cellular homeostasis is maintained even under extreme 
external stimulation (Xie et al. 2000b).
• Third, interactions may allow coordination of responses, presumably 
producing the most effective response to any given stimuli under a number of 
different cellular conditions. PXR appears to be a prime candidate for this last 
role, with increasing evidence demonstrating that it can be regulated by a 
wide-range of both xenobiotics and endogenous chemicals (Lehmann et al. 
1998; Kliewer and Willson 2002; Ourlin et al. 2003).
Based on my results, I propose a model whereby PXR is regulated by LATFs and by 
itself (Figure 6.2). If a LATF is activated, it induces PXR gene expression: If the 
ligand is a PXR ligand it would activate the PXR protein and lead to induction of 
target genes, with PXR down regulating its own transcription to avoid over 
expression. If however the ligand is not a ligand for the PXR, the increase in the PXR 
protein levels could be a “silent” effect; however, if there are enough ligands (either 
endogenous or a co-administered drug) this would activate PXR protein, resulting in 
induction of target genes, which could result in perturbation of normal homeostasis. 
PXR gene transcription could be induced by non-ligands of the PXR protein as a
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safety mechanism against the increase of the co-administered drug or the overload of 
the cells by endogenous compounds that are not usually considered ligands for PXR. 
This phenomenon could be an important issue, with activated LATFs could activate 
an unwanted LATF, such as PXR, which could have a big impact on the appearance 
of side effects.
Figure 6-2 Proposed model for the role of the PXR as a central regulator of body 
responses to LATF stimulation.
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The LATF when activated induces the expression of PXR. If the ligand is a ligand for 
the PXR, it would activate the PXR and induce target genes, but also auto regulate its 
own expression, to avoid over expression. If however the ligand is not a ligand for 
PXR, this effect could be silent in the cells or if there is enough ligands (either 
endogenous or a co-administered drug) would activate PXR and result in the 
induction of target genes and the possibility of adverse side effects.
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My results provide further evidence for the central role of PXR as a key regulator of 
the body’s homeostasis, gathering information from different LATFs and translating 
them to the systems, which are regulated by this receptor. My work shows that PXR is 
regulated by several LATFs and by itself, placing the PXR in the centre of a 
regulatory network designed to gather, assimilate and respond to chemical stimulii.
The induction of PXR by PPARa is an example of PXR being induced by PXR non­
ligands.
An understanding of PXR gene regulation may be useful for therapeutic purposes. For 
example, the treatment of patients suffering from pruritus by prescribing the PXR 
ligand rifampicin (Stedman et al. 2005). Also, the role of PXR in cholesterol 
metabolism, could help to target this receptor to cure patients suffering from high 
cholesterol, like the cerebrotendious xanthomatosis (Sonoda et al. 2005).
The importance of studying PXR gene regulation at the molecular level could not only 
help to understand the normal physiology of the cell but also could help to predict any 
effects secondary to the chronic administration of drugs. For example, patients who 
are taking the hypolipideamic agents clofibrate drugs, tend to take it over several 
years, and could lead to the induction of other genes (for example PXR) which could 
lead to impaired drug metabolism, drug-drug interactions and loss of the effect of a 
co-administered drug.
I have developed a model for the role of PXR as a central regulator of body responses 
to changes in chemical levels in the liver, using literature sources and data presented 
in this thesis.
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6.2 Future directions
The work undertaken in this thesis has concentrated on the transcriptional regulation 
of the PXR gene, in particular its regulation by PPARa. As biological function is 
generated at the protein and not transcript level, a potential caveat of this work is that 
the transcriptional changes observed herein may be biologically silent. Hence, and 
obvious future direction would be to examine whether the rate of transcription 
correlates with the levels of mRNA and protein for PXR: This could be achieved by 
using RT-PCR, and Western blotting. Such work would increase further the 
knowledge on how an important receptor such as PXR is regulated, but also at which 
levels this regulation occurs.
Another potential future direction would be the use of alternate cell lines, for 
example, intestinal or kidney cell lines, and primary hepatocytes. This would give an 
indication as to whether PXR regulation is cell-type dependent, and whether the 
immortalized cell line used in the present study is a valid model: This could help to 
understand Huh7 cell-responses and validate them as an in vitro 
investigative/screening tool.
In my project I have shown that PXR is under the regulation of endogenous 
metabolites, which activate their respective receptor and induce the expression of 
PXR. It would be interesting to use xenobiotics for each of the LATFs used, in order 
to test the ability of PXR to respond to higher doses of exogenous ligands. This would 
strengthen the idea for PXR as being a master regulator of the body homeostasis in 
response to xenobiotic insults.
The functionality of the putative binding sites for AhR, AR, PR, and FXR could be 
tested by using reporter gene assay with expression plasmid for each of the TF, and 
use of the EMSA, supershift, or siRNA. These latter experiments could give a further
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evidence for the role of PXR as being a master regulator of body homeostasis by 
assimilating signals from different TFs.
Use of the established in vivo (transgenic) model to assess the regulation of human 
and mouse PXR would also be of interest: Assessing the activity/expression of PXR 
following over-expression of other LATFs, or exposure to their ligands. These 
experiments could give two indications. First, the difference between the in vivo and 
in vitro models, and second, differences between human and rodent. This could have a 
big impact on the development of animal models for drug development.
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8 Appendix
Figure 8-1 TOPO PCR2.1 plasmid
(Invitrogen) EcoRI cloning site
lacZa: lacZ gene, fl ori: origin of replication of the filamentous phage f l, Ampicillin: 
lactamase conferring resistance to ampicillin, Kanamycin: kanamycin resistance gene, 
pUC ori: pUC origin of replication.
Figure 8-2 SEAP plasmid
Transcription blocker MCS
SEAP
pSEAP2-Basic
4677  bp
Ampr
SV40 polyA
Restriction enzyme sites in multiple cloning site
g #  A
«  I f I f  chi
MCS: multiple cloning site, SEAP: secretory alkaline phosphatase, SV40 polyA: 
SV40 polyadenylation, Ampr: lactamase conferring resistance to ampicillin.
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Figure 8-3 Expression plasmids for the vitamin D receptor, HNFla, and HNF4a
Ampr
E F -la
SV 40 polyA
Blasticidin  
EM -7 promoter^ 
SV 40 pomoter
PEF6A/5 His-hVDR 
7124 bp
B G H  polyA
Ampr
E F -la
hVDR
SV40 polyA
pEF6A/5 His-hHNF1a
6558 bp
BGH polyA
hHNFla
Blasticidin  
EM -7 promoter
SV40 pomoter
Ampr
EF-la
SV40 polyA
pEF6/V5 His-hHNF4a
6822 bp
BG H  polyA
hHNF4a
Blasticidin  
EM-7 promoter 
SV40 pomoter
EF-la: promoter of human elongation factor 1 alpha, T7: T7 promoter, hVDR: cDNA 
coding for the human vitamin D receptor, hHNFla: cDNA coding for the human 
hepatocyte nuclear factor 1 alpha, hHNF4a: cDNA coding for the human heptocyte 
nuclear factor 4 alpha, V5: V5 epitope. His: polyhistidine sequence, BGH polyA: 
bovine growth hormone polyadenylation, fl : origin of replication of the filamentous 
phage fl, EM-7 promoter: promoter for blasticidin, Blasticidin: blasticidin resistance 
gene, SV40 polyA: SV40 polyadenylation, Ampr: lactamase conferring resistance to 
ampicillin.
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Figure 8-4 Expression plasmid for HNF3a and HNF3(3 in pGEM2
CMV promoter
rHNF3apGem-2-rHNF3a
4661 bp
Ampr
SV40 Poly A
CMV promoter
rHNF3bpGem-2-rat HNF3b
4634 bp
Ampr
SV40 Poly A
CMV: CMV promoter, rHNFSa: cDNA coding for the rat hepatocyte nuclear factor 3 
alpha, rHNF3b: cDNA coding for the rat hepatocyte nuclear factor 3 beta, SV40 
polyA: SV40 polyadenylation, Ampr: lactamse conferring resistance to ampicillin.
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Figure 8-5 Expression plasmids for PXR, GRa, ERa and PPARa in pSGS
SV40
f l
b-globin intron
T7
pSG5-hPXR
7293 bp
Ampr
f l
SV40
b-globin intron
T7
pSG5-hPPARa
7093 bp hPPARa
Poly A
Ampr on
on
SV40
f l
b-globin intron
T7
PGS5-hERa
7474 bp hERa
Poly A
Ampr
SV40
 fj
on
b-globin intron 
L T7
pSG5-hGRa
8020 bp L hGRa
Ampr
Poly A
on
SV40: SV 40 promoter, p-globin: p-globin intron, T7: T7 promoter, hPXR: cDNA 
conding for the human PXR, hPPARa: cDNA coding for the human PPAR alpha, 
hORa: cDNA coding for the human OR alpha, hERa: cDNA coding for the human ER 
alpha, ori: origin of replication, Ampr: lactamase conferring resistance to ampicillin, 
fl : origin of replication of the filamentous phage fl
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Figure 8-6 Expression plasmid for RXRa in pSVL
SV40
Ampr
pSVL-hRXRa
6300 bp
hRXRa
SV40: SV40 promoter, hRXRa: cDNA coding for the human RXR alpha, Ampr: 
lactamase conferring resistance to ampicillin.
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